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Glucocorticoids can reduce infarct size when given immediately after myocardial 
infarction (MI) but are detrimental when administration is continued into the post-infarct 
healing phase. A number of experimental studies have shown that reduction of infarct 
expansion by enhancing blood supply to the infarct border reduces remodelling and 
improves heart function post-MI. Previous experiments from this laboratory have shown 
that mice unable to locally regenerate corticosterone due to deficiency in 11β-
hydroxysteroid dehydrogenase type 1 (11HSD1) have an enhanced angiogenic response 
during myocardial infarct healing that is associated with improved cardiac function. We 
hypothesized that the enhanced angiogenic response in 11HSD1 knock out (
-/-
) mice 
would be preceded by augmented inflammation. Moreover this would be associated with 
improved cardiac function.  
This thesis aimed firstly to establish that murine cardiac phenotype was not influenced 
by 11HSD1 deficiency. 11HSD1
-/-
 and C57Bl6 control mice had comparable cardiac 
structure and function. 11HSD1 expression was localised to fibroblasts and vascular 
smooth muscle cells in the myocardium.  
The second aim of this thesis was to characterise the healing response after MI in 
11HSD1
-/-
 mice compared to C57Bl6 mice. Neutrophil infiltration peaked 2 days after 
MI and was significantly enhanced in the 11HSD1
-/-
 mice relative to C57Bl6 mice, 
despite comparable infarct size in both groups. This was followed by increased 
macrophage accumulation in the infarct border. Furthermore, in the 11HSD1
-/-
 mice a 
greater proportion of macrophages were of the alternatively activated phenotype. Left 
ventricular expression of pro-angiogenic IL-8, but not VEGF, was increased. Cellular 
proliferation and vessel density at 7 days were greater in 11HSD1
-/-
 compared to C57Bl6 
hearts. This was associated with improved cardiac function 7 days post-MI. 
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The third aim of this thesis was to determine whether the enhancement in vessel density 
and cardiac function was maintained beyond the initial wound healing phase. 11HSD1
-/- 
mice retained the increased vessel density compared to C57Bl6 mice and these vessels 
were smooth muscle coated suggesting vessel maturation. This was associated with 
sustained improvement in cardiac function and modification of the scar characteristics. 
The final aim of this thesis was to establish whether the effect of the knock out could be 
recapitulated by administration of a small molecule inhibitor of 11HSD1 after MI. Oral 
administration of the 11HSD1 inhibitor had no effect on inflammation, angiogenesis and 
heart function as determined at 7 days post-MI relative to vehicle treated animals.  
In conclusion, the data confirm the enhancement in vessel density and cardiac function 
in 11HSD1
-/- 
mice and demonstrate that this was preceded by enhanced inflammation. 
This was not due to an underlying cardiac phenotype or modification of the infarct size. 
Increased infiltration of alternatively activated macrophages may have been the source 
of pro-angiogenic factor, IL-8, which was also increased at the time of angiogenesis. 
Importantly the enhanced vessel density was retained 4 weeks after MI, these vessels 
were mature suggesting longevity and the improvement in cardiac function was retained. 
While pharmacological inhibition did not recapitulate the effect of the knock out this 
may have been due to route of administration. The data provides compelling evidence 
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Abbreviation    Term 
-/-     knock out 
6PG     6- phosphogluconate 
11HSD    11β-hydroxysteroid dehydrogenase  
αSMA     α-smooth muscle actin  
ACE     angiotensin converting enzyme 
ACTH     adrenocorticotrophic hormone  
Ang     angiopoietin 
ANOVA    analysis of variance 
APN     aminopeptidase-N 
bFGF     basic fibroblast growth factor 
BMDC    bone marrow-derived cells 
BOOST Bone Marrow transfer to enhance ST-elevation 
infarct regeneration 
BrdU     bromodeoxyuridine  
BSA     bovine serum albumin 
C     complement cascade 
CBG     corticosteroid-binding globulin 
CP     crossing point 
CPM     counts per minute 
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CRF     corticotrophin-releasing factor  
CVD      cardiovascular disease 
DAB      3, 3'-diaminobenzidine  
DEPC     diethylpyrocarbonate 
ECM     extracellular matrix 
EF     ejection fraction 
eNOS      endothelial nitric oxide synthase  
EPC     endothelial progenitor cell 
EPHESUS Eplerenone Post-acute myocardial infarction Heart 
failure Efficacy and Survival Study 
ER     endoplasmic reticulum 
FS     fractional shortening 
G6P     glucose-6-phosphate 
GAPDH    glyceraldehyde-3-phosphate dehydrogenase 
G-CSF     granulocyte colony-stimulating factor 
GM-CSF     granulocyte-macrophage colony-stimulating factor 
GPCR     G protein coupled receptors 
GR     glucocorticoid receptor 
GRE     glucocorticoid response elements 
H6PDH    hexose-6-phosphate dehydrogenase 
HCl     hydrochloric acid 
H&E     haematoxylin and eosin 
HIER     heat-induced antigen retrieval 
 x 
 
HIF-1α    hypoxia inducible factor-1α 
HPA axis    hypothalamic-pituitary adrenal axis 
HSP     heat shock protein 
IB     infarct border 
ICAM-1    intercellular adhesion molecule-1  
IκB     inhibitor-κB  
IFN     interferon   
IGF-1     insulin-like growth factor-1 
IL     interleukin 
IP-10     interferon γ inducible protein 
KC     keratinocyte chemoattractant 
LV     left ventricle 
LVEDA    left ventricle end diastolic area 
LVEDD    left ventricle end diastolic diameter 
LVESA    left ventricle end systolic area 
LVESD    left ventricle end systolic diameter 
MCP-1    monocyte chemoattractant protein-1 
M-CSF     macrophage colony-stimulating factor  
MI     myocardial infarction 
MIP     macrophage inflammatory protein 
MMP     matrix metalloprotease 
MR     mineralocorticoid receptor 
 xi 
 
MRI     magnetic resonance imaging  
NAD     nicotinamide adenine dinucleotide 
NADPH    nicotinamide adenine dinucleotide phosphate 
NF-κB     nuclear factor-κB 
NK     natural killer cells 
PAS     Periodic Acid Schiff reaction 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PDGF     platelet-derived growth factor 
PDGFR    platelet derived growth factor receptor 
PECAM-1    platelet-endothelial cell adhesion molecule-1  
PIER     proteolytic-induced antigen retrieval 
PMN     polymorphonuclear cells 
PSR     Picrosirius Red 
PWD     posterior wall thickness at diastole 
PWS     posterior wall thickness at systole 
qRT PCR    quantative real time polymerase chain reaction 
RALES    Randomised ALdactone Evaluation Study 
RANTES  regulation on activation, normal T cell expressed 
and secreted  
ROS     reactive oxygen species 
RV     right ventricle 
SAME     syndrome of apparent mineralocorticoid excess 
 xii 
 
SDF-1α    stromal cell-derived factor-1α 
SCF     stem cell factor 
SEM     standard error of the mean 
SPA     scintillation proximity assay 
TBS     tris buffered saline 
TGF-β     transforming growth factor-β 
TIMPS    tissue inhibitors of matrix metalloproteases 
TLR     toll-like receptor 
TNF-α     tumour necrosis factor-α  
TSP-1     thrombospondin-1  
TTC     triphenyltetrazolium chloride 
u-PA     urokinase-plasminogen activator 
VCAM-1    vascular cell adhesion molecule-1 
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1.1 Cardiovascular disease in the UK 
Cardiovascular disease (CVD) is responsible for 198,000 deaths per year in the United 
Kingdom alone and is a major cause of premature death (British Heart Foundation, 
2008). The term CVD encompasses myocardial infarction (MI), angina, stroke, transient 
ischaemic attack and coronary heart disease. The resultant cardiac damage from 
ischaemic heart disease can result in the development of heart failure, an illness in which 
the cardiac output is insufficient for the body‟s needs. The Hillingdon Heart Study 
estimates that 140 men per 100,000 in the UK have heart failure, with MI being the most 
common cause (Cowie et al., 1999).  
Myocardial infarct size is an important determinant of outcome post MI and its 
limitation can be achieved by conditioning, reperfusion and revascularisation therapies 
(Ishii et al., 2008, Ferdinandy et al., 2007). Pre-conditioning (brief ischaemic events just 
prior to MI) reduces infarct size and subsequent remodelling in MI patients (Nakagawa 
et al., 1995). Additionally brief bouts of ischaemia in the moments succeeding 
reperfusion (restoration of blood flow to the ischaemic myocardium) has also been 
shown to be beneficial in the clinic (Staat et al., 2005). The advent of reperfusion 
therapy in the 1980‟s has resulted in an increase in post-infarct survival (Ferdinandy et 
al., 2007). However, this was also accompanied by an increase in the number of patients 
developing heart failure; improved survival may have increased the pool of people at 
risk of developing heart failure (Velagaleti et al., 2008). Furthermore, reperfusion 
therapy has the potential to cause irreversible tissue injury depending on the duration of 
ischaemia (Ferdinandy et al., 2007). Current therapeutics aimed at reducing post-infarct 
remodelling after reperfusion include β-blockers, diuretics, ACE inhibitors and more 
recently mineralocorticoid receptor antagonists, but despite these interventions the 
prognosis is still poor (van der Horst et al., 2007). There is plentiful evidence to suggest 
that enhancement of angiogenesis on the infarct border can improve heart function and 
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prevent the progression to heart failure (Jujo et al., 2008, Meyer et al., 2006, Yau et al., 
2005) . The work described in this thesis will address the possibility that manipulation of 
post-infarct angiogenesis by glucocorticoids generated in the myocardium may provide a 
new therapeutic option.  
 
1.2 Myocardial infarction 
1.2.1 Cell death 
MI occurs predominantly as a result of occlusion of a coronary vessel by a thrombus, a 
consequence of atherosclerotic plaque rupture. The reduction of local oxygen supply 
prevents aerobic respiration in the cardiac cell resulting in death. Cardiomyocytes are 
susceptible to 3 types of cell death: necrosis, apoptosis and autophagy, with the level of 
energy depletion determining the form of death (Mani, 2008). Necrotic cell death is 
observed in the infarct core where conditions are anoxic. It relies on intrinsic signalling 
by DNA damage and extrinsic signalling via death receptors (Mani, 2008). Necrosis is a 
result of mitochondrial dysfunction typified by energy depletion, Ca
2+
 accumulation and 
an increase in reactive oxygen species (ROS), and is mediated by cathepsin activation 
(Syntichaki et al., 2002, Holler et al., 2000).  This form of cell death is characterised by 
loss of membrane integrity and spillage of cellular contents which can evoke a powerful 
inflammatory response (Schweichel and Merker, 1973). Apoptosis, on the other hand, is 
found in the infarct border where oxygen is present in low concentrations, and in the 
remote regions of the heart that are under haemodynamic and humoural stress (Mani, 
2008, Olivetti et al., 1996, Scarabelli et al., 2001). Like necrosis, it is mediated by 
intrinsic (via the mitochondrial pathway) and extrinsic (via death receptor) signalling. 
These stimuli are integrated by the caspase proteolytic enzymes that cleave intracellular 
proteins and result in morphological changes (Thornberry and Lazebnik, 1998). 
Apoptosis is characterised by chromatin condensation and bulges in the cellular 
membrane, known as blebbing (Potts et al., 2005, Klionsky and Emr, 2000). The role of 
cell autophagy after MI is uncertain but is linked to apoptosis. Recycling of nutrients 
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from old organelles can ensure cell viability in stress states and is, thus, protective 
(Klionsky and Emr, 2000). However, it may also provide ATP which is necessary in 
apoptotic death (Mani, 2008). Insufficient knowledge about necrosis and autophagy 
means that they are not yet targeted therapeutically. On the other hand, inhibitors of the 
apoptosis cascade, by targeting Bax and the caspases, reduce infarct size in experimental 
models and have been associated with preservation of cardiac function indicating that 
preventing early cell death may be beneficial (Hochhauser et al., 2003, Yaoita et al., 
1998). The therapeutic implications of long term inhibition of apoptosis are yet to be 
determined but there is cause for concern as apoptosis does have a homeostatic role 
(Mani, 2008). 
 
1.3 Post-infarct inflammation 
1.3.1 Trigger for inflammation 
Necrosis is a powerful trigger for the inflammatory response. Release of DNA and RNA 
from necrotic cells can activate toll-like receptors (TLR) (Elkon, 2007, Chen et al., 
2007). Subsequent induction of interleukin-1β (IL-1β), keratinocyte chemoattractant 
(KC/IL-8) and macrophage inflammatory protein-2 (MIP-2) can attract neutrophils to 
the site of necrosis (Frangogiannis et al., 2002) . The pathological role of TLR activation 
in infarct healing has been demonstrated by reduced fibrosis and improved cardiac 
function in TLR2 knock-out mice relative to controls (Shishido et al., 2003).  Necrosis 
also results in exposure of mitochondrial proteins, such as cardiolipin, which can trigger 
the complement (C) cascade (Sumitra et al., 2005, Rossen et al., 1994). This cascade 
consists of serine proteases that activate each other sequentially in the hours following 
MI. These proteins are associated with destruction of the cardiac architecture, 
accounting for a significant proportion of ischaemic injury (Rossen et al., 1994, Sumitra 
et al., 2005). 
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ROS, such as hydrogen peroxide, superoxide radicals, hydroxyl radicals and 
peroxynitrite are another trigger for the inflammatory response (Dhalla et al., 2000, 
Levonen et al., 2008). They are a vital part of normal cell signalling but excessive 
production post-MI can overwhelm endogenous antioxidants leading to cell injury 
(Levonen et al., 2008, Kevin et al., 2005). NADPH oxidase is a source of superoxide and 
its expression increases after MI (Zhao et al., 2009). However, deficiency of NADPH 
oxidase does not prevent post-infarct oxidative stress due to compensatory superoxide 
producers (Zhao et al., 2009). Other sources of oxidative stress include xanthine oxidase, 
uncoupled endothelial nitric oxide synthase (eNOS) and mitochondrial dysfunction 
(Levonen et al., 2008).  ROS themselves can cause necrosis by damage of the cell 
membrane via lipid peroxidation and can enhance apoptosis. Furthermore they have a 
role in activating TLR and causing vascular dysfunction and cardiac arrhythmias (Kevin 
et al., 2005, Shishido et al., 2003). Chronic elevation of ROS in the myocardium can aid 
in the progression to heart failure (Dhalla et al., 1996). Antioxidant therapy can prevent 
the adverse effects of oxidative stress; however such therapy has to be highly directed so 
not to affect normal cell signalling (Levonen et al., 2008, Dhalla et al., 2000). 
 
1.3.2 Cytokine and chemokine upregulation 
Cytokines are small (less than 30kDa in size), soluble proteins that regulate cell function 
and are regulated themselves by nuclear factor-κB (NF-κB) (Borish and Steinke, 2003). 
NF-κB is normally found in the cytoplasm in a complex with inhibitor-κB (IκB). ROS, 
IL-1β and tumour necrosis factor α (TNFα) activate pathways that converge on Iκ kinase 
enabling its phosphorylation and subsequent degradation of IκB (Stancovski and 
Baltimore, 1997).  NF-κB is then able to translocate to the nucleus where it can regulate 
genes involved in inflammation, cell proliferation and survival (Lenardo and Baltimore, 
1989).  Preventing activation of NF-κB by targeted deletion of the NF-κB subunit p50 
reduces inflammatory cell infiltration to the myocardium 24 hours after ischaemia 
reperfusion injury demonstrating its vital role in inflammatory cell recruitment (Frantz et 
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al., 2007). Mast cell degranulation has also been implicated in the initiation of the post-
infarct cytokine cascade (Frangogiannis et al., 2002, Dewald et al., 2004).  
Upregulation of inflammatory cytokines occurs within hours of MI and declines over 
several days  (Nian et al., 2004). Persistent cytokine activation can be damaging to the 
myocardium (Nian et al., 2004). Cytokines mediate their actions by dimerisation of 
tyrosine kinase receptors producing intracellular signalling cascades (Borish and 
Steinke, 2003). They can induce myocyte expression of integrins and alter the 
endothelial cell phenotype to an inflammatory or angiogenic one (Nian et al., 2004). 
Anti-cytokine therapy has had limited success in the treatment of heart failure. 
Etanercept, a TNFα inhibitor, lowers plasma TNFα but has no beneficial effect on 
mortality or rate of hospitalisation (Mann et al., 2004). 
Chemokines are small (8-14kDa) chemoattractants that contain 2-4 conserved cysteine 
residues, the bonding of which determines their 3 dimensional structure and, therefore, 
their actions (Borish and Steinke, 2003, Frangogiannis and Entman, 2005). The two 
main classes of chemokine are the CXC family, including IL-8 and IP-10 (CXCL10), 
and the CC chemokines, such as monocyte chemoattractant protein-1 (MCP-1) and MIP-
1β (Frangogiannis and Entman, 2005). Their effects are mediated by G protein coupled 
receptors (GPCRs) and they have roles in inflammation, wound healing and homeostasis 
(Borish and Steinke, 2003). Their principal targets are bone marrow derived cells. Like 
cytokines, chemokines can be upregulated by ROS, complement activation and NF-κB 
activation and this upregulation is rapid and transient (Frangogiannis and Entman, 2005, 
Lakshminarayanan et al., 2001). Chemokine inhibitors impair recruitment of 
monocytes/macrophages, T cells and B cells to inflamed sites and are under 
development for the treatment of atherosclerosis and autoimmune disorders (Reckless et 





1.3.3 Neutrophil infiltration 
Neutrophils are polymorphonuclear cells that mediate the early inflammatory response 
to injury (see Figure 1.1). They destroy and remove pathogens along with cell debris 
(Frangogiannis et al., 2002). In the absence of inflammation neutrophils circulate in the 
blood without interacting with the vessel wall (Frangogiannis et al., 2002). Inflammatory 
stimuli, such as IL-6, IL-8 and TNF-α prime neutrophils and the endothelium for 
translocation into the injured tissue (Jordan et al., 1999, van Es and Devreotes, 1999, 
Sekido et al., 1993, Kukielka et al., 1995b).  An inflammatory environment promotes 
expression of the adhesion molecules; P-selectin and intercellular adhesion molecule-1 
(ICAM-1); on endothelial cells, which can interact with the L-selectin and β2-integrins 
constitutively expressed on neutrophils (Kukielka et al., 1995b, Frangogiannis et al., 
2002, Jordan et al., 1999). The selectin adhesion molecules mediate the initial contact as 
the neutrophils roll along the endothelium and migrate towards chemoattractants. Firm 
adherence is mediated by ICAM-1 and β2-integrins (Kukielka et al., 1995b, Jordan et al., 
1999, Frangogiannis et al., 2002). Adherence of neutrophils to the endothelium alone is 
sufficient to induce damage and can cause vasoconstriction (Ma et al., 1991). Platelet-
endothelial cell adhesion molecule-1 (PECAM-1) is expressed on endothelial cells and is 
reported to be involved in neutrophil translocation through the endothelial cell layer, the 
subendothelial matrix and on to the site of inflammation (Muller et al., 1993, Thompson 
et al., 2001). Additionally, local stimuli, such as IL-8 can induce the metamorphosis of 
these neutrophils which can block blood vessels, (Thelen et al., 1988).  The „no-reflow‟ 
phenomenon in reperfusion injury may be mediated by accumulation of neutrophils and 





Figure 1-1 Infiltration of neutrophils into the heart after myocardial infarction 
Adhesion molecules such as B-selectin and intercellular adhesion molecule-1 (ICAM-1) are 
upregulated in response to inflammatory stimuli. They bind to the L-selectin and β2 integrins 
constitutively expressed on neutrophils, aiding neutrophil rolling and tethering to the vascular 
endothelium. Subsequently neutrophils transmigrate into the heart with the additional help of 
platelet cell adhesion molecule-1 (PECAM-1), otherwise known as CD31. Neutrophils are 
attracted to the site of injury, migrating towards gradients of cytokines and chemokines such as 
IL-6 (interleukin-6), IL-8, TNFα (tumour necrosis factor α), MCP-1 (monocyte chemoattractant 
protein-1) and RANTES (regulation on activation, normal T cell expressed and secreted).  At the 
infarct, neutrophils propagate the inflammatory response by degranulation (releasing proteases 
and inflammatory mediators) and release of reactive oxygen species during the respiratory burst. 
Lastly neutrophils undergo apoptosis, providing a stimulus for macrophage infiltration. Figure 




Increased expression of IL-6 and IL-8 in the hours after MI attracts neutrophils to the 
infarct (Frangogiannis et al., 2002, Kukielka et al., 1995b, Kukielka et al., 1995a, 
Rollins, 1997, Ivey et al., 1995). Such neutrophil attractants can be secreted from 
mononuclear phagocytes, endothelial cells, T cells, fibroblasts, myocytes and 
neutrophils themselves (Borish and Steinke, 2003). Neutrophils infiltration into the 
myocardium peaks 24-48 hours after MI, in murine and canine models, and declines 
rapidly, with very few neutrophils being present at 7 days (Tao et al., 2004, Dewald et 
al., 2004). Genetic ablation of IL-6 shows its importance in neutrophil recruitment and 
wound healing (Gallucci et al., 2000, Cuzzocrea et al., 1999). IL-8 is not expressed in 
mice but its homologue has been identified to be keratinocyte chemoattractant (KC). For 
the purposes of this thesis the homologue will be referred to as IL-8 (Frangogiannis and 
Entman, 2005). Reduction in IL-8 expression or blockade of CXCR2 (the receptor for 
IL-8) results in reduced neutrophil recruitment post-MI and in other ischaemic injuries 
demonstrating its importance in recruiting neutrophils (Kilgore et al., 1998, Kukielka et 
al., 1995a, Coelho et al., 2008, Sekido et al., 1993). The role of IL-8 extends beyond that 
of attracting neutrophils to the site of injury. This chemokine has also been shown to 
induce neutrophil shape change, making them less deformable, and stimulating their 
inflammatory functions (Frangogiannis, 2004, Thelen et al., 1988).  
Once in the tissue neutrophils degranulate releasing damaging proteases, arachidonic 
acid metabolites (such as leukotriene B4 which is itself a neutrophil chemoattractant), 
and other inflammatory mediators (Jordan et al., 1999). Neutrophils are also able to 
phagocytose particles and undergo a „respiratory burst‟ mediated by NADPH oxidase 
activity.  Free radical production from this process can cause further tissue damage and 
propagate the inflammatory response (Rossi, 1986). The vascular endothelium is 
particularly sensitive to free radicals, which can increase adhesion molecule expression 
by endothelial cells and vascular permeability (Deisher et al., 1993, Svendsen and 
Bjerrum, 1992). Neutrophils themselves also die in the infarct and provide a stimulus for 
monocyte infiltration (Savill et al., 1989a, Savill et al., 1989b). Overall the action of 
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neutrophils amplifies the inflammatory response and provides a stimulus for other 
inflammatory cell infiltration.  
Neutrophils can enhance cell death and, in the clinic, high circulating IL-6 and 
neutrophil levels are associated with increased mortality (Kin et al., 2006, Jaremo and 
Nilsson, 2008). In a murine model of MI, depletion of neutrophils using an anti-PMN 
antibody results in reduced apoptosis potentially by reduced NF-ĸB signalling (Kin et 
al., 2006). It is likely that the ability of neutrophils to enhance cell death is related to 
their ability to produce free radicals, as discussed above (Kin et al., 2006). However, 
neutrophils also provide a vital stimulus for subsequent wound healing which is required 
to stabilise the healing infarct. Depletion of neutrophils (prior to and continued after 
injury) results in impairment of necrotic cell removal in mice 7 days post-MI (Heymans 
et al., 1999).  
 
1.3.4 Macrophage infiltration 
Monocytes are derived from bone marrow myeloid progenitor cells that have the 
potential to give rise to a variety of inflammatory cells. Under basal conditions 
monocytes are released into the blood where they remain or they enter the tissue and 
mature to become long-lived, tissue specific macrophages, such as Kupffer cells in the 
liver and osteoclasts in the bone (Mosser and Edwards, 2008). Monocytes patrol the 
vessel wall relying on β2-integrin and CX3CR1-fractalkine-mediated adhesion (Auffray 
et al., 2007). They can extravasate within an hour in response to relevant inflammatory 
stimuli which are released from resident tissue cells, such as myocytes and endothelial 
cells, or from other inflammatory cells, such as neutrophils (see Figure 1.2) (Auffray et 
al., 2007, Lambert et al., 2008).  
Monocytes are recruited by chemoattraction to MCP-1 and MIP-1α, -1β and 2, with 
MCP-1 being the most potent (Frangogiannis et al., 2002, Kakio et al., 2000). MCP-1 is 
localised to the microvascular endothelium, binds to CCR2 and can also attract natural 
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killer (NK) cells and T cells (Lakshminarayanan et al., 2001). These factors increase 
within hours after MI; subsequent macrophage infiltration starts from 2 days after MI, 
peaks between 4 and 7 days, after which it declines (Dewald et al., 2004, Tao et al., 
2004). MCP-1 is involved in several diseases that have monocyte rich infiltrates, such as 
atherosclerosis and rheumatoid arthritis (Nelken et al., 1991, Koch et al., 1992). While 
continuous cardiomyocyte specific over-expression of MCP-1 leads to heart failure and 
premature death which is mediated by enhanced apoptosis (Zhou et al., 2006), transient 
over-expression in a murine model of MI is beneficial and is associated with enhanced 
macrophage infiltration and reduced scar size (Morimoto et al., 2006).  
Monocyte adherence to the extracellular matrix of the infarct can encourage further 
cytokine upregulation (Sunderkotter et al., 1994). Monocytes differentiate into 
macrophages, stimulated by macrophage colony-stimulating factor (M-CSF) and 
caspases, proteolytic enzymes involved in the apoptosis cascade (Figure 1.2, 
Frangogiannis et al., 2002). The beneficial role of this process in infarct healing has been 
indicated by the demonstration that intra-peritoneal injection of M-CSF leads to 
enhanced macrophage infiltration, improved left ventricular function and infarct repair 
in a rat model of MI (Yano et al., 2006b). Macrophages can secrete additional MCP-1, 
amplifying the inflammatory response (Morimoto et al., 2006, MacKinnon et al., 2008, 
Kakio et al., 2000, Frangogiannis et al., 1998, Cathelin et al., 2006). Furthermore, over 
150 secretory proteins have been identified from macrophage cultures including IL-1α, 
IL-1β, IL-6, TNFα, MIP-1α, MIP-1β, MIP-2α, MIP-2β, MCP-1, IL-8, thrombospondin-1 
(TSP-1), platelet derived growth factor (PDGF), proteases, matrix metalloproteases 
(MMPs), M-CSF, basic fibroblast growth factor (bFGF), vascular endothelial growth 
factor (VEGF), transforming growth factor (TGF) α and β, and urokinase-plasminogen 
activator (u-PA) (Lambert et al., 2008, Sunderkotter et al., 1994). This underlines the 
pivotal role of macrophages in the inflammatory response. The roles of macrophages in 
myocardial infarct healing include phagocytosis to remove cell debris, stimulation of 
angiogenesis and scar formation. Depletion of macrophages, using an anti-macrophage 
serum, has demonstrated that they are a vital part of wound healing (Cohen et al., 1987).  
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Detection of necrotic cell debris in the ischaemic core can produce a dramatic change in 
macrophage physiology, including enhancing cytokine production (Mosser and 
Edwards, 2008). On the other hand, phagocytosis of apoptotic cells increases secretion 
of TGF-β which can mediate a decrease in macrophage secretion of a range of pro-
inflammatory cytokines including, IL-1β, IL-8 and TNFα  (Fadok et al., 1998). This 





Figure 1-2 Macrophage action post-MI 
Interaction of monocytes with the vessel wall is mediated by β2 integrins and CX3CR1-
fractalkine-mediated adhesion. They transmigrate into the infarct in response to inflammatory 
stimuli. Macrophage colony-stimulating factor (M-CSF), the complement cascade and toll like 
receptors (TLRs) stimulate the differentiation of monocytes to macrophages in the tissue 
subsequently enabling their migration towards chemotactic stimuli (monocyte chemoattractant 
protein-1 (MCP-1) and macrophage inflammatory proteins (MIP)).The local environment can 
prime macrophages to become M1 (classically-activated macrophages) or M2 (alternatively-
activated macrophages). Tumour necrosis factor α (TNFα) and interferon γ (IFNγ) encourage the 
M1; CCR2+, CXCR1lo, Ly6Chi, CD11clo phenotype while interleukin-4 (IL-4) encourages the 
M2; CCR2-, CXCR1hi, Ly6Clo, CD11chi phenotype. Typical M1 behaviour includes 
phagocytosis, secretion of inflammatory mediators such as IL-1β, IL-6, IL-23 and free radicals 
along with matrix metalloprotease-9 (MMP-9). M2 macrophages secrete pro-angiogenic and pro-
resolution factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF), IL-10, transforming growth factor β (TGFβ) and IL-8.  By secreting such factors 
alternatively-activated macrophages stimulate angiogenesis and wound healing. Figure adapted 
from Lambert et al., 2008 and Mosser and Edwards, 2008  
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1.3.4.1 Macrophage subtypes 
As indicated (above), monocytes and macrophages can be subdivided into regulatory, 
classically-activated (M1) and alternatively-activated (M2) categories (see Figure 1.2). 
However it has recently been acknowledged that instead of each subtype being distinct 
from one another, their activation state should be considered more of a continuous 
„spectrum‟ of phenotypes and that their phenotype can change (Mosser and Edwards, 
2008)..  
Circulating monocytes are a relatively heterogeneous population; however Sunderkötter 
et al have demonstrated that monocytes that have been recently liberated from the bone 
marrow initially have an inflammatory ly6C
hi 
phenotype (Sunderkötter et al., 2004). 
Under steady state conditions these monocytes downregulate ly6C (a 
monocyte/macrophage and endothelial cell differentiation antigen) as they mature. 
These monocytes have a high proliferative capacity and migrate into tissue when there is 
peripheral inflammation (Sunderkotter et al., 2004). Activation of such monocytes by 
TNF and interferon-γ (IFNγ) produces classically-activated macrophages that are 









 (Nahrendorf et al., 2007, Sunderkotter et al., 2004). CCR2 is 
the receptor for MCP-1 and, therefore, these macrophages migrate along its gradient 
(Sunderkotter et al., 2004, Sunderkotter et al., 1994). These classically-activated 
macrophages are primed to secrete pro-inflammatory cytokines, such as IL-1, IL-6 and 
IL-23, and produce free radicals amplifying the inflammatory response (Sunderkotter et 
al., 2004). Excessive production of these cytokines by macrophages may lead to 
autoimmune responses and are, therefore, damaging rather than protective (Sunderkotter 
et al., 2004). In post-infarct healing classically-activated macrophages phagocytose cell 
debris enabling granulation and scar tissue formation and, thus, stabilising the infarct 
(Nahrendorf et al., 2007, van Amerongen et al., 2007). M1 macrophages can activate 
MMP-9 thus favouring degradation of the ECM (Nahrendorf et al., 2007).  
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The role of alternatively-activated macrophages (M2) is to inhibit inflammation (by 
secretion of the anti-inflammatory cytokines TGF-β and IL-10), aid in wound healing 
and to stimulate angiogenesis (Lambert et al., 2008, Mosser and Edwards, 2008, 
Nahrendorf et al., 2007, van Amerongen et al., 2007). M2 activation is dependent on IL-
4, which can be secreted by mast cells and neutrophils (Loke et al., 2002, Brandt et al., 
2000). M2 macrophages have a gene expression profile that is distinct from other 
macrophage types. Nematode infections stimulate a typical M2 response and lead to the 
upregulation of FIZZ1 (RELMα), YM1 and arginase 1 in the macrophages (Nair et al., 
2006, Kreider et al., 2007). FIZZ1 is a resistin-like molecule that can antagonise insulin 
action. The chitinase like activity of YM1 can aid in matrix reorganisation and wound 
healing, and arginase activity enables production precursors of collagen, contributing to 
the extracellular matrix and scar formation (Loke et al., 2002, Lambert et al., 2008, Nair 
et al., 2005, Kreider et al., 2007).  
Macrophage infiltration and angiogenesis are positively correlated in several injury and 
disease models, including stroke and cancer (Manoonkitiwongsa et al., 2001, Banciu et 
al., 2008). The role of alternatively-activated macrophages in angiogenesis involves their 
ability to secrete angiogenic cytokines such as IL-8 (which can also act in an 
inflammatory capacity as mentioned previously), VEGF and bFGF. Macrophages must 
be activated in order to stimulate angiogenesis as it enables them to secrete angiogenic 
cytokines (Polverini et al., 1977, Leor et al., 2006). Activated, but not unstimulated, 
macrophages can stimulate neovascularisation in corneal explant assays (Polverini et al., 
1977). Additionally, intra-cardiac injection of human, activated macrophages after 
coronary artery occlusion in rats enhances vessel density, relative to control, after 5 
weeks‟ recovery (Leor et al., 2006). In vitro IL-8 can enhance endothelial cell 
proliferation and capillary formation, and also increase the expression of MMP-2, MMP-
9 and anti-apoptotic genes (Li et al., 2003). Furthermore, in vivo IL-8 can enhance 
recruitment of bone marrow derived cells to the ischaemic myocardium and contributes 
to neovascularisation (Kocher et al., 2006). Both bFGF and VEGF can stimulate 
endothelial cell migration, proliferation and capillary tube sprouting (reviewed in 
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Sunderkotter et al., 1994). Over-expression of MCP-1 also results in augmentation of 
capillary density and preserves heart function (Morimoto et al., 2006). Macrophages are 
also a source of factors that enhance angiogenesis indirectly, such a prostaglandins and 
angiotensin-converting enzyme (ACE).  Paradoxically they also secrete angiostatic 
factors such as TSP1 and IFNγ (Sunderkotter et al., 1994).  
 
1.3.4.2 Macrophage subtype in injury and disease 
Both M1 and M2 macrophages have been implicated in a variety of diseases including 
atherosclerosis, cancer and diabetes (Galkina and Ley, 2009, Mosser and Edwards, 
2008, Lambert et al., 2008, Martin-Fuentes et al., 2007). An M1 macrophage phenotype 
may aid in the progression of atherosclerosis, whereas encouraging M2 activation may 
improve plaque stability (Martin-Fuentes et al., 2007, Mosser and Edwards, 2008). 
Classically-activated macrophages are implicated in cancer initiation with a switch to 
alternatively-activated macrophages aiding in tumour progression and angiogenesis 
(Sica et al., 2006). Moreover, in a murine model of liver fibrosis M2 macrophages were 
shown to have a dual role in injury and repair. Conditional ablation of M2 monocytes 
during liver injury reduces fibrosis, indicating that M2 macrophages are harmful. 
However, depletion during the recovery phase prevents resolution of fibrosis, suggesting 
they have an important role in healing (Duffield et al., 2005).  





 monocytes infiltrate the myocardial infarct maximally by 3 days, after 
which they decline (Nahrendorf et al., 2007). This peak was associated with enhanced 
MCP-1 expression. Genetic deletion of the receptor for MCP-1 (CCR2) resulted in 
reduced recruitment of M1 macrophages early in myocardial infarct healing (Nahrendorf 
et al., 2007). This was, in part, due to decreased liberation of ly6C
hi
 monocytes from the 




) monocytes peaks between 5 and 7 
days post-MI and is associated with increased VEGF expression and reduced protease 
activity (Nahrendorf et al., 2007). Genetic deletion of CX3CR2, the fractalkine receptor, 
 16 
 
impairs recruitment of ly6C
lo
 monocytes to the healing infarct at 5-7 days indicating that 
it has a vital role in recruiting this type of monocyte (Nahrendorf et al., 2007).   
The crucial role of both classically-activated and alternatively-activated macrophages 
during myocardial infarct healing has been demonstrated using selective depletion with 
clodronate. Depletion of classically-activated monocytes by administering clodronate 
immediately after MI increases cell debris and necrotic tissue area 7 days after MI 
(Nahrendorf et al., 2007). On the other hand, selective depletion of M2 macrophages 
from day 3 decreases the number of CD31-positive endothelial cells, α smooth muscle 
actin-positive smooth muscle cells and collagen deposition (Nahrendorf et al., 2007). 
Furthermore, in a cryo-injury model of left ventricular damage macrophage depletion 
increased 4 week mortality by 28% (van Amerongen et al., 2007). Surviving mice had a 
greater necrotic area, reduced neovascularisation and collagen deposition. This was 
associated with increased ventricular dilation and wall thinning (van Amerongen et al., 
2007) lending support for the requirement of an organised co-ordinated inflammatory 
response in infarct healing. The balance of M1 and M2 activation may determine the 
outcome of post-infarct healing.  
 
1.3.5 Resolution of inflammation 
The processes governing the resolution of inflammation are unclear. There is conflicting 
evidence regarding the effect of deficiency in IL-10, a cytokine reported to inhibit 




increases inflammation and necrosis in a murine model of MI (Yang et al., 2000) 
another has shown that it has a limited effect on inflammation in terms of abundance, 
timing and resolution (Zymek et al., 2007). The importance of inflammatory resolution 
has been shown where the anti-inflammatory and anti-angiogenic TSP-1 has been 
knocked out. Deficiency of TSP-1 post-MI elevates and extends inflammation and is 
associated with scar expansion and adverse remodelling (Frangogiannis et al., 2005).  
Additionally, excessive inflammation can lead to cardiac rupture (Nian et al., 2004). 
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TGF-β is secreted by macrophages and is reported to act as a „stop signal‟ for 
inflammation. Apoptotic neutrophils are phagocytosed by macrophages while there is 
speculation regarding the fate of the infiltrated macrophages. They may die locally, 
migrate out of the tissue or mature into resident macrophages or dendritic cells. 
 
1.4 Angiogenesis in MI 
Neovascularisation encompasses 3 processes that are vital both in embryo growth and in 
adulthood; vasculogenesis, angiogenesis and arteriogenesis (Carmeliet, 2000, Jain, 2003, 
Conway et al., 2001). Vasculogenesis, the production of blood vessels in discrete 
locations by differentiation of progenitor cells, is vital in generating vasculature during 
embryo development but is also possible in adulthood. The expansion of this primitive 
vasculature is mediated by sprouting of new vessels from existing ones and is known as 
angiogenesis. The term arteriogenesis encompasses maturation of pre-existing vessels or 
de novo growth of collateral vessels producing large muscular arteries (Jain, 2003, 
Conway et al., 2001). All three processes require well orchestrated expression of growth 
factors, adhesion molecules and modulators of the extracellular matrix. Lack of co-
ordination may produce abnormal, pathological vasculature (Jain, 2003). Angiogenesis 
has been observed in a variety of disease models, including cancer, haemangioma and 
retinopathy (Folkman and Shing, 1992, Hynes, 2002, Patan, 2000, Carmeliet and Jain, 
2000). Therefore inhibition of this process is an attractive therapeutic target. However, 
angiogenesis is also a vital part of wound healing and enhancing new vessel growth is 
also attractive after limb ischaemia and MI (Sasaki et al., 2007, Payne et al., 2007, Orlic 
et al., 2001, Law et al., 2004, Maulik and Thirunavukkarasu, 2008, Meyer et al., 2006, 
Cheng et al., 2007).  Angiogenesis is a complex event requiring co-ordinated signalling 
from the vessel wall and the extracellular matrix that results in increased vessel 
permeability, endothelial cell proliferation, migration, vessel stabilisation and eventually 





Figure 1-3 Angiogenesis 
The first step of angiogenesis involves the dilation and permeabilisation of a mother vessel. 
Nitric oxide mediates an increase in vessel diameter which is followed by degradation of the 
basement membrane by the matrix metalloproteases MMP-2 and MMP-9. Such degradation 
liberates matrix bound growth factors such as VEGF (vascular endothelial growth factor) and 
bFGF (basic fibroblast growth factor). The second step consists of endothelial cell proliferation 
and migration which is mediated by VEGF and PDGF (platelet derived growth factor) acting on 
their cognate endothelial cell receptors, VEGFR2 and CXCR2.  Integrin receptors, adhesion 
molecules (such as PECAM-1, platelet cell adhesion molecule) and Eph/ephrin receptor ligand 
pairs aid in endothelial cell migration towards sites of angiogenesis. The third step is vessel 
sprouting. In areas of extracellular matrix degradation endothelial cells sprout from capillaries, 
guided by VEGF and Ang2 (Angiopoietin 2). The loops formed by these sprouts will become the 
new vessels. Finally, the angiogenic vessel must be stabilised (step 4). Vessel pruning is 
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mediated by Ang2-induced endothelial cell apoptosis. Appropriate pruning, along with vessel 
maturation, promotes the formation of an organised vascular network. VEGF and Ang1 promote 
endothelial cell survival. Additionally the interaction of Ang1 with the Tie2 receptor tightens cell 
to cell junctions making the vessels leak resistant. PDGF is secreted by endothelial cells and 
recruits smooth muscle cells and pericytes to the vessel wall via interactions with its receptor, 




1.4.1 Stimulation of angiogenesis  
Angiogenesis is mediated by the upregulation of angiogenic factors and modulators of 
the extracellular matrix, along with down-regulation of anti-angiogenic factors. These 
changes can be stimulated by ischaemia (Conway et al., 2001, Steinbrech et al., 2000, 
Shohet and Garcia, 2007). Under hypoxic conditions reduced degradation of hypoxia 
inducible factor-1α (HIF-1α) enables it to translocate to the nucleus where it can up-
regulate its target genes which encode factors involved in angiogenesis, such as VEGF, 
angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and PDGF (Kido et al., 2005, Bates and 
Harper, 2002, Steinbrech et al., 2000). Knock out of HIF-1α impairs development of the 
vasculature whereas over-expression after MI increases vessel density whilst reducing 
infarct size (Kido et al., 2005, Shohet and Garcia, 2007). Hypoxia also leads to the 
upregulation of aminopeptidase-N (APN)/CD13, a marker of angiogenic vessels in vitro 
(Bhagwat et al., 2001). 
Ischaemia can trigger both angiogenesis and inflammation. It is, therefore, difficult to 
determine the contribution of direct (HIF-1α) and indirect (inflammation) effects of 
ischaemia on post-MI angiogenesis.  As mentioned previously, macrophages are known 
to secrete a host of factors, including angiogenic cytokines such as MCP-1, VEGF and 
PDGF (Kayisli et al., 2002, Lambert et al., 2008, Sunderkotter et al., 1994). A non-
inflammatory model of angiogenesis of the cornea, in immuno-deficient mice, 
demonstrates the efficiency of VEGF and FGF as angiogenic agents in the absence of 
inflammation (Kenyon et al., 1996). However, chemokines such as IL-8 can act in both 
an inflammatory manner, recruiting neutrophils to sites of inflammation, and in an 
angiogenic manner, by stimulating endothelial cell chemotaxis and proliferation (Sekido 
et al., 1993, Thelen et al., 1988, Kayisli et al., 2002). Attempts have been made to 
dissect out the contribution of inflammation to angiogenesis using a variety of 
intervention studies.  Depletion of neutrophils early in tumour development reduces 
angiogenesis and tumour growth (Nozawa et al., 2006). Macrophage depletion, with 
clodronate reduces angiogenesis after MI and in aortic ring explants (Fraccarollo et al., 
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2008, Nahrendorf et al., 2007, van Amerongen et al., 2007, Gelati et al., 2008). In 
addition, in a tumour model, depletion of macrophages can reduce angiogenic cytokine 
production and tumour size (Banciu et al., 2008). Additionally, as discussed above,  
polarisation of macrophages to the M2 resolution phenotype may also promote 
angiogenesis (Mosser and Edwards, 2008).  
 
1.4.2 Dilation and permeability 
The constituents of blood vessels can include endothelial cells, smooth muscle cells and 
pericytes (collectively known as mural cells) and an extracellular matrix/basement 
membrane which provides support (Jain, 2003). This organised structure needs to be 
permeablised to enable capillary growth. Initially, vascular nitric oxide dilates blood 
vessels and can increase VEGF expression (see Figure 1.3) (Patan, 2000, Jain, 2003, 
Carmeliet, 2000). Subsequent redistribution of endothelial cell adhesion molecules, 
along with degradation of the basement membrane and extracellular matrix by MMP-2 
and MMP-9, increases vessel permeability (Patan, 2000, Jain, 2003, Haas et al., 2000).  
The composition of the extracellular matrix can modulate endothelial cell shape, thus 
influencing their response to growth factors (Sottile, 2004).  MMPs liberate matrix 
bound growth factors, such as VEGF and bFGF but also release angiostatic molecules 
such as angiostatin and tumstatin (Haas et al., 2000). However, MMPs are generally 
considered to be pro-angiogenic and the angiostatic factor TSP-1 is thought to reduce 
angiogenesis through inhibition of MMPs (Conway et al., 2001). The dilated and 
permeable nature of these nacscent vessels enables plasma protein leakage and 






1.4.3 Endothelial cell proliferation, migration and vessel sprouting 
Several factors, such as those from the VEGF and FGF families along with IL-8 and 
TNF-α, are involved in enhancing endothelial cell proliferation and it is likely that there 
is some redundancy (Risau, 1997, Maulik and Thirunavukkarasu, 2008, Virag and 
Murry, 2003). VEGF acts on the VEGF receptor 2 on endothelial cells promoting 
endothelial cell proliferation, migration and tube formation (see Figure 1.3) (Maulik and 
Thirunavukkarasu, 2008, Gu et al., 1999, Nahrendorf et al., 2007). Blockade of CXCR2, 
the receptor for IL-8 prevents vessel sprouting in aortic rings highlighting its role in 
angiogenesis (Gelati et al., 2008). Such factors, produced by endothelial cells and 
inflammatory cells, may also stimulate the proliferation of smooth muscle cells 
(Folkman and Shing, 1992). Endothelial cell migration requires matrix degradation by 
MMPs and u-PA (Haas et al., 2000, Cheng et al., 2007, Sunderkotter et al., 1994, 
Heymans et al., 1999, Sottile, 2004).  Depletion of MMP-2 reduces angiogenesis in vivo 
in a hindlimb ischaemia model and in vitro in aortic ring cultures (Cheng et al., 2007). 
Heymans et al. demonstrated that deficiency of u-PA in a murine model of MI reduced 
cardiac VEGF expression and angiogenesis and this could not be resolved fully by 
VEGF therapy (Heymans et al., 1999). These studies demonstrate that angiogenesis 
requires more than just growth factors (Heymans et al., 1999, Greenberg et al., 2008). 
Migration of endothelial cells is mediated by the integrin receptors (αvβ3 and α5β1), 
adhesion molecules (PECAM-1), and Eph/ephrin receptor ligand pairs (Jain, 2003). The 
role of integrins in angiogenesis is somewhat controversial as knockout mice and 
antagonists directed against integrins do not necessarily have reduced angiogenesis. 
Indeed, these manipulations have been associated with enhanced angiogenesis (reviewed 
in (Hynes, 2002). Gap junctions, such as VE-cadherin and connexins, link endothelial 
cells as they form the endothelial layer however, some appear to be more important than 
others (Jain, 2003, Stalmans et al., 2002).  Knockout of VE-cadherin and connexin 43 
are embryonically lethal whilst deficiency of connexion 40 results in impaired cardiac 
function (reviewed in Jain, 2003). In contrast, PECAM-1 (CD31) null mice develop 
normally suggesting that loss of action is compensated for by other adhesion molecules 
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during development (Solowiej et al., 2003). As expected, Solowiej et al. found that 
PECAM-1 knockout mice have reduced vessel density in sponge implants (Solowiej et 
al., 2003). Transfer of wild type bone marrow to these mice restores their angiogenic 
ability suggesting that bone marrow cells contribute to the neovascularisation (Solowiej 
et al., 2003). Similarly, mice deficient for aminopeptidase-N (otherwise known as 
CD13), another cell adhesion molecule, develop normally but have reduced 
angiogenesis in low oxygen-induced retinopathy and gelfoams embedded with growth 
factors (Rangel et al., 2007). 
Sprout formation from pre-existing capillaries in areas of matrix degradation is 
stimulated by cues provided by the extracellular matrix such as co-expression of Ang2 
and VEGF (Patan, 2000, Carmeliet, 2000, Conway et al., 2001). These sprouts form the 
loops and networks that will become the capillary bed. The lumen diameter is 
determined by various isoforms of VEGF and Ang1 (Patan, 2000, Carmeliet, 2000, 
Conway et al., 2001).  
 
1.4.4 Stabilisation and maturation 
The longevity of neovascularisation depends on the local balance of pro-angiogenic and 
anti-angiogenic factors (Patan, 2000, Carmeliet, 2000, Conway et al., 2001). While 
survival of the new vessel may be advantageous, vessel pruning is also important. 
Endothelial cell survival is vital for maintenance of these nascent vessels and is 
encouraged by VEGF acting on the VEGF receptor (Conway et al., 2001). The 
interaction of Ang1 with its receptor, Tie 2, stabilises vessels by tightening cell to cell 
junctions making them leak resistant (see Figure 1.3) (Thurston et al., 1999). 
Additionally, Ang1 promotes cell survival (Conway et al., 2001).  The factors that play a 
role in vessel regression, such as Ang2, eliminate excess vessels by endothelial cell 
apoptosis promoting an organised vessel network prior to addition of the stabilising 
mural cell coat (Conway et al., 2001, Patan, 2000, Maisonpierre et al., 1997). 
Interestingly, Ang 2, which also binds to Tie 2 receptors, has a dual role in angiogenesis. 
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In the presence of VEGF Ang 2 stimulates vessel sprouting. However, in its absence 
vessel regression is favoured via destabilisation (Jain, 2003).  
PDGF is secreted by endothelial cells and recruits smooth muscle cells and pericytes, 
expressing the PDGF receptor (PDGRβ) to the vessel wall (Greenberg et al., 2008). 
Lack of PDGF or its receptor is embryonically lethal, demonstrating its vital role in 
neovascularisation (Lindahl et al., 1997). Intriguingly, VEGF has been shown to be a 
negative regulator of PDGF-mediated pericyte recruitment in matrigel implantation 
models and in the chorioallantoic membrane of chick embryos (Greenberg et al., 2008). 
Such findings may explain why cancerous tumours, characterised by high VEGF levels, 
have leaky abnormal vasculature and why anti-VEGF therapy results in pericyte 
coverage and vessel normalisation in tumour models (Greenberg et al., 2008).  
Vessel plasticity declines as pericyte/smooth muscle coverage is gained. Therefore, 
superfluous vessel regression or, alternatively, further endothelial cell proliferation and 
migration may be prevented (Conway et al., 2001). Whilst vessel destabilisation of 
mature vessels may still occur (by removal of pericytes/smooth muscle cells) it is much 
less likely than in an immature vessel (Jain, 2003).  
There has been some debate regarding the origin of pericytes. It has been suggested that 
they may differentiate from mesenchymal stem cells (Bexell et al., 2009), mononuclear 
cells (Conway et al., 2001), epicardial cells (Dettman et al., 1998) or fibroblasts (Njauw 
et al., 2008). TGF-β initiates differentiation of these cells to pericytes (Bergers and 
Song, 2005). The receptor for TGF-β is endoglyn (CD105) which is expressed on 
endothelial cells. Homozygous deletion of endoglyn results in embryonic lethality due to 
impaired angiogenesis, whereas mice heterozygous for endoglyn have reduced 
angiogenesis and impaired cardiac function after MI (van Laake et al., 2006). Pericytes 
are commonly associated with vessel stability but they have many more diverse 
functions. Like smooth muscle cells, pericytes can alter vessel tone in response to 
vasoactive substances (Kutcher and Herman, 2009, Kawamura et al., 2004). Indeed 
pericytes can secrete vasoactive substances, growth factors and cytokines thus 
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influencing vascular function (Conway et al., 2001). They are found in high density at 
the blood-brain barrier where they form a tight boundary (Ramsauer et al., 2002, 
Thomas, 1999). Interestingly in this location pericytes can exhibit macrophage-like 
phagocytic behaviour (Thomas, 1999). Some have hypothesised that they could indeed 
be brain macrophage precursors (Bergers and Song, 2005, Thomas, 1999).  
 
1.4.5 Post-infarct angiogenesis 
Initially after MI the number of vessels across the left ventricle decreases due to loss of 
part of the myocardium (Grass et al., 2006). Additionally, angiostatic chemokines, such 
as interferon γ inducible protein (IP-10), are upregulated to prevent vessel formation 
before the wound is „debrided‟ (Frangogiannis et al., 2001, Grass et al., 2006). From 4 
days post-MI a capillary plexus is formed around the infarct (Ren et al., 2002). As 
infarct healing advances from the inflammatory phase to the proliferative phase there is 
an increase in endothelial cell proliferation and angiogenic cytokines  (Virag and Murry, 
2003). Subsequently, the infarct border vessel density is augmented by 7 days after MI 
(Ren et al., 2002, Grass et al., 2006, Lutgens et al., 1999, Virag and Murry, 2003). As 
the infarct scar matures the neovessels are pruned, a process that is normally complete 
by 4 weeks post-MI (Ren et al., 2002, Grass et al., 2006, Dewald et al., 2004). 
Interventions that result in increased vessel density on the infarct border also improve 
heart function (Kido et al., 2005, Kocher et al., 2001, Liu et al., 2007, Sasaki et al., 2007, 
Orlic et al., 2001, Nahrendorf et al., 2007, Engel et al., 2006). Enhancing perfusion here 
may prevent the infarct from spreading into the healthy myocardium by salvaging 
cardiomyocytes (Liu et al., 2007). While cardiac angiogenesis after MI is beneficial, 
angiogenesis in the absence of injury is deleterious and results in hypertrophy (Tirziu et 
al., 2007). In human infarcted hearts capillary density is negatively correlated with scar 
size and infarct-related artery stenosis showing that increased vessel density is 




1.4.6 Therapeutic angiogenesis 
Experimentally, use of only one growth factor to enhance angiogenesis leads to the 
production of aberrant, disorganised, leaky vasculature (Korpisalo et al., 2008, 
Greenberg et al., 2008). Angiogenesis in cancerous tumours is often a result of VEGF 
over-expression and the vessels produced are disorganised and leaky, characteristic of 
VEGF-induced neovascularisation (Murdoch et al., 2008). However, VEGF therapy has 
been shown to be beneficial. Animal models demonstrate that injection of VEGF into 
the myocardium of infarcted hearts can reduce infarct size, enhance angiogenesis and 
improve cardiac function (Ruixing et al., 2007, Yau et al., 2005). However, in a rabbit 
hindlimb model of ischaemia both VEGF and PDGF were required to improve perfusion 
(Korpisalo et al., 2008, Greenberg et al., 2008). PDGF which is required for pericyte 
priming, aiding in vessel maturation and reducing vessel leakage, can work 
synergistically with VEGF (Greenberg et al., 2008, Korpisalo et al., 2008). Additionally, 
injection of cells engineered to over-express VEGF with IGF-1 into a rodent heart after 
MI improves infarct healing better than VEGF alone (Yau et al., 2005). Several 
strategies may be employed to induce angiogenesis. These include delivery of growth 
factors (individually or in a cocktail) or perhaps more attractively delivery of 
transcription factors that induce expression of several angiogenic factors. The latter 
approach may be more likely to induce the full physiological angiogenic cascade (Jain, 
2003). Unfortunately, injection of growth factors has had limited success to date 
(Simons, 2005, Losordo et al., 1998, Ellis et al., 2006).  
There is increasing evidence that bone marrow-derived cells, including endothelial 
progenitor cells and mononuclear cells, mobilised after injury or injected into the 
myocardium or circulation after injury, may enhance neovascularisation (Orlic et al., 
2001, Kocher et al., 2001, Sesti et al., 2005, Kastrup et al., 2006, Sasaki et al., 2007, 
Simons, 2005, Fazel et al., 2006, Takahashi et al., 1999, Takahashi et al., 2006). Fazel et 
al. reported that c-kit+ cells found in the heart after MI originated from the bone marrow 
(Fazel et al., 2006). In the heart these cells contributed to angiogenesis by increasing 
VEGF and altering the ratio of angiopoietin 1 to angiopoietin 2 providing an 
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environment that favours angiogenesis (Fazel et al., 2006). There is also evidence that 
these c-kit cells are also resident in the myocardium (Beltrami et al., 2003). Whilst some 
studies report that these mobilised progenitors can incorporate into the healing heart 
post-infarction regenerating it (Orlic et al., 2001) others suggest that their beneficial 
actions are mediated by enhancing neovascularisation on the infarct border (Kocher et 
al., 2001). Daily injection of granulocyte colony-stimulating factor (G-CSF) or stem cell 
factor (SCF) which liberate bone marrow-derived cells, improves post-infarct heart 
function in rats independently of improved neovascularisation at 8 weeks. Thus the 
function of  bone marrow-derived cells in this context is not entirely clear (Sesti et al., 
2005). There is confusion in this field as there are also a number of experimental studies 
that report that such factors and cells have no effect on post-infarct healing (Maekawa et 
al., 2004, Terrovitis et al., 2004). A current hypothesis is that homing of progenitors to 
the heart may not contribute directly to cardiac healing by incorporation into the muscle 
or vasculature but act via a paracrine mechanism (Sesti et al., 2005, Takahashi et al., 
2006).  The BOOST clinical trial (BOne marrOw transfer to enhance ST-elevation 
infarct regeneration) attempted to determine the effect of intracoronary infusion of bone 
marrow cells (harvested from and given back to) on MI patients undergoing 
percutaneous coronary intervention with stent implantation. This resulted in a small, 
sustained improvement in ejection fraction, but not left ventricular systolic function, at 
18 month follow-up (Meyer et al., 2006). This is currently being followed up with 
BOOST 2 in which a more comprehensive assessment of the mechanism of early 
improved ejection fraction is being conducted. 
 
1.4.7 ‘Vascular mimicry’ 
It has been acknowledged that rapidly growing tumours are able to enhance perfusion 
independent of angiogenesis by a process called „vascular mimicry‟ (Maniotis et al., 
1999). “Tunnels” have been identified in the myocardium that do not express endothelial 
cell markers, but are positive for elastase. Some of these tunnels contained blood 
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components, such as erythrocytes, with others comprising of endothelial cell-like cells. 
It was hypothesised that this tunnel formation was mediated by macrophages (Moldovan 
et al., 2000, Bendeck, 2000). A similar phenomenon has also been described in the heart 
in cardiac specific MCP-1 overexpressing mice. This was associated with increased 
macrophage infiltration and the development of heart failure as the mice aged 
(Moldovan et al., 2000). However this phenomenon is not reported extensively in the 
literature during post-infarct healing. 
 
1.5 Fibroblasts in MI 
Fibroblasts are derived from mesenchymal cells, are found in close association with 
cardiomyocytes and between myocardial tissue layers and have a homeostatic role in 
maintaining the extracellular matrix (ECM) (Camelliti et al., 2005). They can respond to 
mechanical and biochemical stimuli leading to enhanced cell proliferation, production of 
extracellular matrix and growth factors (Camelliti et al., 2005). One of the components 
of the post-MI healing response involves the differentiation of quiescent fibroblasts to 
myofibroblasts, enabling fibrosis (see Figure 1.4). In the myocardium post-infarct 
myofibroblasts are derived from resident fibroblasts but in extra-cardiac sites fibrosis is 
reported to be mediated by bone marrow-derived fibroblasts (Yano et al., 2005, Forbes 
et al., 2004). Typical fibroblast markers include vimentin and Discoidin Domain 
Receptor 2, (Osborn et al., 1984, Camelliti et al., 2005). However, after differentiation 
they secrete α smooth muscle actin (Dewald et al., 2004, Virag and Murry, 2003). 
Transformation of fibroblasts can be mediated by reactive oxygen species and TGF-β, 
produced by macrophages (Desmouliere et al., 1993, Fadok et al., 1998, Cleutjens et al., 
1995). TGF-β mRNA expression is enhanced from 1 day post-MI and remains elevated 
for a further 6 days (Dewald et al., 2004). Myofibroblast activation follows this with it 
increasing from 3 days post-MI and remaining elevated until day 7, before declining 
(Dewald et al., 2004, Virag and Murry, 2003, Yang et al., 2002, Tao et al., 2004). In this 
activated state myofibroblasts proliferate and can secrete collagen, MMPs, tissue 
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inhibitors of matrix metalloproteases (TIMPS), TGF-β and TNFα  (Virag and Murry, 
2003, Squires et al., 2005). These proteases and cytokines can modulate the extracellular 
matrix and promote scar formation.  
 
 
Figure 1-4 Fibroblast activation after myocardial infarction 
The increase in cardiac reactive oxygen species (ROS) and transforming growth factor β (TGF 
β) as a result of MI mediates the transformation of fibroblasts to myofibroblasts. In this activated 
state fibroblasts proliferate and secrete factors such as matrix metalloproteases (MMPs), tumour 
necrosis factor α (TNFα), TGFβ, which acts in a positive feedback loop to further enhance 
fibroblast transformation, and tissue inhibitor of metalloproteases (TIMPs) which inhibit MMPs. 
Collagen secretion by myofibroblasts and matrix degradation by MMPs permits scar formation in 
the healing myocardial infarct. Negative feedback by collagen prevents excessive fibroblast-





1.6 The extracellular matrix in MI 
The dynamic, highly organised extracellular matrix provides structural and mechanical 
support to tissues along with interacting with cells to modulate their behaviour 
(Dobaczewski et al., 2009, Porter and Turner, 2009). The intense inflammatory response 
associated with MI results in disruption of this influential matrix. This enables 
inflammatory cell infiltration in the inflammatory phase and then infiltration of other 
cell types in the proliferative phase (Cleutjens et al., 1995, Sottile, 2004). Matrix 
degradation liberates matrix bound growth factors such as bFGF, aiding in promotion of 
angiogenesis (Sunderkotter et al., 1994). Within 3 hours of reperfusion, extravasation of 
plasma proteins, via increased vascular permeability, produces a temporary 
fibrin/fibrinogen matrix in the infarcted myocardium, providing support for proliferating 
and migrating cells (Dobaczewski et al., 2006). The basement membrane and 
extracellular matrix constituents laminin and hyaluronan are fragmented within 24 hours 
and replaced with a „second order‟ provisional matrix made of fibronectin (Dobaczewski 
et al., 2006).  Fragments of collagen and hyaluronan can act as neutrophil 
chemoattractants and induce inflammatory gene expression in endothelial cells and 
macrophages respectively (Dobaczewski et al., 2009, Weathington et al., 2006, Taylor et 
al., 2004, Dobaczewski et al., 2006). 
The ECM is degraded by the zinc-dependent proteases known as MMPs that are secreted 
during the inflammatory phase of infarct healing (Tao et al., 2004, Sun et al., 2000). 
Activation of MMPs occurs as early as 10 minutes after ischaemia and these enzymes, 
along with serine proteases, can then degrade collagen which is a constituent of the 
extracellular matrix (Etoh et al., 2001, Dobaczewski et al., 2009). MMP-1 and MMP-8 
are gelatinases that break down intact collagen and enable subsequent collagen 
degradation by MMP-2 and MMP-9 (Birkedal-Hansen et al., 1993, Sun et al., 2000, 
Romanic et al., 2001). MMP-9 has been localised to neutrophils and macrophages, with 
MMP-2 being expressed in macrophages, myocytes, vascular endothelial cells and 
smooth muscle cells (Heymans et al., 1999, Vanhoutte et al., 2006, Romanic et al., 2001, 
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Cheng et al., 2007). Furthermore the temporal expression profiles of MMP-9 and MMP-
2 correspond with neutrophil and macrophage infiltration, respectively (Tao et al., 
2004). MMPs are a vital part of angiogenesis. In a hind limb model of ischaemia and in 
an ex vivo aortic ring culture, deficiency of MMP-2 reduced angiogenesis due to reduced 
migratory and angiogenic capacity of endothelial cells. This was associated with reduced 
inflammation and VEGF expression (Cheng et al., 2007).  
MMP activation can also be damaging. Hearts from patients that had dilated 
cardiomyopathy had increased cardiac levels of MMP-2, MMP-9 and collagen relative 
to control healthy tissue (Sivakumar et al., 2008). Peak expression of MMPs in animal 
models of MI is correlated with the timing of cardiac rupture (Tao et al., 2004), which 
may be mediated by inappropriate removal of the ECM (Vanhoutte et al., 2006). The 
plasminogen system regulates post-infarct ECM turnover and involves MMPs and 
plasminogen activators (Heymans et al., 1999). Reduced matrix degradation in u-PA and 
MMP-9 knockout mice both reduces inflammatory cell infiltration and the incidence of 
cardiac rupture (Heymans et al., 1999). However, this is associated with reduced 
angiogenesis and impaired scar formation (Heymans et al., 1999). While preventing 
cardiac rupture is beneficial, an adequate scar is required to maintain structural integrity 
thus stabilising the infarct and maintaining function (Sun and Weber, 2000). This 
indicates that there is a fine balance in MMP activation being beneficial or detrimental, 
much like inflammation.  
During the post-MI proliferative phase myofibroblast production of TIMPs inhibits the 
actions of MMPs and favours collagen deposition rather than breakdown (Bujak and 
Frangogiannis, 2007, Sun and Weber, 2000). TIMP I, II and III are upregulated from 3 
days post MI, remain elevated at day 28, and their expression is negatively correlated 
with MMP expression (Sun et al., 2000). The role of TIMPs post-MI is reported to 
extend beyond that of just inhibiting MMPs. They have also been implicated in cell 




1.7 Scar formation in MI 
Cardiac fibrosis is determined by the balance of collagen synthesis and degradation by 
the MMPs. Myofibroblasts are activated by factors produced by macrophages. They then 
secrete collagen, with deposition being observed from 3 days post-MI and increasing 
progressively up to 180 days after infarction (Dobaczewski et al., 2006, Dean et al., 
2005, Porter and Turner, 2009, Yang et al., 2002, Virag and Murry, 2003, Sun et al., 
2000, Cleutjens et al., 1995). Infusion of galectin 3 (a lectin that has a role in cell 
interactions) into the rat myocardium induces cardiac fibroblast proliferation and 
collagen deposition while depletion of macrophages impairs scar formation by reducing 
collagen deposition, demonstrating the importance of inflammation in the initiation of 
the fibrotic response (van Amerongen et al., 2007, Sharma et al., 2004).  Fibrillar and 
non-fibrillar collagen is found in the myocardium with fibrillar collagen type I being the 
most abundant (Shamhart and Meszaros, 2009). In cardiac pathology the abundance of 
strong, stiff collagen I and elastic collagen III increases (Pauschinger et al., 1999). 
Furthermore, the proportion of collagen I relative to III increases, favouring production 
of a stiffer scar (Pauschinger et al., 1999). Cross-linking of collagen is vital in providing 
tensile strength and structural integrity to the weakened myocardium (Virag and Murry, 
2003, Dean et al., 2005, Weber, 1989). Direct injection of collagen into the myocardium 
immediately after MI has a beneficial outcome in a rodent model of MI. Six weeks after 
treatment rats injected with collagen had thicker infarcts, reduced infarct expansion 
index and improved ejection fraction (Dai et al., 2005). A thicker scar may be protective 
against cardiac rupture (Nahrendorf et al., 2006). 
The production of collagen may also serve to promote the quiescent phenotype of 
fibroblasts thus providing a negative feedback mechanism. Dermal fibroblasts 
stimulated with TGF-β show decreased collagen production in response to a collagen-
rich environment (Clark et al., 1995). This may prevent excessive fibrosis, which may 
facilitate cardiac arrhythmias (Zannad and Radauceanu, 2005, Li et al., 1999, Kostin et 
al., 2002). High cardiac collagen production has been associated with left ventricular 
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dysfunction in rats (Sharma et al., 2004). Dysfunction was associated with an increase in 
stiff collagen I relative to elastic collagen III. (Sharma et al., 2004). 
The infarct scar, as a result of experimental MI, is found in the apical region of the 
myocardium which is the most vulnerable as it is relatively thin with the greatest 
curvature. Damage here leads to a more pronounced decline in heart function (Pfeffer 
and Braunwald, 1990). Modification of the scar size independent of actual size is well 
reported in the literature (Nahrendorf et al., 2006, Garcia et al., 2007, Hammerman et al., 
1983a, Hammerman et al., 1983b, Brown et al., 1983). Infarct expansion increases the 
scar size and, in humans, is greatest in patients with elevated blood pressure and 
increased vascular resistance.  These patients are more likely to develop complications 
(Pfeffer and Braunwald, 1990, Pierard et al., 1987). 
 
1.8 Cardiac hypertrophy and remodelling 
The initial post-infarct decline in cardiac function is mediated by systolic dysfunction 
which worsens with time (Shioura et al., 2007). In humans, end systolic volume is a 
powerful predictor of death (Pfeffer and Braunwald, 1990, White et al., 1987). The 
tissue loss and hormonal stimulation associated with MI can mediate hypertrophy and 
remodelling, compensatory processes that may maintain normal function (Pfeffer and 
Braunwald, 1990). The extent of this remodelling depends on size and position of 
infarct, collaterals and the patency of the occluded coronary artery (Stanley et al., 2004).  
After MI, cardiomyocytes in the infarct core die while those at the infarct border change 
to a distorted, irregular shape (Kocher et al., 2001). Increased wall stress and subsequent 
upregulation of genes, such as those encoding TNFα, TGF-β and endothelin, alter 
cardiomyocyte expression of cardiac-specific genes, in particular those involved in the 
foetal gene programme (atrial natriuretc factor, ANP, and β myosin heavy chain, β 
MHC) (MacLellan and Schneider, 2000, Kapadia et al., 1997, Sadoshima et al., 1992, 
Sadoshima and Izumo, 1993). Such expression is characteristic of cardiomyocyte 
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hypertrophy, a mechanism occurring after MI to compensate for myocytes loss. This 
means that post-MI, after an initial decline, cardiac muscle mass starts to increase again 
through cell hypertrophy (Stanley et al., 2004). 
Infarct damage results in slippage of cardiomyocytes leading to wall thinning, ventricle 
dilation and a decline in diastolic function (Pfeffer and Braunwald, 1990, Shioura et al., 
2007, Yang et al., 2000). Gaps between capillaries and myocytes widen and may result 
in subendocardial ischaemia (Stanley et al., 2004). Chamber dilation creates a volume 
overload state and cardiac output decreases (Stanley et al., 2004). During remodelling 
the remote region (part of heart not affected by the MI) undergoes morphological 
changes too. The ventricle changes shape from its normal elliptical shape to become 
more spherical (Athanasuleas et al., 2004). The increased left ventricle cavity size and 
its distorted shape bestow a mechanical burden on the failing heart exacerbating 
remodelling and cardiac function may decline further (Douglas et al., 1989). Current 
therapeutics given to MI patients, such as ACE inhibitors, β blockers and 
mineralocorticoid receptor (MR) antagonists, can prevent ventricular dilation, decrease 
left ventricle volume and mass, and reduce collagen turnover to a certain extent but do 










Glucocorticoids have a plethora of physiological functions including modulating 
metabolism, the stress response, inflammation and blood pressure. The first use of 
glucocorticoids clinically was in the 1940‟s when Hench et al. demonstrated their use as 
anti-inflammatory agents to treat rheumatoid arthritis (Hench et al., 1950). Since then 
glucocorticoids have revolutionised the treatment of a variety of disorders including 
asthma and arthritis and can be used to prevent acute transplant rejection.  
 
1.9.1 Synthesis, release and metabolism 
Glucocorticoids are steroid hormones that are synthesised in the zonae 
fasciculate/reticularis of the adrenal cortex in response to a regulated hormone network 
between endocrine tissues (Buckingham, 2006). The precursor for glucocorticoids is 
cholesterol which undergoes side-chain cleavage by cytochrome P450 enzymes to 
produce pregnenolone (Lin and Achermann, 2004). Sequential hydroxylations lead to 
the production of cortisol in humans and corticosterone in rodents (Lin and Achermann, 
2004). Rodent and human glucocorticoids differ due to the lack of 17α-hydroxylase (the 
enzyme that catalyses the production of cortisol) in the rodent adrenal glands (Lin and 
Achermann, 2004). 
Glucocorticoid release is under the control of the hypothalamic pituitary adrenal (HPA) 
axis. Corticotrophin-releasing factor (CRF) is secreted from the hypothalamus (fuelled 
by stimuli such as excessive temperatures, infections or injury) and stimulates the 
release of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland 
(Aguilera et al., 2001, Jacobson, 2005). ACTH in turn stimulates glucocorticoid 
synthesis and release from the adrenal cortex. The HPA axis has negative feedback 
mechanisms, including ACTH on hypothalamic CRF production and glucocorticoids on 
both hypothalamic CRF and anterior pituitary gland ACTH release (Aguilera et al., 
2001, Jacobson and Sapolsky, 1991, Jacobson, 2005, Buckingham, 2006). Vasopressin, 
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also known as antidiuretic hormone may also exert stimulatory actions on glucocorticoid 
synthesis and release by promoting ACTH release (Aguilera et al., 2001, Jacobson and 
Sapolsky, 1991). ACTH can also stimulate mineralocorticoid production and release 
from the adrenal gland but such production is also regulated by the renin-angiotensin 
system and the electrolyte composition of the blood. In healthy adult humans, 
approximately 15mg of cortisol are secreted by the adrenal gland into the bloodstream 
every day (Esteban et al., 1991) in a pulsatile fashion (Buckingham, 2006).  There is a 
diurnal pattern to this secretion with it peaking in humans on waking and being very low 
in the evening (the opposite is true in rodents due to their nocturnal nature) (Kerrigan et 
al., 1993, Jacobson, 2005).  
Circulating glucocorticoids are normally bound to corticosteroid-binding globulin 
(CBG) which sequesters them preventing access to receptors. Normally 95% of 
glucocorticoid will be bound to the CBG and this will buffer the glucocorticoid levels 
(Hammond et al., 1990, Buckingham, 2006). Glucocorticoids can be metabolised by a 
variety of routes. The major route involves the reduction of carbons 4-5 of the A ring by 
hepatic 5α or 5β reductases (Figure 1.5) (Tomlinson et al., 2004). Alternatively, 
glucocorticoids may be metabolised via reduction by 20α- or 20β- hydroxysteroid 
dehydrogenase, oxidative side chain removal, hepatic hydroxylation producing 6β-
hydroxycortisol/corticosterone, or inter-conversion of active cortisol/corticosterone with 
inactive cortisone/11-dehydrocorticosterone by the 11β-hydroxysteroid dehydrogenase 
enzymes (Tomlinson et al., 2004). The latter route of metabolism is the subject of this 






Figure 1-5 Glucocorticoid structures 
The predominant glucocorticoids cortisol, in humans, and corticosterone, in rodents, are 
inactivated by the dehydrogenase activity of 11β-hydroxysteroid dehydrogenase type 2 
(11HSD2) that removes a hydroxyl group from carbon-11. Inactive cortisone and 11-
dehydrocorticosterone are reactivated by the reductase activity of 11HSD1.  Carbon numbers 




1.9.2 The glucocorticoid receptor 
Glucocorticoids mediate their actions via intracellular nuclear receptors called 
glucocorticoid receptors (GR). They have high sequence homology to other steroid 
receptors particularly in the DNA binding domain (Funder, 1997, Buckingham, 2006).  
GR is rendered inactive in the cytoplasm by a 300kDa complex that binds to it. This 
complex is made up of a 90kDa heatshock protein (hsp90), hsp70, p23 and 
immunophilins (Pratt, 1993). Hsp90 acts as a chaperone and prevents the unoccupied 
GR translocating to the nucleus. Upon ligand binding this complex dissociates enabling 
receptor dimerisation by hydrophobic interactions, nuclear localisation and modulation 
of gene transcription (see Figure 1.6) (Bledsoe et al., 2004). Some glucocorticoid target 
genes encode glucocorticoid response elements (GREs) in their promoters. These GREs 
are imperfect palindromic sequences that are 2 hexamer half sites that are separated by a 
3bp and are recognised by the activated GR homodimer (Barnes, 1998). Varying 
compositions of the GREs, transcription factors present and the transcription regulatory 
proteins recruited can modulate whether GR binding to the GRE will enhance or repress 
gene transcription (Barnes, 1998). For example, GRs and transcription factors can bind 
to the co-activator CREB binding protein which can acetylate histones thus opening up 
the DNA structure and enabling gene transcription. However GR can also bind to co-
repressors that favour tight coiling of the DNA around histones therefore preventing 
gene transcription (Barnes, 1998). GR may also influence gene transcription 
independently of DNA binding by interacting with transcription factors (Jonat et al., 
1990). Alternate splicing of the GR transcript produces 2 isoforms of the receptor that 
differ at the C terminus; GRα and GRβ. GRβ may act as a dominant negative inhibitor of 
GRα as it does not bind glucocorticoids but can bind to DNA preventing access of 
ligand activated GRα (Oakley et al., 1996, Barnes, 1998). 
Due to the nature of nuclear receptors it can take hours for the effects of GR activation 
to appear (Losel and Wehling, 2003). However, there are glucocorticoid-mediated 
responses that take a matter of seconds or minutes that suggests there is another 
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mechanism by which glucocorticoids act (Losel and Wehling, 2003). This is by binding 
to membrane bound or cytoplasmic receptors and can result in modulation of calcium 
influx and the inflammatory response (Losel and Wehling, 2003). The role of membrane 






Figure 1-6 Glucocorticoid receptor activation 
The glucocorticoid receptor (GR) is rendered inactive in the cytoplasm by the binding of a 
complex that is made up of proteins including heatshock protein 90 (hsp90). Upon ligand binding 
the complex is dissociated, GR dimerize and they subsequently translocate to the nucleus. In 
the nucleus GR pairs interact with glucocorticoid response elements in the DNA thus enabling 
gene transcription or gene repression. Gene transcription leads to the production of mRNA 
which is translated into proteins. One such protein is IκB. IκB binds to NF-κB rendering it inactive 
in the cytoplasm and preventing it from translocating to the nucleus and activating transcription 




1.9.3 Glucocorticoids and the corticosteroid receptors 
Glucocorticoids can also mediate their actions via the mineralocorticoid receptors (MR) 
(Buckingham, 2006). The expression of GR and MR is tissue specific. Expression of GR 
is ubiquitous in glucocorticoid target tissues such as the liver, brain, cells of the immune 
system and the lungs. In the cardiovascular system GR has been found in 
cardiomyocytes, cardiac fibroblasts, vascular smooth muscle cells and the vascular 
endothelium (Hadoke et al., 2006, Ullian, 1999).  It has low affinity for glucocorticoids 
having a KD of 10-20nM for cortisol and corticosterone, and shows no binding of the 
mineralocorticoid, aldosterone. MR, on the other hand, has high affinity for both 
glucocorticoids and mineralocorticoids (KD for both is approximately 0.5-2nM) 
(Buckingham, 2006). The distribution of MR is restricted in comparison to that of GR. 
MR are found in mineralocorticoid target tissues such as, the distal tubule of the kidney, 
sweat glands, colon and brain. In the cardiovascular system MR has also been identified 
in cardiomyocytes and the vascular endothelium and smooth muscle cells (Milik et al., 
2007, Buckingham, 2006,(Hadoke et al., 2009). As circulating levels of 
cortisol/corticosterone are 100 fold greater than those of aldosterone, and the level of 
glucocorticoid in the tissue is likely to be 0.5-1nM at the diurnal nadir, it is likely that 
under basal conditions where both receptors are expressed MR, rather than GR, will be 
occupied by glucocorticoids (Esteban et al., 1991, Funder, 1997). It has been suggested 
that in epithelial tissues glucocorticoids act as MR agonists whereas in non-epithelial 
tissues they act as antagonists (Gomez-Sanchez et al., 1990, Funder, 1997). This view is 
still somewhat controversial and requires further investigation. To confer aldosterone 
specificity the MR must be protected from illicit activation by glucocorticoids. This is 
achieved by pre-receptor metabolism of glucocorticoids by the 11β-hydroxysteroid 




1.10 11β-hydroxysteroid dehydrogenase enzymes 
The 11β-hydroxysteroid dehydrogenase enzymes were initially thought to be one 
enzyme that changes the direction of its activity depending on its environment. However 
in the 1980‟s and 1990‟s the two distinct isoforms of the enzyme were identified and 
characterised (Stewart and Krozowski, 1999, Seckl and Walker, 2001). These isozymes 
belong to the short-chain dehydrogenase/reductase superfamily that has over 3000 
members (Tomlinson et al., 2004). 
 
1.10.1 11β-hydroxysteroid dehydrogenase type 1 
11β-hydroxysteroid dehydrogenase type 1 (11HSD1) catalyses the conversion of 
inactive cortisone and 11-dehydrocorticosterone to active cortisol and corticosterone, in 
humans and rodents respectively (see Figure 1.7). The biological activity of cortisol and 
corticosterone results from the presence of a hydroxyl group on carbon-11 of the 
glucocorticoid structure. 11HSD1 reduces the oxygen at carbon-11 thus reactivating the 
glucocorticoid and amplifying it locally. Since GR are relatively low affinity receptors 
the presence of 11HSD1 may increase their activation by generating high concentrations 
of the appropriate ligand in target tissues (Walker and Seckl, 2003). The direction of 
11HSD1 activity has been the subject of some debate. In tissue homogenates and 
microsomes the enzyme can act as a dehydrogenase or reductase but in intact tissues and 
organs it predominantly catalyses the reductase reaction (Gao et al., 1997, Seckl, 2004). 
Analyses of enzyme kinetics have demonstrated that rat 11HSD1 has a Km of 
1.83±0.06µM for corticosterone and 17.3±2.24µM for cortisol (Draper and Stewart, 
2005, Stewart and Krozowski, 1999). For this reason it is termed a low affinity enzyme 
as the Km is relatively high compared to the circulating levels of free corticosterone (in 
the nM range).  
11HSD1 is found in the endoplasmic reticulum (ER) with its catalytic domain in the ER 
lumen. It is found in proximity to hexose-6-phosphate dehydrogenase (H6PDH) which 
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catalyses the conversion of glucose-6-phosphate to 6-phosphogluconolactonate, 
producing NADPH, the vital cofactor for 11HSD1 activity, in the process. Deletion of 
H6PDH has shown that this enzyme is crucial to the reductase activity of 11HSD1 
(Lavery et al., 2006). The structure of 11HSD1 is highly conserved across species, 
particularly in the cofactor binding site and the catalytic domain (Tomlinson et al., 2004) 
Like the GR, 11HSD1 has a wide expression including in the liver, kidney, brain 
adipose, bone, gastrointestinal tract, vasculature, heart and the gonads (Walker and 
Seckl, 2003, Tomlinson et al., 2004).  Its expression and activity is regulated by a wide 
range of factors that include cytokines, growth factors, insulin, sex steroids and 
glucocorticoids themselves (Tomlinson et al., 2004). 
The role of 11HSD1 has been studied using genetically-modified mice. In transgenic 
mice overexpressing 11HSD1 specifically in the adipose (to a similar extent as observed 
in the adipose of obese humans) adipose corticosterone levels are increased and this is 
associated with increased central fat mass (Masuzaki et al., 2001, Rask et al., 2001). 
Mice with liver-specific over expression of 11HSD1 exhibit insulin resistance, fatty liver 
and dyslipidemia without changes in adipose mass (Paterson et al., 2005).  Additionally, 
mice with targeted disruption of the 11HSD1 allele have been generated. Homozygous 
„knockout‟ mice (
-/-
) are viable, producing normal pups, show no detectable changes in 
blood pressure and generally are phenotypically normal (Kotelevtsev et al., 1997). While 
adrenalectomised wild type mice can convert 11-dehydrocorticosterone (from implanted 
pellets) to corticosterone, 11HSD1
-/-
 mice could not (Kotelevtsev et al., 1997). This 
shows that 11HSD1 is the only enzyme capable of regenerating inactive glucocorticoids 
(Kotelevtsev et al., 1997). The adrenal glands of 11HSD1
-/-
 mice on the MF1/129 
background, but not those on the C57Bl6 background, are enlarged and morphometric 
analysis shows that this is due to adrenocortical hyperplasia (Harris et al., 2001, Paterson 
et al., 2006, Kotelevtsev et al., 1997, Paterson et al., 2007). This may be a result of 
diminished negative feedback to the HPA axis (Harris et al., 2001). Peak levels, 
however, are not different from wild type litter mates (Kotelevtsev et al., 1997, Harris et 
al., 2001). Deficiency of 11HSD1 in mice produces a plethora of potentially beneficial 
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effects that include resistance to diabetes and obesity (Morton et al., 2004, Morton et al., 
2001). 11HSD1
-/-
 mice have an improved lipid profile, increased liver insulin sensitivity 
and improved glucose tolerance (Morton et al., 2001, Kotelevtsev et al., 1997). 
Furthermore, these mice have reduced visceral fat accumulation, when on a high fat diet 
compared with wild type mice and resist development of diabetes when fed a hyper-
calorific diet (Morton et al., 2004). These beneficial metabolic effects were associated 
with reduced expression of phosphoenolpyruvate carboxykinase (PEPCK, a rate limiting 
enzyme involved in gluconeogenesis) and increased expression of enzymes involved in 
lipid oxidation in the liver (Kotelevtsev et al., 1997, Morton et al., 2001). The beneficial 
effects of 11HSD1 knockout extend beyond that of improving metabolic parameters.  
11HSD1
-/-
 mice also are protected against age associated cognitive decline (Yau et al., 
2001). Of particular interest to the work described in this thesis is that 11HSD1
-/-
 mice 
exhibit enhanced angiogenesis in MI wound healing and improved cardiac function 7 
days post-MI (Small, 2005, Small et al., 2005).   
Cortisone reductase deficiency is a rare disorder that represents the “putative human 
11HSD1 knockout” and is typified by hyperandrogenism and in some cases, obesity 
(Tomlinson et al., 2004). There is increased metabolic clearance of cortisol resulting in 
increased ACTH secretion as an effort to maintain cortisol levels but this is at the 
expense of a subsequent increase in androgen synthesis (Tomlinson et al., 2004). 
Treatment with the synthetic glucocorticoid, dexamethasone, suppresses this increase in 





Figure 1-7 The 11β-hydroxysteroid dehydrogenase (11HSD) isozymes 
Both 11HSD isozymes are found in the endoplasmic reticulum (ER). The catalytic site of 
11HSD1 is situated in the ER lumen in proximity to hexose-6-phosohate dehydrogenase 
(H6PDH) which catalyses the conversion of glucose-6-phosphate (G6P) to 6-
phosphogluconolactoneate (6PG), producing NADPH (nicotinamide adenine dinucleotide 
phosphate) in the process. NADPH is a cofactor required for the reductase activity of 11HSD1, 
which reactivates glucocorticoids locally. 11HSD2 catalyses the opposite reaction, inactivating 
glucocorticoids, with its dehydrogenase activity aided by the cofactor NAD (nicotinamide adenine 






1.10.2 11β-hydroxysteroid dehydrogenase type 2 
11β-hydroxysteroid dehydrogenase type 2 (11HSD2) catalyses the inactivation of 
glucocorticoids; cortisol and corticosterone are converted to cortisone and 11-
dehydrocorticosterone in humans and rodents respectively (see Figure 1.7). Its main role 
is to reduce the concentration of local glucocorticoids thus preventing elicit activation of 
high affinity MR.  Aldosterone, in contrast, is not a substrate for 11HSD2 (Funder, 
1997). Like 11HSD1, 11HSD2 is found in the ER but the bulk of this enzyme is in the 
cell cytoplasm rather than in the ER lumen (Draper and Stewart, 2005). NAD is the 
required cofactor for 11HSD2 which is an exclusive dehydrogenase. This enzyme has 
high affinity for its substrate with a Km of 50nM for cortisol and 5nM for corticosterone 
(Draper and Stewart, 2005, Stewart and Krozowski, 1999). Corresponding with its role, 
11HSD2 is expressed in mineralocorticoid target tissues including the collecting ducts 
and medulla of the kidney, the colon and the placenta (Brown et al., 1996, Edwards et 
al., 1988). In the kidney 11HSD2 prevents illicit activation of the renal MR by 
glucocorticoids enabling the reabsorption of sodium in the distal tubules and increased 
secretion of potassium. 11HSD2
-/- 
mice have been generated however, 50% die within 
48 hours of birth due to motor weakness (Kotelevtsev et al., 1999). The surviving mice 
are characterised by enlarged kidneys, hypokalaemia, hypotonic polyuria, increased 
blood pressure and impaired vascular function compared to wild types (Kotelevtsev et 
al., 1999, Hadoke et al., 2001). The presence of 11HSD2 in MR expressing cells confers 
mineralocorticoid specificity on the MR. This enzyme is present in the placenta and has 
a vital role preventing glucocorticoids passing from mother to foetus. Glucose 
intolerance is observed in offspring exposed to high levels of glucocorticoid in utero 
(Nyirenda et al., 1998).  
Mutations in the human 11HSD2 gene result in the syndrome of apparent 
mineralocorticoid excess (SAME). The symptoms of this disease resemble those seen in 
the 11HSD2
-/-
 mice and include hypertension, sodium retention and hypokalaemia 
(Draper and Stewart, 2005).  However, the name of this disease is deceptive as this is not 
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truly a disorder of mineralocorticoid excess. Aldosterone is actually reduced, but 
defective glucocorticoid deactivation results in excessive MR activation by 
glucocorticoids (Draper and Stewart, 2005). 
 
1.10.3 Inhibitors of the 11HSDs 
The therapeutic benefit of pharmacological 11HSD1 inhibition was initially shown with 
liquorice derivatives that are relatively non-selective (Monder et al., 1989). 
Carbenoxolone reduces plasma cholesterol levels, glucose production and improves 
insulin sensitivity in humans. However, it also has detrimental effects that are consistent 
with inhibition of 11HSD2 (Walker et al., 1995, Andrews et al., 2003). More recently, 
selective inhibitors of 11HSD1 have been developed including compound 544 (Merck), 
BVT.14225 (Biovitrum) and compound 2922 (Amgen) which have IC50 values of 97nM, 
52nM and 161±23nM respectively, indicating high potency (Hermanowski-Vosatka et 
al., 2005, Barf et al., 2002, Lloyd et al., 2009). Hermanowski-Vosatka et al. have shown 
that administration of compound 544 is beneficial in murine models of obesity, diabetes 
and atherosclerosis (Hermanowski-Vosatka et al., 2005). In diet-induced obesity the 
drug lowers body weight, insulin, fasting glucose, triglycerides and cholesterol while in 
a model of type 2 diabetes fasting glucose, insulin, glucagon, triglycerides and free fatty 
acids are reduced and glucose tolerance improved (Hermanowski-Vosatka et al., 2005). 
Furthermore, compound 544 slows atherosclerotic plaque progression in ApoE deficient 
mice (Hermanowski-Vosatka et al., 2005). Selective inhibitors are currently in Phase II 
clinical trials for the treatment of diabetes. Additional development of 11HSD1 






1.11 Glucocorticoid-related human diseases 
Maladaptive glucocorticoid responses form the basis of several human disorders. Excess 
glucocorticoids are associated with metabolic syndrome which includes visceral obesity, 
hypertension, insulin resistance and alterations in glucose and lipid metabolism (Walker 
and Seckl, 2003, Draper and Stewart, 2005). In idiopathic obesity tissue cortisol is 
increased independently of plasma levels and this is associated with increased 11HSD1 
activity in the adipose (De Bosscher et al., 2003). Cortisol can stimulate the 
differentiation of preadipocytes to adipocytes which may enable expansion of the 
adipose tissue (Kleiman and Tuckermann, 2007, Draper and Stewart, 2005, Tomlinson 
et al., 2004). As there is strong evidence for a genetic component to obesity investigators 
are currently attempting to identify polymorphisms in the 11HSD1 gene of obese 
patients (Walker and Seckl, 2003). Cushing‟s syndrome is a disease of cortisol excess 
and the symptoms resemble metabolic syndrome. It is typified by increased abdominal 
fat, muscle wasting, skin thinning and poor wound healing (De Bosscher et al., 2003). 
Metabolic syndrome may represent a low cortisol Cushing‟s syndrome.  The opposite of 
this is the rare disease known as chronic adrenal insufficeincy or Addison‟s disease. 
Insufficient corticosteroid production by the adrenal glands results in reduced blood 
pressure, fatigue and weight loss.  
 
1.12 Glucocorticoids and the cardiovascular system 
Treatment with glucocorticoids has been correlated with increased risk of cardiovascular 
disease (Souverein et al., 2004, Wei et al., 2004). GR and MR are expressed in a variety 
of different cell types across the cardiovascular system. Firstly if we consider the 
vasculature; GR and MR are expressed in smooth muscle cells and endothelial cells, 
(Walker et al., 1991, Takeda et al., 2007, Hadoke et al., 2006, Ullian, 1999, Yang and 
Zhang, 2004). While glucocorticoids (both local and systemic) have a role in 
maintaining blood pressure under pathological situations they can also promote 
hypertension (Ullian, 1999, Whitworth, 1994, Whitworth et al., 2002, Yang and Zhang, 
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2004). Glucocorticoids can suppress the local production of vasodilators, such as nitric 
oxide and prostacyclin, along with potentiating the actions of vasoconstrictor hormones 
such as α adrenoreceptor agonists and endothelin (Whitworth et al., 2002, Yang and 
Zhang, 2004, Ullian, 1999, Hadoke et al., 2006). Additionally, local glucocorticoids may 
also induce vascular remodelling by enhancing vascular smooth muscle cell hypertrophy 
in response to angiotensin II (Ullian, 1999, Hadoke et al., 2006) and by inhibiting 
angiogenesis (Small et al., 2005). 
In the myocardium GR expression has been localised to cardiomyocytes and fibroblasts 
while MR are located in cardiomyocytes (Walker et al., 1991, Slight et al., 1993, Takeda 
et al., 2007, Slight et al., 1996, Pujols et al., 2002, Lombes et al., 1992). Genetic 
manipulation of corticosteroid receptors in the heart has demonstrated their importance 
physiologically. Ninety percent of GR knockout mice die at birth due to delays in lung 
maturation while conditional cardiac over-expression of GR is associated with 
bradycardia and atrio-venricular block (Cole et al., 1995, Sainte-Marie et al., 2007). 
Conditional cardiac knock-down of MR induces severe heart disease and premature 
death (Beggah et al., 2002). Conversely, conditional cardiac over-expression of MR 
leads to early sudden death and, in those mice surviving, cardiac arrhythmias (Ouvrard-
Pascaud et al., 2005). This could be related to the modulation of electrical and 
mechanical activities of the heart that have been attributed to glucocorticoids. For 
example, the contractile force of rat papillary muscles is reduced after adrenalectomy, 
but this can be prevented by dexamethasone treatment (Lefer et al., 1968).   As increased 
glucocorticoids have been associated with adverse cardiovascular outcomes, such as 
heart failure for example (Wei et al., 2004),  reducing their actions is attractive in the 
setting of cardiovascular disease. However, systemic blockade of the GR can result in 
compensatory increases in the HPA axis, and therefore in circulating glucocorticoids, 
making direct inhibition of the GR an unsuitable therapeutic approach (Bamberger and 
Chrousos, 1995, Spiga et al., 2007). 
Co-expression of the corticosteroid receptors with 11HSD1 or 11HSD2 amplifies and 
reduces local glucocorticoid action respectively (see Figure 1.8). In the vasculature 
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11HSD1 is expressed in smooth muscle cells while 11HSD2 is expressed in endothelial 
cells (Slight et al., 1996, Walker et al., 1991, Takeda et al., 2007, Hadoke et al., 2006, 
Christy et al., 2003). Distribution of the 11HSDs varies depending on the vascular 
territory (Hadoke et al., 2006). In the myocardium 11HSD1 is expressed in 
cardiomyocytes and fibroblasts and 11HSD2 is expressed in cardiac fibroblasts only 
(Morton et al., 2004, Masuzaki et al., 2001, Vliegen et al., 1991, Slight et al., 1993, 
Slight et al., 1996). Mice with selective 11HSD1 isozyme deletion have been used to 
determine the influence of the 11HSDs on the cardiovascular system. 11HSD2
-/-
 mice 
develop hypertension, endothelial dysfunction and cardiac hypertrophy (Christy et al., 
2003, Hadoke et al., 2001, Kotelevtsev et al., 1999). The role of 11HSD2 in the vascular 
wall and the myocardium may be to prevent the detrimental effects of local MR 
activation by glucocorticoids. However, it is difficult to determine the direct local effects 
of glucocorticoids on the cardiovascular system relative to those mediated by the 
increase in blood pressure (systemic glucocorticoid). In contrast, inactivation of 
11HSD1 has no effect on vascular function and blood pressure (Kotelevtsev et al., 1997, 
Hadoke et al., 2001). While 11HSD1 does not appear to have a role in basal vascular 
function (Hadoke et al., 2001) it may have a role in vascular inflammation. Treatment of 
apoE deficient mice with an 11HSD1 inhibitor prevented atherosclerotic plaque 
progression that was associated with reduced expression of the inflammatory cytokine, 
MCP-1 (Hermanowski-Vosatka et al., 2005). However, in a more recent study by Lloyd 
et al., pharmacological inhibition of 11HSD1 had no effect on pro-inflammatory 
cytokines or atherosclerosis (Lloyd et al., 2009). The mechanism by which 11HSD1 





Figure 1-8 Occupancy of GR and MR in cells of the cardiovascular system 
The presence of both 11β-hydroxysteroid dehydrogenase (11HSD) type 1 and type 2 in 
cardiomyocytes means that glucocorticoids (GC) can be both inactivated and reactivated in the 
same cell. For this reason it is likely that both the glucocorticoid receptor (GR) and 
mineralocorticoid receptor (MR) are activated by glucocorticoids, with the mineralocorticoid 
aldosterone, activating MR only.  The presence of 11HSD1 in cardiac fibroblasts will amplify 
glucocorticoids locally thus enhancing GR activation. In vascular smooth muscle cells 11HSD1 
amplification of glucocorticoids will ensure activation of both GR and MR by the steroid. 
Aldosterone has to compete for the MR. On the other hand vascular endothelial cells express 
11HSD2 which will prevent MR activation by glucocorticoids and will favour that by aldosterone.  
Solid arrows represent the predominant activation and dashed represent the less likely activation 






1.12.1 Glucocorticoids and inflammation 
Glucocorticoids have a role in mediating the fine balance between a beneficial robust 
inflammatory response immediately after injury, a type 2 resolution response (part of the 
inflammatory response) and in preventing chronic inflammation (McEwen et al., 1997). 
This is achieved in part by programming. For example, sustained increase in 
glucocorticoid secretion by the HPA axis can programme the inflammatory system to be 
predominantly pro-resolution, preventing chronic inflammation. While quick resolution 
of inflammation may be beneficial, a robust type 1 inflammatory response is required in 
many situations to clear cell debris and pathogens (McEwen et al., 1997).  
Glucocorticoids are immunomodulatory molecules that can exert their actions by a 
genomic and non genomic mechanisms (Barnes, 1998). They inhibit the production of a 
range of inflammatory cytokines including IL-1β, IL-2, IL-3, IL-6, IL-11, TNF-α, and 
chemokines such as IL-8, RANTES, MCP-1 and MIP-1α (Galon et al., 2002, Cupps and 
Fauci, 1982, Barnes, 1998). In parallel, GR activation up-regulates anti-inflammatory 
genes, such as IL-10 and lipocortin-1 (Barnes, 1998, Galon et al., 2002, Cupps and 
Fauci, 1982). For many of these inflammatory mediators GREs are not present upstream 
of their promoters, suggesting that modulation of their expression is not due to direct GR 
mediated alteration of transcription. GR can enhance synthesis of IκB, which renders 
NF-κB inactive in the cytoplasm preventing it from augmenting inflammation (please 
refer to Section 1.2.3 and Figure 1.6) (Barnes, 1998). Inhibition of  NF-κB activity by 
glucocorticoids can also diminish the synthesis of nitric oxide, which can also reduce 
inflammation (Barnes, 1998). Additionally, GR can interact with activator protein-1 
(AP-1) preventing it from mediating its inflammatory actions (Barnes, 1998, Jonat et al., 
1990, Buckingham, 2006, De Bosscher et al., 2003). Non-genomic actions of 
glucocorticoids are apparent, as their effects on inflammation occur within minutes 
rather than hours. In vitro, high doses of corticosterone can inhibit macrophage 
phagocytosis in less than 30 minutes (Long et al., 2005) and high doses of 6-α 
methylprednisolone prevent neutrophil degranulation within 5 minutes (Liu et al., 2005). 
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Furthermore glucocorticoids can arbitrate mRNA breakdown, as seen with granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Barnes, 1998). 
Glucocorticoids can mediate their effects on the inflammatory system due to the wide 
expression of their receptors and 11HSD1. GR and MR are expressed in inflammatory 
cells such as macrophages and lymphocytes, as is 11HSD1 (Gilmour et al., 2006, 
Brereton et al., 2001, Thieringer et al., 2001). Exposure of monocytes to glucocorticoids 
as they mature into macrophages programmes them to be phagocytic and anti-
inflammatory (Heasman et al., 2003). 11HSD1 is up-regulated upon differentiation of 
monocytes to macrophages, serving to amplify glucocorticoids in areas of inflammation 
(Gilmour et al., 2006, Chapman et al., 2006). Within 3 hours of a thioglycollate injection 
into the peritoneum (a model of sterile peritonitis) there is an increase in 11HSD1 
activity in cells recruited to the area (Gilmour et al., 2006). The elastase produced by 
neutrophils has been shown to cleave cortisol from CBG (Hammond et al., 1990). This 
process aids in delivery of the anti-inflammatory glucocorticoid to sites of inflammation 
(Hammond et al., 1990). This local increase in glucocorticoids in an inflamed site may 
place a „brake‟ on the self-amplifying process of inflammation preventing overshoot 
which may threaten homeostasis (Munck et al., 1984). Several cytokines such as, IL-4, 
IL6, MCP-1 and TNF-α up-regulate 11HSD1 in inflammatory cells and vascular smooth 
muscle cells (Thieringer et al., 2001, Cai et al., 2001). This is not associated with a 
parallel increase in 11HSD2 activity (Cai et al., 2001).  
Synthetic glucocorticoids can enhance macrophage phagocytosis of apoptotic cells. In 
agreement with this Gilmour et al. demonstrated a delay in macrophages gaining 
phagocytic competence in 11HSD1
-/-
 mice (Liu et al., 1999, Gilmour et al., 2006).  
Glucocorticoids also accelerate eosinophil apoptosis while also enhancing neutrophil 
survival and modulating the secretion of pro- and anti- inflammatory mediators from 





1.12.2 Glucocorticoids and angiogenesis 
Angiogenesis is a tightly regulated process and can be inhibited by glucocorticoids. As 
mentioned previously, GR, MR and the 11HSD enzymes are found in the vessel wall 
(Hadoke et al., 2006, Hadoke et al., 2001, Christy et al., 2003, Ullian, 1999, Walker et 
al., 1991, Yang and Zhang, 2004). Corticosterone and 11-dehydrocorticosterone inhibit 
angiogenesis in vitro in aortic ring angiogenesis assays and in vivo in sponge models 
(Small et al., 2005). While corticosterone can reduce vessel sprouting in 11HSD1
-/-
 
mice, the inactive molecule, 11-dehydrocorticosterone cannot (Small et al., 2005). This 
compliments results from a sponge implant model using the human glucocorticoids, 
cortisol and cortisone (Small et al., 2005). Angiogenesis is enhanced by addition of 
RU38486 (Mifepristone), a GR antagonist, suggesting that the angiostatic effects of 
glucocorticoids are mediated by the GR (Small et al., 2005). 11HSD1
-/-
 mice and 
RU38486 treated mice also have enhanced neovascularisation of cutaneous surgical 
wounds (Small et al., 2005). It follows that individuals with Cushing‟s syndrome, who 
have excess glucocorticoids, have impaired wound healing (Gordon et al., 1994). 
Particularly relevant to the work presented in this thesis is that the observation that 
11HSD1
-/-
 mice have enhanced cardiac angiogenesis 7 days post-MI (Small et al., 2005).  
Rat osteocarcinoma cells transfected with 11HSD1, but not 11HSD2, are sensitive to the 
angiostatic effects of cortisol (Rabbitt et al., 2002). 11HSD2 transfected cells show an 
increase in cell proliferation suggesting that endogenous glucocorticoids have a tonic 
angiostatic effect (Rabbitt et al., 2002, Rabbitt et al., 2003). In agreement with these 
findings, vascularised tumours express 11HSD2 and not 11HSD1 which acts in an anti-
inflammatory, pro-differentiation manner (Rabbitt et al., 2003). 
There are several mechanisms by which glucocorticoids might exert their angiostatic 
effect. Firstly, this may be by reducing angiogenic cytokine production or secretion. 
Dexamethasone can block the increase in VEGF expression in response to hypoxia 
(Steinbrech et al., 2000) and Hori et al. found that steroids produced a dose-dependent 
decrease in sponge angiogenesis that was associated with decreased expression of TNF-
α and IL-6 (Hori et al., 1996). Furthermore, in an in vivo tumour model, GR mediated 
 55 
 
suppression of cancer growth and angiogenesis occurred in conjunction with reduced 
expression of IL-8 and VEGF (Yano et al., 2006a). Glucocorticoids also inhibit PDGF-
induced VEGF expression in human aortic vascular smooth muscle cells (Nauck et al., 
1998). Finally they can inhibit nitric oxide production which is involved in the initiation 
of angiogenesis (Ullian, 1999). 
Glucocorticoids may also hinder cell proliferation. Incorporation of [
3
H]-thymidine into 
the nuclei of replicating endothelial cells and skin fibroblasts is reduced by 
glucocorticoid treatment in vitro (Sakamoto et al., 1987, (Derbyshire et al., 1996). 
Glucocorticoids, but not aldosterone, inhibit smooth muscle cell and endothelial cell 
growth suggesting that the anti-angiogenic behaviour of glucocorticoids is mediated by 
their activation of GR rather than MR (Longenecker et al., 1982, Longenecker et al., 
1984). Haemangiomas are tumours of the microvasculature that form due to 
proliferation of endothelial cells, but are mostly harmless. Removed haemangiomas that 
are subsequently cultured show decreased capillary growth in response to a variety of 
glucocorticoids, including dexamethasone and methylprednisolone (Hasan et al., 2003). 
This is associated with a reduction in IL-6 transcripts and enhanced expression of the 
apoptotic gene clusterin/apolipoprotein J suggesting that reduced inflammation and 
enhanced cell death played a role (Hasan et al., 2003).  This inhibition of cell 
proliferation is achieved by preventing transition from the G1 phase (cells increase in 
size and prepare for division) to the S phase (DNA synthesis). Two different 
mechanisms that are cell specific have been proposed for this anti-mitotic activity. 
Firstly, glucocorticoids up-regulate the cyclin-dependent kinase inhibitors (CKIs), p27 
and p21 (Rogatsky et al., 1997). CDKIs bind to cyclin-cyclin dependent kinase (CDK) 
complexes, preventing their catalytic activity, and ultimately, their progression through 
the cell cycle (Rogatsky et al., 1997). Secondly, glucocorticoids repress mitogenic 
factors, including cyclin D3, CDK4 and CDK6, that are required for the cell cycle 




Alternative ways in which steroids may restrain angiogenesis include alteration of 
endothelial cell morphology (Folkman and Ingber, 1987) and promotion of vessel 
regression. Glucocorticoids have been shown to reduce MMP-2 production and secretion 
and to enhance TIMP-2 secretion in rat smooth muscle cells (Pross et al., 2002). Small 
immature vessels are favoured by glucocorticoids for involution and this is mediated by 
basement membrane degradation and subsequent detachment of endothelial cells from 
the vessel wall leading to their death (Folkman and Ingber, 1987). In new vessels it is 
likely that the basement membrane is less stable and has a greater turnover, leaving it 
susceptible to degradation (Folkman and Ingber, 1987). In the chick chorioallantoic 
membrane model glucocorticoids reduce collagen synthesis (Maragoudakis et al., 1989). 
Furthermore, co-administration of collagen production inhibitors with steroid synergises 
their angiostatic actions (Folkman and Ingber, 1987).   
Conversely to the previously reported literature it has been suggested that steroids can be 
angiostatic independent of their ability to activate GR or MR (Folkman and Ingber, 
1987). Tetrahydrocortisol is an inactive glucocorticoid and is angiostatic. Folkman et al. 
suggest that the distribution of hydroxyl groups across the steroid structure is vital in 
determining its angiostatic ability (Folkman and Ingber, 1987). However there is 
overwhelming evidence (as mentioned above) that the corticosteroid receptors are 
involved therefore, these reports should be taken with caution. 
 
1.13 Glucocorticoids and MI 
It has been demonstrated that glucocorticoids can decrease inflammation and 
angiogenesis, processes that are vital in the MI healing response and therefore 
modulation of glucocorticoids after MI may have adverse effects on the recovery 
process. Indeed, exogenous glucocorticoid therapy is associated with a greater risk of MI 
and heart failure (Wei et al., 2004, Souverein et al., 2004).  However, in the 1970‟s 
glucocorticoid administration post-MI was proposed to have a favourable outcome. 
Libby et al. showed, in dogs, that a single dose of methylprednisolone given 30 minutes 
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or 6 hours after MI reduces ischaemic cell death (Libby et al., 1973). This was followed 
by clinical studies that found that a single dose of glucocorticoid within 2 days of MI 
decreases mortality and infarct size (Barzilai et al., 1972, Morrison et al., 1976). The 
protective influence of these drugs was hypothesised to be due to stabilisation of 
lysosomal membranes preventing their rupture and subsequent release of their damaging 
digestive enzymes (Lefer et al., 1980, Libby et al., 1973). More recently Hafezi-
Moghadam et al. reported that a single high dose of dexamethasone (40mg/kg) given to 
mice 1 hour prior to MI reduced infarct size at 24 hours (Hafezi-Moghadam et al., 
2002). It was postulated that this protection was bestowed by enhanced nitric oxide 
synthesis which may have enhanced coronary blood flow (Hafezi-Moghadam et al., 
2002). These protective effects were mediated by GR as RU38486 abrogated the 
beneficial effects of dexamethasone (Hafezi-Moghadam et al., 2002).  It has also been 
proposed that the cardioprotective effects may involve inhibition of NF-κB and 
activation of protein kinase Akt (Thiemermann, 2002). Conversely, several clinical 
studies conducted in the 1970‟s also reported no effects or even detrimental effects of 
glucocorticoids post-MI (Madias and Hood, 1982). Roberts et al. found that 8 doses of 
methylprednisolone given after MI increased infarct size and contributed to ventricular 
arrhythmias (Roberts, 1976). Additionally chronic corticosterone therapy was associated 
with an increased infarct size in rats (Scheuer and Mifflin, 1997). Taken together, these 
data suggest that glucocorticoids are beneficial early in infarct healing as they limit the 
infarct size. However, when such therapy continues into the healing phase it is 
detrimental. This may be mediated by the anti-inflammatory and anti-angiogenic effects 
of glucocorticoids. The inflammatory response is required for adequate scar formation 
and prevention of this can lead to the development of cardiac aneurysms and rupture 
(Hammerman et al., 1984). Systemic blockade of glucocorticoids after MI and, during 
infarct healing is not a realistic therapeutic strategy as it may lead to an Addisonian 
crisis or reduced negative feedback on the HPA axis. 
In humans serum levels of glucocorticoids increase post-MI and remain elevated for 
several days (Ceremuzynski, 1981). It has been speculated that the sudden increase in 
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circulating glucocorticoids may overwhelm the CBG that normally renders it inactive, 
thus increasing the effects of glucocorticoids (Ceremuzynski, 1981). Extrapolating from 
the exogenous glucocorticoid evidence it may be hypothesised that this release is 
protective. Aldosterone is also reported to be increased post-MI and is correlated with 
poorer outcome (Ceremuzynski, 1981). It is also well known that catecholamines are 
increased immediately after MI (Gazes et al., 1959). The relationship between 
glucocorticoids and catecholamines is a reciprocal one. Glucocorticoids can regulate 
catecholamine synthesis in the adrenal medulla but catecholamines can stimulate 
adrenocorticotrophin release from the anterior pituitary, which can then stimulate 
glucocorticoid release from the adrenal cortex (Axelrod and Reisine, 1984). After this 
transient increase in systemic glucocorticoids levels the modulation of glucocorticoid 






 mouse has been well characterised in terms of its metabolic and vascular 
phenotype. However, very little is known about the effect of its deletion on the function 
of the heart. Any differences in the basal cardiac phenotype of these mice may have an 
effect on the post-MI outcome. 
The first hypothesis that is investigated, therefore, is that the cardiac architecture of 
11HSD1
-/-
 mice is similar to that of C57Bl6 control mice and this is associated with 
comparable heart function.  In addition, the localisation of 11HSD1 protein is to be 
confirmed. 
The literature suggests that glucocorticoids are beneficial immediately after MI but 
continued administration of exogenous glucocorticoids in the healing phase is 
detrimental. This effect may be mediated by the ability of glucocorticoids to reduce 
inflammation and angiogenesis, processes that are vital in the healing response. It was 
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previously shown by Small et al. that 11HSD1
-/-
 mice have enhanced angiogenesis 7 
days after MI and this was associated with improved cardiac function (Small et al., 
2005). However the stimulus for this was unknown.  
The second hypothesis is that the initial systemic increase in corticosterone post-MI is 
sufficient to confer protection on the heart from ischaemic damage despite the lack of 
intracellular regeneration of glucocorticoids in 11HSD1
-/-
 mice. Furthermore, it is 
proposed that the mechanism for the post-infarct enhancement in vessel density in 
11HSD1
-/-
 mice involves an enhanced inflammatory response and promotion of 
associated pro-angiogenic signalling during early infarct healing.  
Despite there being enhanced vessel density 7 days after MI in 11HSD1
-/-
 mice the 
longevity of these vessels was not established. It is reasonable to expect that the 
augmented vessel density is required for sustained improvement in cardiac function 
following infarction. Vessels undergo pruning 14-21 days after MI becoming stable and 
mature by 28 days (Grass et al., 2006, Ren et al., 2002).  
The third hypothesis is that the enhanced vessel density previously reported 7 days 
after MI in 11HSD1
-/-
 mice is retained when infarct healing is complete (28 days) and is 
associated with sustained improvement in cardiac function. Furthermore, it is postulated 
that the enhanced blood supply will reduce scar formation.  
Finally, it is desirable that the beneficial effects of 11HSD1 inhibition demonstrated in a 
transgenic mouse model can be translated to the clinic. Selective 11HSD1 inhibitors are 
in development for treatment of a variety of disorders including diabetes, obesity and 
atherosclerosis.  
The fourth hypothesis is that administration of a selective inhibitor of 11HSD1 
(compound 544) will recapitulate the effect of genetic deletion of 11HSD1. Drug treated 
mice will be expected to show enhanced inflammation and angiogenesis, and improved 









colony bred in-house) and C57Bl6 (Harlan, UK) mice 
used in experiments were 10-16 weeks old, unless otherwise stated. The mice were 
maintained on a 12 hour light/ 12 hour dark cycle in a room with regulated temperature 
(21±2°C) and humidity (50±10%). Animals had free access to standard chow (or 
vehicle/drug diet in the inhibitor study) and water. All breeding, maintenance and 
experimental protocols were approved by the University of Edinburgh ethics committee 
and performed in accordance with the Animals (Scientific Procedure) Act (UK) 1986 
under project licence number 60/3570 and personal licence number 60/10361. 
 
2.1 Colony management 
2.1.1 Breeding strategy 
11HSD1 (
-/-
) mice were generated in-house by Yuri Koteletsev (see Figure 2.1 for a 
simplified scheme of the knockout strategy) (Kotelevtsev et al., 1997, Morton et al., 
2004). Initially 3 males heterozygous for 11HSD1 were mated with 3 females null for 
11HSD1 to produce litters of 11HSD1 heterozygotes and null mice. Subsequent matings 
were conducted as straight knock-out crosses to avoid surplus mice being produced. 
C57Bl6 male mice (Harlan) served as controls 
 
2.1.2 DNA extraction 
DNA was extracted from ear clips taken from mice at weaning. Ear clips were digested 
overnight with 300µl tail buffer (0.05M Tris HCl pH 8.0, 0.1M EDTA pH 8.0, 0.1M 
NaCl, 1%SDS) and 17.5µl Proteinase K (10mg/ml) at 55°C. 10µl RNase (20µg/ml) was 
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added and incubated for a further hour at 37°C. Samples were placed on ice for 10 
minutes to precipitate the SDS then centrifuged at 9660g for 2 minutes. 300µl of 
isopropanolol was added to the supernatant and rotated for 6 minutes. Tubes were 
centrifuged for a further 2 minutes at 9660g. The supernatant was removed to leave the 
DNA pellet. Pellets were washed with 70% ethanol and centrifuged again. Ethanol was 
removed and the DNA pellet was suspended in 50µl TE buffer (0.1mM Tris.Cl pH 8, 
0.002mM EDTA). DNA was allowed to dissolve for 45 minutes at 37°C before storage 
at -20°C.  
 
2.1.3 Polymerase Chain reaction to genotype 
The polymerase chain reaction (PCR) enables the amplification of specific sequences of 
DNA, using specific primers, which can be run on a gel and the product identified by its 
size. Three primers were used to genotype the mice: 5‟-TTC TTC GTG TGT CCT ACA 
GG-3‟, 5‟-CCC GCC TTG ACA ATA AAT TG-3‟ and 5‟-CAC TGC ATT CTA GTT 
GTC GTT TGT CC-3‟. 1µl of extracted DNA was used for a 20µl reaction volume that 
also contained 1x buffer, 0.05mM dNTPs, 1U Taq Polymerase, 10ρM of each primer 
and 11.2µl autoclaved water. PCR was initiated in a MJ Research PTC Peltier 
Thermocycler with a 5 minute DNA denaturing step at 98°C. Following this there were 
36 cycles of: 95°C for 1 minute (denaturing and activating the Taq Polymerase enzyme), 
61°C for 1 minute (primer annealing), 72°C for 2 minutes and 10 seconds (primer 
extension). Final extension was conducted at 72°C for 10 minutes and finally samples 
were held at 4°C until ran on a 2% agarose gel. Ethidium bromide was used to visualise 
bands on the gel in an Uvitec box. Mice heterozygous for 11HSD1 had 2 bands between 
900 and 1000 base pairs with the knockout having a single band closer to 900 when 





ladder +/- -/- +/- +/- +/- +/-+/- -/- -/-
 
Figure 2-1 Production and Identification of 11HSD1
-/-
 mice by genotyping using the 
polymerase chain reaction 
(a) Simplified diagram of the 11HSD1 knockout strategy adapted from Kotelevstev et al., 1997. A 
targeting vetor containing a neomycin resistance cassette was used to excise exons encoding 
the catalytic domain of 11HSD1. The targeted allele was electroporated into embryonic stem 
cells, neomycin resistant clones were selected and injected into C57BL6 blastocytes before 
being transferred into a foster mother. Chimeras were bred to MF1 mice and the progeny were 
genotyped for the knockout.  (b) Samples of DNA were run on an ethidium bromide gel. Mice 
heterozygote for 11HSD1 (
+/-
) are identified by the presence of 2 bands between 900 and 1000 
base pairs. In contrast 11HSD1 knock-out mice (
-/-










2.2 In Vivo work 
2.2.1 Coronary artery ligation 
There are several murine models of myocardial infarction (MI) including cyro-injury, 
coronary artery cauterization and coronary artery ligation. Cryo-injury is achieved by 
applying a cryo-probe to the anterior left ventricle free wall for approximately 10 
seconds followed by removal using saline at room temperature. This produces 
transmural infarction that reduces fractional shortening and left ventricular contractility 
(van den Bos et al., 2005). However there are several limitations to this model. The 
infarct area is small, there is little left ventricular remodelling and the injury is not 
ischaemic, therefore not exemplary of clinical MI (van den Bos et al., 2005). Coronary 
artery cauterization is more representative of MI as the injury is caused by ischaemia, 
but there is substantial secondary damage to the heart rendering this model inutile 
(Moskowitz et al., 1979). Coronary artery ligation is a well established model of 
ischaemic myocardial infarction that produces a consistent infarct size in the same 
location. The left descending main coronary artery is ligated with a suture, either 
permanently or transiently before reperfusion. Ischaemia followed by reperfusion is 
more clinically relevant but results in less remodelling than permanent occlusion. The 
effect of an experimental intervention is therefore less likely to be seen after reperfusion 
which may result in the need for larger experimental groups (Vandervelde et al., 2006). 
For this reason the permanent occlusion model, which has become the standard, was 
used for the work described herein for consistency with previous studies from our 
laboratory and with published work. 
Male, 10-16 week old 11HSD1
-/-
 and C57BL6 (Harlan) mice were weighed and 
anaesthetised with an intraperitoneal injection of medetomidine (1mg/kg), ketamine 
(75mg/kg) and atropine (600µg/kg). Upon induction of anaesthesia buprenorphine 
(0.05mg/kg) was administered subcutaneously as an analgesic. Doses were repeated 
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every 12 hours for 24 hours. Whilst under anaesthesia mice were kept on a heating pad 
at 37°C to maintain temperature.  The skin on the chest was shaved and cleaned with an 
alcohol wipe. Mice were placed in a supine position with limbs taped down onto the 
heating pad. The trachea was intubated with a blunted 12g needle and mechanical 
ventilation began with room air (stroke volume 200µl, stroke rate 120 per min, Hugo 
Sachs Elektronik Minivent Harvard Apparatus). Eyes were coated with Lacri-Lube gel 
(Genusexpress, Aberdeen) to prevent desiccation. A 1cm subcutaneous incision was 
made over the left thorax extending medially and the subcutaneous tissue was separated 
from the muscle layers by blunt dissection. The major and minor pectoral muscles were 
separated and retracted with 5.0 Mersilk sutures (Ethicon, Livingstone) exposing the 
ribs. The left thorax was opened at the 4
th
 intercostal space by blunt dissection. The 
chest was held open using a 1cm chest retractor and a hole was made in the pericardium 
above the left atria and ventricle. The left main descending coronary artery was found 
beneath the left atrial notch in the left ventricle where pulsation of the vessel was visible. 
A 6.0 Proline suture (Ethicon, Livingstone) was pulled underneath the artery, as close to 
the atrium as possible and avoiding entering the left ventricular cavity. The needle was 
brought out approximately 1-2mm from the incision site and the suture was tied, ligating 
the artery. Successful ligation was evident from blanching of the left ventricle. In sham 
operated animals the suture was pulled under the artery but not tied. The pericardium 
was replaced over the heart and 2 single stitches with 5.0 Mersilk sutures were used to 
close the thoracic wall. Muscles were replaced into their former positions and the skin 
was stitched with continuous 5.0 Mersilk sutures. To speed recovery animals received 
atipamazole (Antisedan, an α2 antagonist 5mg/kg) and 1.5ml sterile saline 
intraperitoneally along with air supplemented with 20% oxygen through a funnel in 
which the mouse‟s head was placed. Recovery was evident by self breathing movement, 
whiskers twitching and myoclonic jerks at which point the intubation was removed. 







Myocardial function in mice can be assessed invasively by the pressure volume loop (P-
V) using a specialised conductance catheter placed into the left ventricle, or non-
invasively by magnetic resonance imaging (MRI) or ultrasound  (echocardiography). A 
benefit of the P-V method is that it enables simultaneous measurements of the left 
ventricle pressure and volume giving a comprehensive assessment of heart function 
(Shioura et al., 2007). However non-invasive methods are advantageous as they are 
technically less difficult and the assessment of cardiac function can be performed 
serially in the same mouse. MRI images which can be clarified with use of a contrast 
agent, give excellent spatial resolution and enable assessment of regional contractile 
function, cardiac dimensions and infarct size (Van Laake, 2007). However, this 
technique requires prolonged periods of imaging and is expensive. On the other hand, 
echocardiography requires a short imaging time under light anaesthesia and is less 
expensive. Until recently echocardiography has been limited by its resolution and its 1 
dimensional view.  However advances in high resolution ultrasound (such as with the 
Vevo 770 or Vevo 2100, VisualSonics) are increasing the number of parameters that can 
be measured, making ultrasound more comparable to MRI.  Ventricle dimensions may 
be measured using echocardiography enabling calculation of ejection fraction (the 
fraction of blood that is pumped out of the ventricle with each heart beat) and fractional 
shortening (the change in ventricle diameter between the contracted and relaxed state). 
When the heart is failing a decrease in ejection fraction (EF) and fractional shortening 
(FS) are seen (Van Laake, 2007, Sasaki et al., 2007, Orlic et al., 2001, Engel et al., 
2006). In the current study mice were anaesthetised with isofluorane and 
echocardiography was conducted using a Diasus ultrasound machine (10-22MHz probe 
Dynamic Imaging, Livingstone UK). The chest was shaved and the transducer, coated in 
Henleys ultrasound gel (Dunlops Veterinary Supplies, Dumfries) was placed alongside 
the sternum (parasternally) to obtain a 2D image of the myocardium taken at the mid-
papillary muscle level. Images were saved and analysed offline using Diasus software 
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(Dynamic Imaging). The ejection fraction ((LVEDA-LVESA)/LVEDA x 100) and 
fractional shortening ((LVEDD-LVESD)/LVEDD x 100) measurements enabled 
assessment of left ventricular function (Table 2.1). 
 
 
Left ventricle parameter Abbreviation 
Left ventricle end diastolic area LVEDA 
Left ventricle end systolic area LVESA 
Left ventricle end diastolic diameter LVEDD 
Left ventricle end systolic diameter LVESD 
Posterior wall thickness  at diastole PWD 
Posterior wall thickness  at systole PWS 
Fractional shortening FS 
Ejection fraction EF 
 
Table 2-1 Left ventricle parameters assessed from echocardiography 
Left ventricular parameters were measured offline using Diasus software. Measurements were 







2.2.3 Blood sampling 
Plasma samples were required to analyse circulating corticosterone levels after MI. 
Samples were taken at 7:30am, the diurnal nadir, as differences between C57Bl6 and 
11HSD1
-/-
 mice would be more pronounced (Harris et al., 2001). 2mm was cut from the 
end of the tail using surgical scissors. The tail was then milked for blood into an EDTA 
coated, capillary tube (Microvette CB300, Sarstedt, Leicester) as the mouse moved 
freely for a maximum of 1 minute. Blood sample were obtained quickly in order to 
prevent the stress response to handling confounding the corticosterone levels. Tubes 
were spun at 6000g for 10 minutes. The upper plasma layer was taken carefully and 
frozen at -20°C. Samples for flow cytometric analysis were taken just prior to culling via 
cardiac puncture. A 26g EDTA (5%) coated needle was placed into the left ventricle and 
blood was collected steadily. Samples were placed in Eppendorf tubes on ice. 
Approximately 1 ml of blood can be obtained using this method while the mouse is 
anaesthetised under isofluorane.  
 
2.2.4 Drug dosing 
For experiments described in Chapter 6 an 11HSD1 inhibitor, compound 544 (3-(1-
adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4] triazolo [4,3-α] azepine, Enamine Ltd, 
Ukraine), was administered to mice in their food. Previous work by Merck and in our 
laboratory showed that this was an effective method of dosing (Hermanowski-Vosatka et 
al., 2005). During this study drug was to be administered after induction of MI therefore 
any dosing that may increase stress levels, such as repeated intraperitoneal injections and 
gavaging, was not feasible. Prior to surgery and dosing mice were separated into pairs 
and weighed daily, along with their food, in order to determine their daily food intake. 
For 500g diet 180g powdered diet (normal chow mix) was combined with 19g gelatine 
dissolved in 151ml hot water and 150ml drug carrier solution. Compound 544 was 
dissolved in methylcellulose (0.5%) and Tween 80 (5%) and mixed thoroughly with the 
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food. Vehicle diet contained the methylcellulose and Tween 80 only. The drug was 
administered at 30mg/kg/day assuming a food intake of 10g daily calculated from pre-
surgery observations. Food was packed tightly into 60ml tubes and placed in the cages. 
Food tubes and mice were weighed daily after the commencement of the study to 
monitor drug intake. Food tubes were changed when empty or when signs of mould 
were detected.   
 
2.3 Histology 
After mice had been culled via cervical dislocation hearts were removed from the body 
and washed with ice cold PBS. Hearts for triphenyltetrazolium staining were frozen on 
dry ice then stored at -80°C.  
For histology and immunohistochemistry the tissue must be preserved by fixation in 
solutions such as 10% neutral buffered formalin and zinc fixative (Ramos-Vara, 2005, 
Ismail et al., 2003).  Fixation prevents autolysis, stabilises the tissue and stops bacterial 
growth. However this process also can distort the tissue and may create excessive 
protein cross linking that may mask the antigen and thus prevent antibody binding (see 
Section 2.5 Immunohistochemistry). To prevent over fixation tissues were fixed in 10% 
neutral buffered formalin (Sigma, Dorset, UK) for 24 hours then placed in 70% ethanol 
until processing. Whilst ethanol itself is also considered a fixative it has low penetration 
and therefore is more commonly used in this capacity in immunocytochemistry. An 
alternative approach to preserving antigen availability is to use frozen tissue sectioned 
with a cryostat. Better antigen preservation is seen where cryostat tissue sections are 
used. However, resolution is lower in frozen sections than fixed ones due to greater 
section thickness, and morphological changes during the freezing process may produce 
artefacts (Chiu et al., 1994). Fixation in formalin and subsequent embedding in paraffin 
wax is a superior way to preserve the tissue in terms of stability and morphology, and 
therefore was the option taken here. Fixed tissue was passed through as series of graded 
ethanols and xylene to clear and infiltrate the tissue prior to embedding in paraffin wax. 
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Tissue was carefully positioned during embedding in paraffin wax to ensure the best 
orientation for sectioning along the longitudinal axis of the heart. Paraffin blocks were 
placed in the freezer prior to cutting 5µm sections from each embedded heart using a 
Leitz Weltzlar 1512 microtome. Sections were floated in a Thermo water bath set at 
40°C to remove wrinkles prior to mounting on charged glass slides (VH Bio, Tyne and 
Wear). Sections were then baked at 37°C overnight. 
 
2.3.1 Triphenyltetrazolium staining 
Triphenyltetrazolium chloride (TTC) reacts with dehydrogenase enzymes and cofactors 
to stain healthy tissue a bright red colour whereas necrotic tissue, which lacks such 
activity, remains unstained (Ytrehus et al., 1994). Frozen hearts were defrosted and cut 
into 5 transverse sections using surgical blades and each section was incubated (15 
minutes; 37°C) in 1% TTC (Sigma, Dorset, UK) dissolved in PBS. Sections were then 
incubated for a further 10 minutes in 10% neutral buffered formalin at room temperature 
to enhance contrast of the stain. Hearts were blotted dry on tissue paper and digitally 
photographed at 10x magnification (Leica). For each section the area of infarct 
(unstained) as a percent of the left ventricle (stained red) was calculated using MCID 
software (Interfocus Imaging Ltd, Cambridge).  
 
2.3.2 Haematoxylin and Eosin (H&E) stain 
An H&E stain was utilised to identify neutrophils which have distinctive multi-lobed 
nuclei. Nuclei appear purple with the cytoplasm being pink (Figure 2.2). The staining 
protocol was as follows. Slides were deparaffinised and rehydrated in xylene (solution 1) 
for 10 minutes, xylene (solution 2) for 30 seconds, 100% ethanol for 1 minute, 2 x 1 
minute incubations in 74 OP (ethanol) then 5 minutes in running tap water. Sections 
were stained by placing in Gill‟s haematoxylin (Sigma) for 1 minute followed by 
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washing in running tap water and placing in alkaline tap water (see Appendix 1) for a 
further 1 minute. The nuclei were differentiated by placing in acid alcohol (see 
Appendix 1) for 5 seconds followed by washing. Slides were then placed in 70% ethanol 
followed by Eosin Y (alcoholic; Sigma) for 30 seconds. After a further tap water wash 
slides were dehydrated through graded alcohols (74 OP; 2 x 1 minute incubations 100% 















Figure 2-2 Haematoxylin and eosin stained heart section 
Typical examples of (a) a longitudinal section and (b) high magnification detail from a 
haematoxylin and eosin-stained heart from a C57Bl6 mouse 2 days after myocardial infarction 
surgery. IA is the infarct area and arrows point to neutrophils present within the infarcted area. 





2.3.3 Periodic Acid Schiff Reaction (PAS) 
The Periodic Acid Schiff Reaction (PAS) is used to assess the extracellular matrix. It 
stains glycogen and other carbohydrates in the basement membrane (magenta) and the 
nuclei (blue). Sections were stained by Susan Harvey (Medical Research Council/Centre 
for Inflammation Research Histology Service). Slides were deparaffinised and 
rehydrated as before then placed in water prior to oxidation in 1% Periodic acid for 5 
minutes. Slides were then washed in water followed by incubation in Schiff‟s reagent 
(Sigma) for 15-20 minutes and then another wash in water for 10 minutes. Nuclei were 
stained with Harris‟s haematoxylin (Sigma) for 2.5 minutes and sections were then 
rinsed in water. Nuclear staining was differentiated with acid alcohol as in H&E 
staining. Slides were washed again before being dehydrated and coverslipped as 
previously.  
 
2.3.4 Picrosirius Red staining (PSR) 
Collagen deposition in the left ventricle is a measure of fibrosis but it is found in the 
heart under normal conditions as part of the basement membrane. Picrosirius red (PSR) 
stains collagen fibres pink/red with a yellow background. Sections were stained by 
Susan Harvey (Medical Research Council/Centre for Inflammation Research Histology 
Service). Slides were deparaffinised and rehydrated (as for H&E), incubated in 
Weigert‟s haematoxylin (see Appendix 1) for 8 minutes then washed under tap water for 
10 minutes. Slides were then placed in Picrosirius Red (prepared in-house, see Appendix 
1) for 1 hour followed by 2 washes in acidified water. Finally slides were dehydrated 





2.3.5 Masson’s Trichrome stain 
Masson‟s Trichrome is a standard stain used to assess infarct size in hearts (Kido et al., 
2005). This stain distinguishes collagen fibres (blue) and nuclei (black) from the 
background (red). Sections were stained by Susan Harvey (Medical Research 
Council/Centre for Inflammation Research Histology Service). Slides were 
deparaffinised and rehydrated as before, washed in distilled water, then placed in 
Weigert‟s iron haematoxylin for 10 minutes. Sections were rinsed in warm running tap 
water for 10 minutes followed by further washing in distilled water. Staining was 
differentiated in phosphomolybdic-phosphotungstic acid solution (see Appendix 1) until 
collagen was no longer red (approximately 15 minutes). Subsequently sections were 
incubated in aniline blue solution (see Appendix 1) for 10 minutes, washed, then placed 
in 1% acetic acid for 2-5 minutes. After more washing in distilled water slides were 
dehydrated and coverslipped.  
 
2.3.6 Quantification 
Qualitative assessment of gross heart structure, the extracellular matrix and basal 
collagen from H&E, PAS and PSR staining in un-operated hearts was conducted by 
David Brownstein, an expert rodent pathologist. Quantification of neutrophils, collagen 
deposition and scar size after MI or sham operation were conducted using Image Pro6.2, 
Stereologer Analyser 6 MediaCybernetics (Buckinghamshire, UK) with sections being 
tiled at x50 or x100 magnification. The entire left ventricle (including the apex and 
posterior and anterior wall) was identified as an area of interest using the Image Pro6.2 
computer programme after image acquisition. Neutrophils were identified by their 
distinctive multi-lobed nuclei at x1000 magnification. Cells were counted in the left 
ventricle and expressed as the average number (from 10 randomly selected areas) per 
40µm
2
. Collagen deposition and scar size were quantified as a percentage of the total 
area of the left ventricle. Scar thickness was calculated from the thickness of 3 points 
along the scar and averaged. Endocardial and epicardial infarct lengths were calculated 
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as a percentage of the total circumference of the left ventricle using the following 
equation:   
Infarct length (%) = infarct length/ left ventricle circumference x 100 (Kido et al., 2005). 




Immunohistochemistry allows the visualisation of antigens in a tissue by the application 
of an antibody specific for that antigen enabling assessment of antigen localisation and 
expression. Please refer to Section 2.4 Histology for details of fixation, embedding and 
sectioning. For immunohistochemistry 2 sections were placed on each microscope slide 
giving an adjacent negative control. Sections were then baked at 37°C overnight and for 
a further 30 minutes at 55°C immediately prior to staining to ensure good section 
adherence to the slide. Slides were taken through a series of xylenes (3 x 5 minutes) and 
graded ethanol (100% for 5 minutes and 74OP 2 x 5 minutes) to remove the wax and 
rehydrate the tissue.  
As described in Section 2.4 (Histology) tissue fixation may result in protein cross-
linking that may mask the antigen of interest. Unmasking cross-linked antigens can be 
achieved using antigen retrieval steps which involve exposing the tissue to high 
temperatures or to enzymatic digestion (Ramos-Vara, 2005). Heat-induced epitope 
retrieval (HIER) involves heating the sections in the microwave in either low or high pH 
buffers such as citrate pH6 buffer and Tris-EDTA pH9 buffer. Buffers are heated to 
boiling, slides are added and placed in the microwave on high power for 10 minutes. 
Slides are subsequently cooled in the buffer for a further 20 minutes.  Proteolytic-
induced epitope retrieval (PIER) uses enzymes such as trypsin and Proteinase K to 
unmask the antigen (see Appendix 1 for recipe). Slides are incubated with these 
enzymes usually at 37°C for 20 minutes.  
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Antibodies are immunoglobulins found in the serum and plasma. They are made by 
introducing the relevant antigen into a host, preferably a different species, causing the 
production of antibodies. Blood is collected and the antibody is isolated and purified. 
Polyclonal antibodies recognise several epitopes of the antigen and have relatively low 
specificity and high variation between batches. Monoclonal antibodies do not have this 
drawback as they are immunochemically identical. After the host has been immunised B 
cells (cells that produce the antibody) are harvested, fused with myeloma cells producing 
an immortal cell line that yield the antibody of interest (Ramos-Vara, 2005). However 
one disadvantage of such antibodies is that if fixation has cross-linked the specific 
antigen that the particular monoclonal antibody recognises it may not bind. As 
polyclonal antibodies recognise an array of epitopes they will be more likely to adhere. 
Both polyclonal and monoclonal antibodies have been used in the current work. 
All of the immunohistochemistry protocols used in this study use avidin biotin 
technology for detection (Figure 2.3). The unconjugated primary antibody binds to the 
antigen. A biotinylated secondary antibody directed against the primary is applied 
followed by extravidin peroxidase which recognises the biotin of the secondary 
antibody. Subsequent incubation with the chromagen (3, 3'-diaminobenzidine; DAB), 
results in the development of a brown colour (due to peroxidase activity) at sites where 
extravidin peroxidase is bound. This system enables amplification of the target antigen 
as the secondary antibody and extravidin peroxidase can bind to several epitopes of the 
primary antibody and secondary antibody respectively, thus increasing sensitivity. 
However, such amplification may also amplify background staining which may have 
several sources. Endogenous peroxidase activity is seen in tissue containing 
haemoproteins (e.g. haemoglobin, myogloblin) and may produce background staining by 
reacting with DAB. In the present study, endogenous peroxidase activity was quenched 
by application of 3% hydrogen peroxide for 15 minutes. Some tissues also express 
endogenous biotin and, therefore, require blocking by pre-treating with avidin followed 
by saturating with biotin. Fixation of tissues increases hydrophobicity. Both 
hydrophobic and ionic non-specific interactions between the tissue and antibodies may 
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cause background staining. This may be reduced by incubation with non-fat dry milk 
and bovine serum albumin (BSA) as a separate step and/or addition of BSA (1-5%) in 
the diluting buffer.  Inappropriate binding of the secondary antibody to the tissue is 
prevented using serum from the species in which the secondary antibody was raised. 
Substantial background staining is seen when an antibody is directed against the same 
species in which it was raised. To prevent this incubation with a mouse-on-mouse 
blocking kit for 1 hour was conducted and proved successful. Furthermore thorough 
washing between all incubation steps, with the exception of milk/BSA, serum blocking 
and mouse on mouse blocking, with buffer (either PBS or TBS-Tween) prevents 
















Figure 2-3 Schematic of immunohistochemistry using avidin biotin technology 
Immunohistochemistry is used to label specific antigens in tissue sections by application of a 
relevant antibody. Addition of a biotinylated secondary antibody that recognises the primary 
antibody but not the host tissue is applied, after removal of the excess primary. The secondary is 
removed by washing and extravidin peroxidase is added to recognise the biotinylation of the 
previous antibody. DAB recognised the peroxidase activity of the extravidin peroxidase and 





A brief overview of the protocols is given in Table 2.2.  Each different antibody was 
stained for on 1 slide per animal. Where several different antibodies were used in a study 
sequential slides were used where possible. For all immunohistochemistry protocols 
5µm sections were deparaffinised in xylene and rehydrated through various 
concentrations of ethanol then placed in running tap water. Endogenous peroxidase 
activity was blocked using 3% hydrogen peroxide diluted in distilled water for up to 15 
minutes. Primary antibody concentrations were determined after pilot experiments using 
a range of antibody dilutions around those suggested by the manufacturer. Control 
antibodies (immunoglobulins from pre-immune animals) were diluted as the primary 
antibody (Table 2.3). After application of the secondary antibody, sections were washed 
in PBS or TBS and incubated with extravidin peroxidase (Sigma) diluted 1/200 in buffer 
for 30 minutes. After more washing the sections were incubated with DAB Substrate 
(Vector, Peterborough, UK) for the relevant time. DAB was placed on one positive slide 
from each experiment and watched under the microscope until the brown colour 
developed. The length of time required for this was then used for the rest of the slides. 
Sections were washed for 5 minutes in tap water then counterstained with haematoxylin, 
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11HSD1 Polyclonal sheep anti-
mouse anti 11HSD1 
(generated in house) 
No 2.5%milk/2.5





Overnight 4°C Biotinylated rabbit 
anti sheep (Vector) 
1/200, 30 minutes 
Table 2-2 Protocols for immunohistochemistry 
Brief details of the immunohistochemistry protocols used including antigen retrieval, blocking, primary and secondary antibody incubations. 
BSA=bovine serum albumin; PBS= phosphate buffered saline TBS= tris buffered saline, 11HSD1= 11β-hydroxysteroid dehydrogenase, 







Primary antibodies Control antibodies (same 
concentration as primary) 
 Mac 2, CD45R, CD31  Rat IgGa κ 
BrdU, α smooth muscle actin Mouse ascites fluid 
YM1, CD3  Rabbit IgG 
11HSD1 Sheep IgG 
 
Table 2-3 Relevant control antibodies for immunohistochemistry 
Control antibodies (immunoglobulins from pre-immune animals) were diluted and applied in the 
same manner as the primary antibodies.  
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2.4.2 Identification of macrophages 
A variety of macrophage markers are used in immunohistochemistry, including F4/80, 
mac 3, factor VIIIa and mac 2. F4/80 is a widely expressed on monocytes and 
macrophages, and antibodies directed against it have been used for 
immunohistochemistry frozen tissue or in tissue fixed in Methyl Carnoys solution 
(Morimoto et al., 2006, Henderson et al., 2008). In the current study tissues were fixed 
in 10% formalin, and despite attempts to optimise the protocol, F4/80 staining was not 
sufficiently clear for quantification (Figure 2.4). Mac 2, otherwise known as galectin 3, 
is another well-characterised cell surface marker that is expressed and secreted by 
activated macrophages, and was used successfully in the current study in identifying 
macrophages (MacKinnon et al., 2008). After peroxidase blocking, sections were 
incubated with 10% normal goat serum (Vector) diluted in PBS for 30 minutes. The 
monoclonal rat anti-mouse mac 2 primary antibody (VH Bio) was diluted 1/6000 in 
PBS/1%BSA and incubated with the sections overnight at 4°C. After PBS washes the 
biotinylated goat anti-rat antibody (Vector) was added in a 1/200 dilution in 




Figure 2-4 Immunohistochemistry for the macrophage marker F4/80 
Mouse heart tissue 7 days post-MI demonstrating typical F4/80 positive and negative staining 











2.4.3 Identification of alternatively activated macrophages 
Anti-RELMα/FIZZ1 (a resistin-like molecule) and YM1 (a chitinase-like lectin) 
antibodies have been used to detect alternatively activated macrophages using 
immunohistochemistry (Loke et al., 2002, Nair et al., 2005). Immunohistochemistry for 
RELMα showed cell staining in positive control sections (nematode infected lungs) but 
not in hearts after MI. YM1 on the other hand was expressed in both positive control 
tissue and in infarcted hearts (for examples see Section 4, Figure 4.13). Therefore this 
marker was chosen to detect alternatively activated macrophages in the healing infarcts. 
HIER was conducted by microwaving slides in hot citrate buffer pH 6.0 (see Appendix 
1) for 5 minutes followed by cooling for a further 20 minutes. After peroxidase 
blocking, sections were incubated with Avidin/Biotin blocking solutions (Vector), 
following manufacturer‟s instructions, and 10% normal goat serum (Vector) diluted in 
PBS (30 minutes). The polyclonal rabbit anti-mouse YM1 primary antibody (Stem Cell 
Technology, France) was diluted 1/50 in PBS/1%BSA and incubated with sections for 
60 minutes at room temperature. After washes with PBS sections were incubated with 
the biotinylated goat anti-rabbit secondary antibody (Vector) diluted 1/400 in 
PBS/1%BSA for 30 minutes.  
 
2.4.4 Identification of other inflammatory cells 
For immunohistochemistry to detect T-cells, antigens were retrieved by heating in Tris-
EDTA buffer pH9.0 (see Appendix 1) for 10 minutes in the microwave, followed by 
cooling. After peroxidase blocking, sections were incubated in 20% normal goat serum 
(Vector) diluted in PBS for 30 minutes. The polyclonal rabbit anti-human CD3 primary 
antibody (Dako, Cambridgeshire) was diluted 1/400 in PBS/1%BSA and incubated for 
60 minutes at room temperature. After washing the biotinylated goat anti-rabbit 
secondary antibody (Vector) was diluted 1/200 in PBS/1%BSA and incubated with the 
sections for 30 minutes. For B cell staining sections were blocked in 10% normal rabbit 
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serum (Vector) in PBS for 30 minutes. The monoclonal rat ant-mouse CD45R primary 
antibody (BD Bioscience, Oxford) was diluted 1/50 in PBS/1%BSA and incubated with 
sections for 30 minutes at room temperature. Slides were washed then incubated with a 
biotinylated rabbit anti rat secondary antibody (Vector) diluted 1/200 in PBS/1%BSA. 
 
2.4.5 Identification of neovascularisation 
A number of endothelial cell markers have been used for immunohistochemical 
detection of endothelial cells, including isolectin B4, CD34, von Willebrand factor and 
Tie-2. Ismail et al conducted an extensive comparison of several endothelial cell markers 
in tissues prepared in a variety of fixatives (Ismail et al., 2003). They found that CD31, 
otherwise known as platelet endothelial cell adhesion molecule-1 (PECAM-1), was a 
superior endothelial cell marker in formalin fixed paraffin embedded tissue as it detects 
both macro- and micro-vessels (Ismail et al., 2003). This makes it ideal to assess 
neovascularisation. The CD31 antigen was retrieved by proteolytic tissue digestion in 
Proteinase K (20µg/ml in TE buffer, Roche, West Sussex, UK) for 20 minutes at 37°C 
and a further 20 minutes cooling. After peroxidase blocking sections were blocked 
further by incubation with 20% normal rabbit serum (Vector) in PBS for 30 minutes. 
The monoclonal rat anti mouse CD31 primary antibody (BD Bioscience) was diluted 
1/50 in PBS/1%BSA and incubated with sections overnight at 4°C. After washing the 
biotinylated rabbit anti-rat secondary antibody (Vector) was diluted 1/200 in 
PBS/1%BSA and incubated with the sections for 30 minutes. 
 
2.4.6 Identification of cell proliferation 
Proliferating cells can be identified by exposure to bromodeoxyuridine (BrdU) which is 
incorporated into the nucleus during replication and can subsequently be detected with a 
specific antibody. Injecting a bolus dose of BrdU in vivo enables assessment of cell 
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proliferation from time of injection. In this study BrdU (2.5mg in warmed saline, 
5mg/ml, Sigma) was injected into the peritoneum of mice 1 hour prior to sacrifice to 
allow incorporation into the nuclei of replicating cells. In heart sections, antigens were 
retrieved by incubating slides in 2N HCl (see Appendix 1) for 15 minutes at 37°C 
followed by trypsin digestion (see Appendix 1) for 30 minutes at 37°C. All washes were 
with TBS-Tween (see Appendix 1) to reduce background staining due to hydrophobic 
interactions. Blocking of non-specific antibody binding was by incubation with an 
Avidin/Biotin blocking kit and mouse-on-mouse blocking kit as per manufacturer‟s 
instructions (Vector). The monoclonal mouse anti-mouse primary antibody was diluted 
1/1000 (Sigma) in TBS/10% normal goat serum/5%BSA and incubated for 1 hour at 
37°C. After washing with TBS-Tween sections were incubated with the biotinylated 
goat anti-mouse secondary antibody (Vector) diluted 1/200 in TBS/1%BSA for 30 
minutes.  
 
2.4.7 Double immunohistochemistry 
The study described in Chapter 4 was designed to identify which cells were 
proliferating. In order to achieve double immuno-labelling for mac2 positive 
macrophages and BrdU positive proliferating cells the protocols were run sequentially. 
Mac 2 immunohistochemistry was run first followed by the BrdU protocol immediately 
after the DAB step. BrdU was visualised using a SG substrate kit following 
manufacturer‟s instructions (Vector) to produce a blue/grey colour. Sections were then 
washed (counterstaining with haematoxylin was omitted) and dehydrated as with other 
protocols. Attempts to co-localise BrdU with CD31 were unsuccessful when protocols 





2.4.8 Myofibroblast activation 
Blocking of non-specific background staining was achieved by incubating sections with 
2.5%milk/2.5%BSA in PBS for 1 hour followed by a mouse-on-mouse blocking kit for a 
further hour and 10% normal goat serum (both Vector) in PBS for 30 minutes. The 
monoclonal mouse anti-mouse α-smooth muscle actin (αSMA) primary antibody 
(Sigma) was diluted 1/400 in PBS/1%BSA and incubated with the tissue at room 
temperature for 60 minutes. After washing the biotinylated goat anti-mouse secondary 
antibody (Vector) was diluted 1/200 in PBS/1%BSA and incubated with the slides for 30 
minutes.  
 
2.4.9 11HSD1 expression 
Attempts to achieve immunostaining with commercially bought 11HSD1 and 11HSD2 
(Cayman Chemicals, Michigan, USA) were unsuccessful. However, an antibody 
generated in-house against a murine 11HSD1 fragment over-expressed in E.coli (raised 
in sheep) was available. The sheep plasma was purified by Fu Yang (Centre for 
Cardiovascular Science, The University of Edinburgh) using a Hightrap protein G 
column (GE Healthcare). In heart and positive control tissue (liver and kidney) 
background staining was blocked by incubating sections for 1 hour in 2.5% powdered 
milk/2.5% BSA in PBS followed by 30 minutes in 10% normal rabbit serum (Vector). 
The polyclonal sheep anti-mouse 11HSD1 was diluted 1/2000 in PBS/5%BSA and 
incubated with sections overnight at 4°C. After washing in PBS the biotinylated rabbit 
anti-sheep secondary antibody (Vector) diluted 1/200 in PBS/1%BSA was added for a 







Quantification of immunohistochemistry was conducted using Image Pro 6.2, 
Stereologer Anaylser 6 MediaCybernetics. Sections were tiled at x100 and the entire left 
ventricle (including the apex and posterior and anterior wall) or infarct border (area 
between the infarcted tissue and the healthy myocardium) were selected as the area of 
interest (after image acquisition using Image Pro 6.2) in which all measurements were 
made. Macrophage infiltration (both mac 2 and YM1) was quantified as the percent of 
infarct border stained. The area was assessed automatically after a threshold had been set 
manually. Small vessels (<200 µm
2
 diameter) positively stained for the endothelial cell 
marker, CD31, were counted in the left ventricle as the number per 400µm
2
 and 
expressed as an average of 10 areas in the left ventricle randomly selected by the 
computer programme. Counting was conducted during acquisition on the computer 
using a scale bar. BrdU positive cells were counted in the left ventricle and expressed as 
number of cells per mm
2
. Activated myofibroblast activation was quantified as 
percentage staining in the left ventricle.  
 
2.5 Biochemical and molecular techniques 
2.5.1 Corticosterone Radioimmunoassay 
The corticosterone radioimmunoassay, developed in-house, is a competition assay that 
has been used here to determine plasma levels of corticosterone after myocardial 
infarction. Samples are incubated with radiolabelled corticosterone (
3
H-B), a primary 
antibody directed against corticosterone, and a secondary antibody directed against the 
primary conjugated to scintillation proximity (SPA) beads. When these SPA beads are in 
close proximity to the 
3
H-B light is emitted and can be detected by scintillation counters. 
When there is little unlabelled corticosterone in the sample most of the primary antibody 
will bind to the radiolabelled corticosterone stimulating the SPA beads to emit light after 
exposure to the secondary antibody (Figure 2.5). Where there is more unlabelled 
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corticosterone (i.e. more corticosterone in the sample) this will compete for the primary 
antibody, reducing the amount of the 
3
H-B in proximity to the SPA bead conjugated 
secondary antibody and, therefore, will reduce SPA stimulation (Figure 2.5).  
At the diurnal nadir (7:30am) blood was collected by tail tip from the mice as described 
in Section 2.3.3. Samples were spun at 6000g at 4°C and the plasma was removed to a 
fresh tube before freezing at -20°C. When ready to assay samples were diluted 1 in 5 
with borate buffer (se Appendix 1). The majority of plasma corticosterone is normally 
bound to corticosterone binding globulin and this was liberated by denaturing at 75° for 
1 hour. Samples were then kept on ice until ready to assay. Standards of 0, 0.3, 0.6, 1.25, 
2.5, 5, 10, 20, 40, 80, 160 and 320nM corticosterone were made from concentrated stock 
solution (32µM) in borate buffer. 20µl of sample or standard were added to wells in a 96 
well flexible plates in duplicate. 50µl of the radiolabelled corticosterone (radiation count 
of 8-12000 counts per minute (CPM), 1.5nM) and the primary antibody (rabbit anti-
mouse corticosterone antibody made in-house by Dr Chris Kenyon, Centre for 
Cardiovascular Science, The University of Edinburgh) diluted 1/100 in borate buffer 
was added to each well. Plates were incubated at room temperature for 2 hours before 
adding 50µl anti-rabbit SPA beads (5mg/ml made up in borate buffer) to each well. 
Plates were inverted to mix. Emitted light was measured in the Wallac 1450 Microbeta 
Scintillation Counter after further 16 hour incubation. The standards (x axis) were 
plotted against the CPM (y axis) to generate a standard curve. Sample corticosterone 












Figure 2-5 Corticosterone radioimmunoassay 
Corticosterone in the sample competes with 
3
H-corticosterone for the primary antibody and 
subsequently the complex binds to the SPA secondary. Light is emitted when the SPA is in 
proximity to 
3
H-corticosterone which is measured in a beta counter. SPA= scintillation proximity 
assay. 


























Figure 2-6 Corticosterone standard curve 
A standard curve was generated for each corticosterone radioimmunoassay plate in order to 
determine the corticosterone concentration in plasma samples.  
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2.5.2 RNA extraction 
Heart tissue was excised, washed in ice cold PBS and bisected before freezing on dry 
ice. Samples were stored at -80°C before being used. Trizol (Invitrogen) was used to 
extract RNA from the tissue. Half of a heart was homogenised in 1ml Trizol using 3mm 
Retsch metal beads in a Retsch MM301 ball miller at room temperature (Retsch, Leeds). 
Full homogenisation was achieved after 3.5 minutes at 25Hz. Samples were then moved 
to a fresh autoclaved eppendorf and spun at 12000g for 10 minutes at 4°C.  This extra 
isolation step removed insoluble material such as collagen. The supernatant was 
removed to a fresh tube and incubated at room temperature for 5 minutes. 0.2ml 
chloroform was added, samples were shaken vigorously then incubated at room 
temperature for 3 minutes. Samples were spun at 12000g for 15 minutes at 4°C. The 
colourless upper aqueous phase contained the RNA and was removed to a fresh tube. 
0.5ml isopropanolol was added to precipitate the RNA over a 10 minute incubation 
period. After another spinning step (12000g for 10 minutes at 4°C), a gel-like RNA 
pellet was formed. The pellets were washed with 70% ethanol in DEPC water and spun 
again (7500g for 5 minutes at 4°C). The ethanol was removed and the pellets dried 
before re-dissolving the RNA in 30-50µl DEPC treated water (see Appendix 1). RNA 
quantity and quality in 2µl were analysed using the Nanodrop 2000 analyser 
(Wilmington, USA). All RNA had an A260/A280 ratio of 1.8-2.2 which suggests high 
quality RNA with low contamination with carbohydrates or proteins. RNA was treated 
with DNase I amplification grade (Invitrogen) to prevent degradation by endogenous 
DNases. Briefly, 1µg RNA was incubated with 1x DNase reaction buffer and 1 unit 
DNase Amp Grade for 15 minutes at room temperature. The reaction was inactivated by 
adding 2.5mM EDTA and incubating at 65°C for 10 minutes. Samples were kept at -





2.5.3 cDNA synthesis 
RNA cannot be used in PCR and for this reason it is converted to single stranded cDNA 
using reverse transcription. This was achieved using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Warrington). A mastermix containing 1x RT 
buffer, 1 x dNTPs, 1x RT random primers (short primers that give uniform amplification 
of RNA), 1µl multiscribe RT, 1µl RNase inhibitor and 3.2µl nuclease free water was 
mixed together on ice. RNase inhibitors were used to prevent RNA degradation. 10µl of 
this mastermix was added to eppendorf tubes along with 10µl DNase-treated RNA 
(approximately 1µg). Solutions were mixed using a pipette before being loaded onto a 
Thermocycler. The reverse transcription was carried out under the following conditions; 
25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes. cDNA was 
subsequently transferred to a freezer at -20°C for storage. To check that the reverse 
transcription had worked a GAPDH PCR was conducted. GAPDH is a housekeeping 
gene expressed in all cell types and therefore should be present in cDNA samples. A 
mastermix containing 1x buffer, 0.05mM dNTP mix, 1 unit Taq Polymerase, 10ρmol of 
the forward and reverse primers (forward 5‟-TCA AGA AGG TGG TGA AGC AGG C-
3‟, backward 5‟-CTC TCT TGC TCA GTG TCC TTG C-3‟) and autoclaved water. A 
25µl reaction mixture was produced by adding 1µl DNA to the mastermix. The PCR 
reaction was initiated with a denaturing step (95°C, 4 minutes)  followed by 30 cycles of 
94°C for 1 minute, 53°C for 1 minute and 72°C 2 minutes. Final extension was achieved 
with 10 minute incubation at 72°C. Samples were run on a 2% agarose gel containing 
ethidium bromide and visualised using an Uvitec box. A DNA ladder was used to 
identify GAPDH bands at 280 base pairs. 
 
2.5.4 Quantitative Real Time PCR 
Quantitative real time PCR (qRT PCR) is a highly sensitive method that enables the 
quantitative analysis of tissue mRNA levels. It is similar to conventional end point PCR 
in that there are cycles of primer annealing, extension and target amplification. 
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However, unlike end point PCR, detection of mRNA is achieved as the reaction occurs 
giving higher sensitivity and resolution. In this study a Roche Lightcycler was used for 
qRT-PCR. This method utilises fluorescent resonance energy transfer (FRET) where the 
primer-probe contains a 5‟ high energy reporter that is attached to a 3‟low energy 
quencher.  When the probe and primer are close together energy is transferred from the 
high energy reporter to the quencher upon light excitation.  During the PCR reaction the 
primer-probe becomes annealed to complementary strands of cDNA. As the Taq 
Polymerase enzyme copies the cDNA its 5‟ nuclease activity cleaves the primer-probe 
preventing the energy transfer. Fluorescent emission from the reporter is captured by the 
Lightcycler instrument. Emissions are detected over several cycles of primer annealing, 
extension and amplification. The detection system produces an amplification plot which 
shows the fluorescence level and cycle number (Figure 2.7). From this a crossing point 
(CP) value may be extrapolated. This value is the cycle at which the level of 
fluorescence in the reaction is distinguishable from the background. The lower the CP 
value the fewer the number of cycles required to get a significant level of fluorescence 
indicating a greater mRNA abundance. This is normalised to a housekeeping 
gene/endogenous control, in this case GAPDH, to compensate for potential differences 
in the amount of cDNA put into the reaction. GAPDH was a suitable candidate as it was 
not altered by infarction (as seen from data from the current study) and remained similar 
across the samples.  
Initially a small volume of cDNA from a variety of experimental groups was pooled 
then serially diluted to produce a standard curve. The amount of cDNA required for the 
qRT PCR reaction was optimised from this standard curve for each gene. cDNA for IL-
6, MCP-1 and IL-8 qRT PCR was used undiluted. cDNA for VEGF, GR, MR and 
11HSD1 was diluted 1 in 5 in PCR grade water just prior to use. Each reaction included 
2µl cDNA, 1x Lightcycler Probes Master, 4x primer probe (Applied Biosystems pre-
optimised probes) and PCR grade water to a volume of 10µl. The primer probes are 
listed below in Table 2.4. The programme used on the Lightcycler 480 was: pre 
incubation at 95°C for 10 minutes (ramp rate 4.8°C/s); 40 cycles of amplification  95°C 
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for 10 seconds (ramp rate 4.8°C/s), 60°C for 20 seconds (ramp rate 2.5°C/s), 72°C for 20 
seconds (ramp rate 4.8°C/s single acquisition); cooling 40°C for 10 seconds (ramp rate 
2.5°C/s). 
The volumes used are very small thus increasing the likelihood of a pipetting error. 
Therefore samples were run in triplicate. Triplicates were averaged unless there were 
discrepancies (greater than 10%) between values. In such cases the inconsistent value 
was removed. These average CP values were then expressed as a fold change relative to 
the GAPDH CP value. Expression was normalized for GAPDH expression and 











Figure 2-7 Typical amplification curve produced by qRT-PCR 
In samples where the gene of interest is expressed fluorescent emissions increase beyond that 
of the background (shown by an upward curve). The cycle (crossing point, CP, where the line 











Gene Assay ID 
Interleukin-6 (IL-6) Mm99999064_m1 
Monocyte chemoattractant protein 1 
(MCP-1) 
Mm00441242_m1 
Interleukin 8 (IL-8) Mm00433859_m1 
Vascular endothelial growth factor A 
(VEGF A) 
Mm00437306_m1 
Glucocorticoid receptor (GR) Mm00433832_m1 
Mineralocorticoid receptor (MR) Mm01241596_m1 




Table 2-4 Primer-probes used for qRT-PCR 
TAQman ® Gene Expression Assays were used to detect mRNA levels of IL-6, MCP-1, IL-8, 




2.6 Power Calculations and Statistical Analysis 
Sample size was determined on the basis of cardiac function (ejection fraction i.e., the 
fraction of blood pumped out of the left ventricle in one beat, assessed by 
echocardiography) as the primary end point. Based on previous work in the laboratory 
and published work, I assumed ejection fraction to be 30% 7 days after MI (normal 
ejection fraction is approximately 65%) and that increasing angiogenesis may improve 
ejection fraction by 10% (to 40%) with a standard deviation of 8%. This would 
necessitate a sample size of ≥6 mice per MI group tested for there to be 80% power in 
the experiment. As the difference in sham and MI values for ejection fraction are 
relatively large (normally >30%) the sample size required in the sham-operated groups 
is much lower (≥3 mice per goup tested). Sample size was determined using GraphPad 
Statmate 2.  
Statistical analysis was conducted using GraphPad Prism software. In each Chapter all 
data are expressed as mean ± SEM. Analysis of mortality and cause of death data were 
conducted using Fisher‟s exact test and the Chi squared test. Other comparisons are by 
unpaired Student‟s t test, 1 way ANOVA and 2 way ANOVA. Please see individual 




APPLIED BIOSYSTEMS, WARRINGTON, UK 
High capacity cDNA reverse transcription kit, TAQman ® Gene Expression Assays; 
Interleukin-6 (Il-6) Mm99999064_m1, Monocyte chemoattractant protein 1(MCP-1) 
Mm00441242_m1, Interleukin 8 (Il-8) Mm00433859_m1, Vascular endothelial growth 
factor A (VEGF A) Mm00437306_m1, Glucocorticoid receptor (GR) 
Mm00433832_m1, Mineralocorticoid receptor (MR) Mm01241596_m1 and 11 β 
hydroxysteroid dehydrogenase type 1 Mm00476182_m1, mouse GAPDH endogenous 
control (FAM/MGB probe non primer limited) 
BD BIOSCIENCES, OXFORD, UK 
Monoclonal rat anti mouse CD31 antibody , rat IgG2a,k control antibody,  
CEDARLANE, SUPPLIED THROUGH VH BIO, TYNE AND WEAR, UK 
Monoclonal rat anti mouse mac 2 
DAKO, CAMBRIDGESHIRE, UK 
Polyclonal rabbit anti human CD3 antibody 
DUNLOP‟S VETERINARY SUPPLIES, DUMFRIES, UK 
Henleys Ultrasound gel 
ENAMINE LTD, UKRAINE 
Compound T5293658 
 
ETHICON, LIVINGSTONE, UK 
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Mersilk sutures 5/0 75cm (W581), Prolene sutures  6/0 (W8712)  
FISHER SCIENTIFIC, LEICESTERSHIRE, UK 
Tris HCl, Tris base, sodium chloride (NaCl), 74 O.P, Hydrochloric acid, potassium 
dihydrogen orthophosphate (KH2PO4), calcium chloride (CaCl3), sodium hydrogen 
carbonate (NaHCO3), Shandon MB35 Premier microtome blades 
GE AMERSHAM, BUCKINGHAMSHIRE, UK 
Anti-Rabbit YSi SPA Scintillation Beads, 
3
H- Corticosterone,     
GENUSEXPRESS, ABERDEEN, UK 
Lacri-lube gel 
INVITROGEN, PAISLEY, UK 
Rat anti mouse CD11b PE antibody, hamster anti mouse CD11c-APC antibody, Trizol, 
DNase I amplification grade 
INTERFOCUS IMAGING LTD, CAMBRIDGE, UK 
MCID software 
LONZA, SLOUGH, UK 
Dulbecco‟s PBS without magnesium or calcium 
PROMEGA, SOUTHAMPTON, UK 
RNase, agarose, 100bp DNA ladder, loading buffer, GoTaq DNA Polymerase, dNTPs 





Reastain Quick Diff kit 
RETCSH, LEEDS, UK 
3mm cone balls 
ROCHE, WEST SUSSEX, UK 
Proteinase K, Collagenase (type), Lightcycler 480 multiwell plates 384, Lightcycler 480 
Probes Master 
SAINSBURY‟S, UK 
Gelatin, non fat dried milk 
SARSTEDT, LEICESTER, UK 
Microvette CB300 blood collection tubes 
SIGMA, DORSET UK 
EDTA, Isopropanolol, SDS, Ethidium Bromide, 10% neutral buffered saline, 
triphenyltetrazolium chloride, Harris‟s Haematoxylin, Gill‟s Haematoxylin, Weigert‟s 
Haematoxylin, Eosin Y, DPX (Fluka), BrdU (Fluka), mouse anti mouse BrdU antibody, 
mouse anti mouse α smooth muscle actin antibody, control mouse ascites fluid, bovine 
serum albumin fraction V, bovine serum albumin, Extravidin peroxidase, 30% hydrogen 
peroxide, ammonia hydroxide, methylcellulose, Tween 80, citric acid, boric acid 
(B6768), potassium chloride (KCl), corticosterone, diethyl pyrocarbonate (DEPC), 
Bradford reagent, Direct Red, Collagenase type IA-S (C-5894), magnesium sulphate 
(MgSO4),  ammonium chloride (NH4Cl), Ethylenediaminetetraacetic acid disodium salt 
dehydrate (Na2EDTA), Potassium bicarbonate (KHCO3), Periodic acid, Schiff‟s 
Reagent,  Collagenase Type IA-S. 
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STEM CELL TECHNOLOGIES, GRENOBLE, FRANCE 
Polyclonal rabbit anti mouse YM-1 
VECTOR, PETERBOROUGH, UK 
Normal goat serum, normal rabbit serum, biotinylated goat anti rat secondary antibody, 
biotinylated goat anti rabbit secondary antibody, biotinylated goat anti mouse secondary 
antibody, biotinylated rabbit anti rat antibody, biotinylated rabbit anti sheep, avidin 
biotin blocking kit, M.O.M mouse IgG blocking reagent (PK-2200), DAB substrate kit 
(SK-4100), rabbit IgG, sheep IgG 
VH BIO, TYNE AND WEAR, UK 
11HSD1 primers 5‟-TTC TTC GTG TGT CCT ACA GG-3‟, 5‟-CCC GCC TTG ACA 
ATA AAT TG-3‟ and 5‟-CAC TGC ATT CTA GTT GTC GTT TGT CC-3‟ 
GAPDH primers: forward 5‟-TCA AGA AGG TGG TGA AGC AGG C-3‟, backward 
5‟-CTC TCT TGC TCA GTG TCC TTG C-3‟ 
VWR-BDH, LEICESTERSHIRE, UK 






Basal cardiac phenotype of the 11HSD1 deficient mouse 
3.1 Introduction 
Glucocorticoids have a plethora of physiological functions including modulating 
metabolism, the stress response, inflammation and blood pressure. However, 
pathological excess of glucocorticoids is correlated with adverse cardiovascular effects 
(Kerrigan et al., 1993). Their action is mediated by activation of either low affinity 
glucocorticoid (GR) or high affinity mineralocorticoid (MR) receptors that are expressed 
across the cardiovascular system, including in the heart and vasculature (Sheppard and 
Autelitano, 2002, Lombes et al., 1995, Hadoke et al., 2006, Yoshikawa et al., 2009, 
Takeda et al., 2007). These receptors are often co-expressed with the 11β-
hydroxysteroid dehydrogenase (11HSD) enzymes which are also present in the 
myocardium and vasculature (Hadoke et al., 2006, Slight et al., 1993, Slight et al., 1996, 
Christy et al., 2003, Takeda et al., 2007, Walker et al., 1991). 11β-hydroxysteroid 
dehydrogenase type 1 (11HSD1) reactivates cortisone in humans and 11-
dehydrocorticosterone in rodents, to cortisol and corticosterone respectively, by its 
ability to act as a reductase. It is found in glucocorticoid target tissues and amplifies 
glucocorticoids locally. Conversely, protection of the MR from illicit activation by 
glucocorticoids is achieved via „pre-receptor‟ inactivation of cortisol/corticosterone by 
11β-hydroxysteroid dehydrogenase type 2 (11HSD2).  
Glucocorticoids have a diverse array of effects in the myocardium including regulation 
of electrical and mechanical activities of the heart (Yoshikawa et al., 2009). 
Dexamethasone, a synthetic glucocorticoid, can increase cardiac L-type Ca
2+
 channel 
currents, increase contraction and relaxation velocities, and in healthy human volunteers 
can reduce resting heart rate (Whitehurst et al., 1999, Penefsky and Kahn, 1971, 
Brotman et al., 2005). However, studies have also shown that MR activation can 
modulate electrical activities of the heart (Ouvrard-Pascaud et al., 2005) and fibrosis 
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(Benard et al., 2009). A recent comprehensive study of the specific role of GR activation 
on metabolism in rat cardiomyocytes was conducted by Yoshikawa et al. using the GR 
selective agonist cortivazol and the GR antagonist RU-38486 (Yoshikawa et al., 2009). 
Selective GR activation upregulated pro-hypertrophic and pro-apoptotic genes which 
may increase cell size and increase cell death (Yoshikawa et al., 2009). 
As excess endogenous glucocorticoids have been associated with adverse cardiovascular 
outcomes reducing their actions is attractive in the setting of cardiovascular disease. 
However, systemic blockade of the GR can result in compensatory increases in the 
activity of the hypothalamic-pituitary-adrenal (HPA) axis, and therefore in circulating 
glucocorticoids, making direct inhibition of the GR an unsuitable therapeutic target 
(Spiga et al., 2007, Bamberger and Chrousos, 1995). Manipulation of local levels of 
glucocorticoids without this adverse effect on the HPA axis can be achieved by 
inhibition of 11HSD1. Until recently there were no selective inhibitors of 11HSD1 and 
so to investigate the effect of its deficiency a mouse with selective disruption of the 
HSD1B1 gene (11HSD1
-/-
) mouse was generated (Kotelevtsev et al., 1997). 11HSD1
-/- 
mice are viable, producing normal pups, show no detectable changes in blood pressure 
and cannot regenerate corticosterone from 11-dehydrocortiosterone, indicating that 
11HSD1 is the only enzyme responsible for reactivating glucocorticoids (Kotelevtsev et 
al., 1997). The adrenal glands of 11HSD1
-/- 
mice are enlarged and morphometric 
analysis showed that this is due to adrenocortical hyperplasia. The functional 
significance of this is demonstrated by enhanced basal corticosterone levels in these 
mice although peak corticosterone levels are not different from wild-type litter mates 
(Kotelevtsev et al., 1997, Harris et al., 2001). 11HSD1
-/- 
mice are resistant to diet-
induced obesity, are protected against age-related cognitive decline and have improved 
insulin sensitivity (reviewed in (Paterson et al., 2005, Tomlinson and Stewart, 2005)). It 
has also been shown previously that 11HSD1
-/- 
mice have enhanced cardiac angiogenesis 
and improved heart function 7 days after myocardial infarction (MI) (Small et al., 2005, 
Small, 2005). Despite these interesting observations very little is known about the basal 
cardiac phenotype of 11HSD1
-/- 
mice with published papers merely reporting that there 
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is no difference in organ weights (Kotelevtsev et al., 1997, Morton et al., 2004). As 
11HSD1
-/- 
mice have improved heart function 7 days after MI it is vital to know whether 
this is because of some basal differences in cardiac architecture and function. 
Furthermore, there is a lack of consistency in the literature regarding the localisation of 
11HSD1 in the myocardium. It is hypothesised that the cardiac architecture of 11HSD1
-/- 
mice is similar to that of C57Bl6 controls and that this is associated with comparable 
cardiac function. Simultaneously, the localisation of 11HSD1 within the myocardium is 
investigated with the hypothesis that expression is localised to cardiomyocytes, 


















Male C57Bl6 (Harlan, UK) and 11HSD1 homozygous null (
-/-
) mice (bred from an in-
house colony on a C57Bl6 background) (Kotelevtsev et al., 1997, Morton et al., 2004) 
aged 10-12 weeks were used. Mice were killed by cervical dislocation. For histological 
analysis hearts were bisected transversely while for immunohistological analysis hearts 
were bisected down the longitudinal axis. This was followed by fixation, processing and 
embedding in paraffin wax as described in Section 2.4.  
 
3.2.2 Immunohistochemistry 
Identification of 11HSD1 was conducted using a polyclonal sheep anti-mouse 11HSD1 
antibody generated in-house diluted 1/2000 in PBS/5% BSA. For details of the 
procedure please refer to Section 2.5 and 2.5.9 and Table 2.2. Immuno-reactivity for 
11HSD1 yielded weak staining and, therefore, it was not quantifiable. 3 sections of heart 
taken from each genotype (C57Bl6 and 11HSD1
-/-
 mice) were stained with liver sections 
serving as a positive control. 
 
3.2.3 Echocardiography 
Cardiac function was assessed by echocardiography as described in section 2.3.2. The 








Haematoxylin and eosin staining was used to assess the gross cardiac structure. The 
cardiac endomysial, epimysial and adventitial matrix were assessed using Picrosirius 
Red and Periodic-Acid-Schiff staining. These stains highlight collagen and tissue 
glycogen respectively. Staining was conducted by Susan Harvey (Medical Research 
Council/ Centre for Inflammation Research Histology Service) and was assessed by Dr 




All values are expressed as mean ± SEM. Comparisons of body weight, heart weight and 














Expression of 11HSD1 in the myocardium 
Immunohistochemistry for 11HSD1 showed high levels of immunoreactivity in the liver 
of C57Bl6 mice which was used as a positive control (Figure 3.1). The negative control 
showed no immunoreactivity. In the heart vascular smooth muscle cells, but not 
endothelial cells, expressed 11HSD1 as seen in Figure 3.1. This was seen in vessels of 
varying size. Cardiomyocytes stained weakly for 11HSD1 (Figure 3.1). Cardiac 
fibroblasts are found interstitially, have ovoid nuclei with drawn out cytoplasm and can 
form fibres. They also stained positively for 11HSD1 and were distributed evenly across 
the myocardium (Figure 3.1). The 11HSD1
-/-
 mice did show some weaker staining in 
liver positive control sections, cardiac smooth muscle cells, cardiomyocytes and cardiac 








Figure 3-1 Immunohistochemistry for 11HSD1 
A sheep anti-mouse 11HSD1 antibody was used to identify 11HSD1 in murine heart tissue. Liver 
was used as a positive control for 11HSD1 immunoreactivity (a) with the negative control 
showing no staining (b). (c) Immunoreactivity is evident in the smooth muscle of coronary 
vasculature and fibroblasts with weaker staining in cardiomyocytes of heart tissue (identified 
morphologically, open arrow point to vascular smooth muscle cells, red arrow points to 
fibroblasts, closed arrows point to cardiomyocytes). (d) No staining was observed in the negative 
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control. (e and f) Arrows point to positive cells staining in heart sections that are likely to be 
fibroblasts. 11HSD1
-/-
 mice show weak staining (g). Pictures are representative of sections taken 
from 3 mice. Bar is 10µm.  
Body and heart weight 
Male 10-12 week old C57Bl6 and 11HSD1
-/- 
mice had similar body weights (Figure 
3.2). In contrast, heart weight was significantly lower in 11HSD1
-/- 
mice compared with 
C57Bl6 controls (Figure 3.2; P<0.05). This relationship remained when expressed 
relative to body weight (Figure 3.2). There was no difference in other organ weights. 
 
Histopathogical analysis of the myocardium 
Gross inspection of hearts from C57Bl6 and 11HSD1
-/- 
mice showed that there were no 
obvious malformations in the hearts of 11HSD1
-/- 
mice (Figure 3.3). This was confirmed 
by cross-sections of the heart which were stained with haematoxylin and eosin (Figure 
3.4). Periodic Acid Schiff showed that deficiency of 11HSD1 had no effect on the 
endomysial, epimysial or adventitial matrix in the heart (Figure 3.5). Histological 
assessment by the independent pathologist found that there was a tendency for   
11HSD1
-/- 
mice to have smaller cardiomyocytes upon gross observation although this 








 mice had comparable left ventricular dimensions as assessed by 
echocardiography (Table 3.1). Furthermore heart function expressed as ejection fraction 









 mice (male, 10-12 weeks old, C57Bl6 n=10, 11HSD1
-/-
 n=8) were a similar weight to 
age matched C57Bl6 control mice (a). Despite this, heart weight (b) was significantly reduced in 
the 11HSD1
-/- 
mice compared with controls. The reduction in heart weight was also evident when 
expressed relative to body weight (c).  Data are expressed as mean ± SEM. *P<0.05 when 




Figure 3-3 Gross comparisons of hearts from 11HSD1-/- and C57Bl6 mice 
Photographs of frontal and dorsal views of typical hearts excised from C57Bl6 (a) and 11HSD1
-/- 
(b) mice showing that there are no overt structural abnormalities observable with the naked eye.  
 
Figure 3-4 Haematoxylin and eosin stained hearts 
Typical cross sections of haematoxylin and eosin stained sections obtained from hearts of 
C57Bl6 and 11HSD1
-/- 
mice demonstrating no overt structural abnormalities between the groups. 




Figure 3-5 Picrosirius Red staining of the myocardium 
Cross sections of hearts from C57Bl6 and 11HSD1
-/- 
mice following Picrosirius Red staining. The 
section has been digitally inverted, filtered and equalised in order to bring up the endomysium. 
There are no differences in the extracellular matrix between C57Bl6 and 11HSD1
-/-
 mice. 







LVEDA 19.92 ± 1.12 17.81 ± 0.48 
LVESA 6.25 ± 0.74 5.61 ± 0.86 
LVEDD 4.33 ± 0.28 3.73 ± 0.14 
LVESD 2.54 ± 0.18 2.44 ± 0.17 
PWD 0.85 ± 0.05 0.79 ± 0.07 
PWS 1.28 ± 0.11 1.12 ± 0.08 
EF (%) 69.74 ± 2.68 66.4 ± 3.94 
FS (%) 41.37 ± 2.27 34.95 ± 3.42 
 
Table 3-1 Left ventricle dimensions by echocardiography 
LVEDA (left ventricle end diastolic area), LVESA (left ventricle end systolic area), LVEDD (left 
ventricle end diastolic diameter), LVESD (left ventricle end systolic diameter), PWD (posterior 
wall thickness at diastole), PWS (posterior wall thickness at systole), EF (ejection fraction) and 
FS (fractional shortening) were assessed in isofluorane anaesthetised C57Bl6 and 11HSD1
-/- 
mice. Genotype had no influence on any parameter assessed by echocardiography. Data are 











Figure 3-6 Quantified data from echocardiography of C57Bl6 and 11HSD1
-/- 
mice. 
Ejection fraction (a) was calculated from the left ventricle end diastolic area (LVEDA) and left 
ventricle end systolic area (LVESA) and expressed as a percent. Fractional shortening (b) was 
calculated from the left ventricle end diastolic diameter (LVEDD) and left ventricle end systolic 
diameter (LVESD) and expressed as a percent. Genotype has no influence on basal cardiac 








Previous work has shown that 11HSD1
-/-
 mice have enhanced angiogenesis and 
improved heart function 7 days after MI but the basal cardiac phenotype of these mice 
has not been described (Small, 2005, Small et al., 2005). The aim of the current work 
was to investigate the distribution of the 11HSD1 protein in the myocardium and 
determine the consequences of 11HSD1 deletion on cardiac structure and function. 
11HSD1 immunoreactivity was localised to cardiac fibroblasts, vascular smooth muscle 
cells and cardiomyocytes. Whilst there was a decrease in heart weight in the 11HSD1
-/-
 




Expression of both corticosteroid receptors and both 11HSD isozymes has been 
described previously in the myocardium and vessel wall (Walker, 2007b, Hadoke et al., 
2006). Furthermore 11HSD1 activity has been detected in the rodent myocardium and 
artery wall (Small, 2005, Klusonova et al., 2009, Hadoke et al., 2001). GR expression 
has been localised to cardiomyocytes, cardiac fibroblasts and the vasculature (smooth 
muscle and endothelial cells) with MR expression also being found in cardiomyocytes 
and the vasculature (Walker et al., 1991, Slight et al., 1993, Takeda et al., 2007, Slight et 
al., 1996). Consistent with these previous investigations 11HSD1 immunoreactivity was 
observed in the cardiac fibroblasts and vascular smooth muscle cells with faint staining 
also evident in cardiomyocytes (but not endothelial cells) (Small, 2005, Morton et al., 
2004, Masuzaki et al., 2001, Deuchar, 2009, Camelliti et al., 2005, Christy et al., 2003, 
Vliegen et al., 1991). 11HSD2 distribution was not examined here but previous studies 
have shown it to be expressed in cardiomyocytes and vascular endothelial cells (Slight et 
al., 1996, Christy et al., 2003, Takeda et al., 2007).  Interestingly the 11HSD1
-/- 
mice still 
showed some positive staining for 11HSD1 although this was much fainter than the 
C57Bl6 controls. Previous studies from this laboratory have shown that a truncated form 
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of the 11HSD1 protein can still be translated in the 11HSD1
-/- 
mice with approximately 
5% enzyme activity in the liver (Tijana Mitic, personal communication). This is in line 
with previous work that has demonstrated that 11HSD1
-/-
 mice on the MF1/129 
background have no enzyme activity in the brain, less that 5% enzyme activity in the 
liver and 6.36% activity in thoracic aortas (Kotelevtsev et al., 1997, Hadoke et al., 
2001).  This great reduction in 11HSD1 activity is the result of targeted replacement 
exon 3 and 4 (which encode the catalytic domain of the enzyme) with a neomycin 
resistance cassette during the production of the knockout (see Figure 2.1 for the 
knockout strategy) (Kotelevstev et al., 1997, Tomlinson et al., 2004). The truncated 
proeitn, therefore, does not contain this vital domain (Kotelevstev et al., 1997, 
Tomlinson et al., 2004). The in-house produced antibody is polyclonal, recognises 
several epitopes of the antigen and, thus, can bind to several sites on the 11HSD1 
protein. It is possible that some but not of these epitopes are present on the truncated 





The results presented here replicate those found previously; showing that in male mice 
aged 10-12 weeks old there was no difference in body weight between C57Bl6 and 
11HSD1
-/-
 mice (Kotelevtsev et al., 1997, Morton et al., 2004). Interestingly 11HSD1
-/-
 
mice have been shown to resist diet-induced obesity whereas over-expression of 
11HSD1 in adipocytes (to a level comparable to that seen in obese humans) results in the 
development of features of metabolic syndrome, including visceral obesity (Morton et 
al., 2004, Masuzaki et al., 2001). The mice used in the current study were maintained on 
standard chow diet and had not, therefore, been metabolically challenged.  
In the present study, 11HSD1
-/-
 mice were shown for the first time to have significantly 
decreased heart weight relative to C57Bl6 controls. Mice with high tissue levels of 
corticosterone, due to deficiency of 11HSD2 have enlarged hearts (Deuchar, 2009). 
Furthermore, in neonatal hearts, high corticosterone levels increased heart weight (Reini 
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et al., 2008). This effect could be reversed by an MR but not a GR, antagonist, 
suggesting that glucocorticoid-dependent changes in heart weight may be mediated by 
MR activation (Reini et al., 2008). Tissue glucocorticoid levels were not determined in 
this study, but we would predict that they are reduced in the 11HSD1
-/-
 mice compared 
to C57Bl6 control as they would not be locally regenerated within the target tissues. The 
independent pathologist suggested that the decrease in heart weight in 11HSD1
-/-
 mice 
may be due to a decrease in cardiomyocyte cross-sectional area (Dr. David Brownstein, 
personal communication) and we have demonstrated here that cardiomyocytes have 
weak expression of the 11HSD1 protein. Glucocorticoids stimulate pro-hypertrophic 
genes and we can speculate that a local reduction in corticosterone might reduce 
cardiomyocyte size via this mechanism (Yoshikawa et al., 2009).  Additionally 
activation of GR can modulate the electrical and mechanical activities of the heart. This 
suggests that preventing cardiac regeneration of corticosterone may alter basal cardiac 
phenotype (Yoshikawa et al., 2009). Despite hearts from 11HSD1
-/- 
weighing 10% less 
than those from their C57Bl6 counterparts, gross inspection and qualitative histological 
analysis showed that the structure of the myocardium was comparable suggesting no 
overt structural abnormalities.  
Although 75% of the myocardium consists of cardiomyocytes but this translates to only 
30-40% of total cell number (Camelliti et al., 2005, Vliegen et al., 1991). Other cells 
found in the heart under normal conditions include fibroblasts, endothelial cells and 
vascular smooth muscle cells. 11HSD1 protein has been detected in cardiomyocytes, 
fibroblasts and vascular smooth muscle cells but not in endothelial cells (Porter and 
Turner, 2009, Camelliti et al., 2005). Fibroblasts account for approximately 60% of the 
total cardiac cell number and are regulators of extracellular matrix production (Porter 
and Turner, 2009). They lie between muscle layers providing continuity between cells 
(Porter and Turner, 2009). The significance of reduced glucocorticoid activity in cardiac 
fibroblasts of 11HSD1
-/-
 mice is yet to be determined. The relative abundance of 
fibroblasts in the myocardium, their secretion of a diverse array of cytokines and growth 
factors and their proximity to cardiomyocytes suggests that modulating fibroblast 
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function may be important to recovery after MI (Porter and Turner, 2009). 
Glucocorticoids have been shown to reduce fibroblast proliferation, growth and can 
inhibit secretion of pro-inflammatory proteins (Pratt, 1978, Porter and Turner, 2009, 
Hardy, 2008). Under basal conditions 11HSD1 deficiency does not alter the extracellular 
matrix, suggesting it has limited impact on basal fibroblast function.  
 
It may be predicted that lack of 11HSD1 in the vasculature might modulate vascular 
tone since stimulation of GR in the vascular smooth muscle can increase contractility 
(Walker et al., 1992, Sudhir et al., 1989) and in endothelial cells can impair 
vasodilatation (Mangos et al., 2000). However, despite the ability of 11HSD1 to amplify 
glucocorticoids locally within the vascular smooth muscle, its deficiency has no effect 
on vessel function or blood pressure (Kotelevtsev et al., 1997, Hadoke et al., 2001).   
 
Cardiac function 
The results of histological analysis of the C57Bl6 and 11HSD1
-/-
 myocardium 
correspond with the echocardiography data. 11HSD1
-/-
 has no detectable impact on left 
ventricle dimensions or heart function as assessed by ejection fraction and fractional 
shortening. As 11HSD1
-/-
 mice have reduced heart weight, with potentially smaller 
cardiomyocytes it is possible that the individual cardiomyocyte function is altered in 
these animals. Whilst this was not studied in the work presented here it would be 
interesting to determine whether the expression of contractile proteins and the response 
to hypertrophic stimuli were the same in 11HSD1
-/-
 mice and C57Bl6 controls.  
Studies in which the expression of GR and MR have been manipulated show their 
importance physiologically. Conditional cardiac over-expression of GR is associated 
with bradycardia and atrio-venricular block, whilst 90% of GR knockout mice die at 
birth due to delays in lung maturation (Cole et al., 1995, Sainte-Marie et al., 2007). On 
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the other hand, conditional cardiac knock-down of MR induces severe heart disease and 
premature death (Beggah et al., 2002) whereas conditional cardiac over-expression of 
MR leads to early sudden death and (in those mice surviving) cardiac arrhythmias 
(Ouvrard-Pascaud et al., 2005).  We have not observed an obvious cardiac phenotype in 
the 11HSD1
-/-
 mice such as those when the receptors for corticosterone are modulated. 
However, when 11HSD2, the enzyme that inactivates glucocorticoids, is knocked out 
mice become hypertensive, develop severe cardiac enlargement and have impaired 
vascular function independent of renal sodium retention (Deuchar, 2009, Hadoke et al., 
2001).  
The activation of cardiac MR is likely to be mediated by both aldosterone and 
corticosterone. Corticosterone circulates in concentrations 100 fold greater than those of 
aldosterone. This together with the expression of 11HSD1 in fibroblasts, cardiomyocytes 
and vascular smooth muscles suggests that MR in the heart may be exposed to high 
concentrations of corticosterone (Esteban et al., 1991, Linde et al., 1981). There is also 
evidence that the enzymes capable of de novo synthesis of corticosterone and 
aldosterone are present in the myocardium. However, the contribution of this to total 
tissue levels appears to be small (Kayes-Wandover and White, 2000, Takeda et al., 
1994, Silvestre et al., 1999).  
Pharmaco-epidemiological data suggests that individuals treated with glucocorticoids 
may be at increased risk of developing cardiovascular disease (Wei et al., 2004, Walker, 
2007b). Moreover, the use of glucocorticoids is associated with the development of heart 
failure (Souverein et al., 2004). Deficiency of 11HSD1 has proved beneficial in murine 
models of obesity, diabetes and atherosclerosis (Hermanowski-Vosatka et al., 2005). It 
has also been shown previously that mice with 11HSD1 deletion have augmented 
angiogenesis and improved heart function 7 days post MI (Small, 2005, Small et al., 
2005). The mechanism for this and the downstream effect of these observations is 
uncertain. The data presented in the current Chapter have demonstrated that the 
enhanced angiogenesis and improved heart function observed 7 days after MI in 
11HSD1
-/-





 Characterisation of the response to myocardial infarction in 11HSD1 deficient 
mice 
4.1 Introduction 
11HSD1 is expressed in myocardial fibroblasts, in the smooth muscle of the cardiac 
vasculature and cardiomyocytes (Chapter 3) (Sheppard and Autelitano, 2002, Klusonova 
et al., 2009). Deficiency of 11HSD1 has no effect on basal cardiac pathology and heart 
function (Chapter 3). However, 7 days after MI 11HSD1
-/-
 mice have enhanced 
angiogenesis (Small et al., 2005) and improved heart function (Small, 2005). The 
mechanisms underlying these alterations have yet to be determined. These form the basis 
of the work described in this Chapter.  
Infarct size is an important determinant of outcome following MI (Yang et al., 2002). 
Therapeutic strategies aimed at reducing infarct size (such as reperfusion) have led to 
reduction of acute mortality post-MI but patients still develop heart failure (Ferdinandy 
et al., 2007, Velagaleti et al., 2008). A number of experimental studies have 
demonstrated that reduction of infarct expansion by enhancing blood supply to the 
infarct border reduces remodelling and improves heart function post-MI (Engel et al., 
2006, Sasaki et al., 2007, Orlic et al., 2001). Improving perfusion can provide vital 
oxygen and nutrients required for tissue survival. This has been achieved by direct 
injection of putative cell progenitors or pro-angiogenic factors into the myocardium 
(Sasaki et al., 2007, Orlic et al., 2001). However, translation of these strategies to the 
clinic has had limited success to date (Kastrup et al., 2006, Lasala and Minguell, 2009, 
Meyer et al., 2006). An alternative approach is to manipulate endogenous mechanisms 
involved in infarct healing so that the associated angiogenic response is enhanced.  
Neovascularisation by angiogenesis (the synthesis of new blood vessels from pre-
existing vasculature) is a complex series of events that occurs on the infarct border in 
response to pro-angiogenic signals from adjacent cells in the infarct. The vessels are 
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usually formed transiently and are pruned after maturation of the infarct scar (Grass et 
al., 2006, Ren et al., 2002). Glucocorticoids are recognised inhibitors of angiogenesis 
reducing new blood vessel growth in vivo after implantation of sponges beneath the skin, 
in tumour models and ex vivo in aortic ring cultures (Small et al., 2005, Hori et al., 1996, 
Banciu et al., 2008b). Inhibition of angiogenesis during infarct healing increases the area 
of necrosis and depresses cardiac function highlighting its importance after MI 
(Heymans et al., 1999). Since 11HSD1
-/-
 mice exhibit enhanced angiogenesis in 
response to other stimuli (Small et al., 2005), it was proposed that locally-generated 
glucocorticoids have an angiostatic influence in the heart following injury. 
Consequently, inhibition of 11HSD1 may provide a means to improve blood supply, 
reduce cardiomyocyte loss and improve function post-MI.  
Glucocorticoids are released into the systemic circulation acutely after MI (Donald et al., 
1994) and initially appear to be cardioprotective, as glucocorticoid receptor (GR) 
antagonism can increase infarct size (Libby et al., 1973, Morrison et al., 1976, Hafezi-
Moghadam et al., 2002). In contrast, when glucocorticoids are given chronically in the 
healing phase post-MI they are detrimental. Chronic glucocorticoid therapy increases 
infarct size in experimental and clinical studies (Scheuer and Mifflin, 1997, Roberts, 
1976), an effect that may be mediated by glucocorticoid action on the mineralocorticoid 
receptor (MR). In the EPHESUS clinical trial treatment with epleronone (an MR 
antagonist) starting 3-14 days after MI reduced the risk of cardiovascular mortality. 
Similarly, epleronone reduced scar thinning and improved heart function in a rat model 
of this condition (Pitt et al., 2005, Fraccarollo et al., 2008). The deleterious effects of 
chronic glucocorticoid administration after MI may be due to their ability to inhibit 
inflammation (Gilmour et al., 2006, Chapman et al., 2009, Cupps and Fauci, 1982, 
Galon et al., 2002) and angiogenesis (Small et al., 2005, Small, 2005, McNatt et al., 
1999, Hasan et al., 2000, Hori et al., 1996, Folkman and Ingber, 1987), processes that 
are vital to the healing response.  
The post-infarct inflammatory response consists of neutrophil influx into the 
myocardium which subsequently results in recruitment of monocytes to the area. 
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Monocytes then differentiate into classically-activated and alternatively-activated 
macrophages, which enables them to fulfil two vital roles.  The first of these, fulfilled by 
classically-activated macrophages, is to remove cell debris by phagocytosis (Nahrendorf 
et al., 2007, van Amerongen et al., 2007). Secondly, alternatively-activated macrophages 
stimulate angiogenesis by secretion of pro-angiogenic factors such as VEGF and IL-8 
(Loke et al., 2002, Mosser and Edwards, 2008). Recent work showing that 11HSD1
-/-
 
mice have increased macrophage infiltration into sites of inflammation in peritonitis, 
pleurisy and serum arthritis models has highlighted the anti-inflammatory role of 
11HSD1 (Gilmour et al., 2006, Chapman et al., 2009, Coutinho et al., 2009).  
Sponge implant and tumour models of angiogenesis have a clear inflammatory 
component which may contribute to vessel formation. There is recent evidence that 
angiogenesis in the aortic ring model may also involve inflammation; depletion of 
adventitial macrophages reduces VEGF expression and vessel sprouting (Gelati et al., 
2008). The inextricable link between inflammation and angiogenesis in post-infarct 
healing is well documented. Selective depletion of macrophages after MI reduces 
angiogenesis and results in impaired scar formation and heart function (van Amerongen 
et al., 2007). Scar formation by collagen deposition is another vital component of the 
healing response and is mediated by the transformation of fibroblasts to myofibroblasts. 
Reactive oxygen species, hypoxia and transforming growth factor-β (TGF-β) secreted 
from macrophages all contribute to fibroblast transformation (Cleutjens et al., 1995, 
Desmouliere et al., 1993, Fadok et al., 1998). Preventing adequate collagen deposition 
can also impair cardiac function (van Amerongen et al., 2007).  
While the effects of manipulating systemic glucocorticoids after MI have been 
investigated by other groups the effect of reducing local levels is undetermined (Scheuer 
and Mifflin, 1997, Roberts, 1976, Morrison et al., 1976, Libby et al., 1973, Hafezi-
Moghadam et al., 2002). The current study aimed to establish whether the high systemic 
corticosterone level, immediately and acutely after MI, swamps the contribution of local 
glucocorticoid regeneration by 11HSD1 and, therefore, lack of 11HSD1 in the early 
phase does not diminish the protective action of glucocorticoids on reducing ischaemic 
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damage. Once the systemic hypercorticosteronaemia has settled 11HSD1 is likely to 
play a role in infarct recovery. It is hypothesised that the mechanism for the post-infarct 
enhancement of vessel density in 11HSD1
-/-
 mice involves an enhanced inflammatory 
response post-MI and promotion of associated pro-angiogenic signalling in early infarct 
healing. Furthermore, it is proposed that enhancement of vessel density leads to an 




















4.2.1 Coronary artery ligation 
Male C57Bl6 mice (Harlan, UK) and 11HSD1 homozygous null (
-/-
) mice (bred from an 
in-house colony on a C57Bl6 background) aged 10-12 weeks were used for all 
experiments. Mice underwent coronary artery ligation for induction of MI with sham-
operated mice serving as controls, as described in Section 2.3.1. 
 
4.2.2 Echocardiography 
Cardiac function was assessed by echocardiography as described in Section 2.3.2. Mice 
underwent echocardiography 2, 4 and 7 days after surgery in order to obtain 
measurements of ventricular dimensions. The observer was blinded for the purpose of 
echocardiography measurements and all other subsequent analysis of tissue.  
 
4.2.3 Tissue collection  
For analysis of circulating corticosterone levels blood was taken 24 hours post-surgery, 
by tail tip at 7:30am (the diurnal nadir) as described in Section 2.3.3. The mice were 
then killed cervical dislocation. Mice killed at days 2, 4 and 7 after surgery were given 
an intraperitoneal injection of 2.5mg BrdU, dissolved in saline, 1 hour prior to cervical 
dislocation. The heart was excised and washed in ice cold PBS. For infarct size 
assessment the whole heart was frozen on dry ice prior to storage at -80°C. For other 
analyses, hearts were bisected down the longitudinal axis (apex to base) and one half 
fixed in 10% neutral buffered saline as described in Section 2.4. The other half was 




4.2.4 Infarct size measurements 
Hearts were stained with triphenyltetrazolium chloride (TTC) in order to determine 
infarct size, as described in Section 2.4.1.  
 
4.2.5 Circulating corticosterone 
A corticosterone radioimmunoassay was conducted on plasma samples to determine 




Sections were stained with haematoxylin and eosin to allow identification of neutrophils 
by their distinctive multi-lobed nuclei, as described in Section 2.4.2. Quantification of 
the number of neutrophils in the left ventricle was conducted using Image Pro6.2, 
Stereologer Analyser 6 MediaCybernetics, as described in Section 2.4.6.  
 
4.2.7 Immunohistochemistry 
Identification of blood vessels was conducted using a monoclonal rat anti-mouse CD31 
primary antibody (BD Bioscience) diluted 1/50 in PBS/1%BSA. Cell proliferation was 
detected using a monoclonal mouse anti-mouse BrdU antibody (Sigma) diluted 1/1000 
in TBS/10% normal goat serum/5%BSA. Macrophages and alternatively-activated 
macrophages were recognised with a monoclonal rat anti-mouse mac 2 primary antibody 
(Cedarlane) diluted 1/6000 in PBS/1%BSA and a polyclonal rabbit anti-mouse YM1 
primary antibody (Stem Cell Technologies) diluted 1/50 in PBS/1%BSA respectively. T 
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and B cells were identified with a polyclonal rabbit anti-human CD3 primary antibody 
(Dako) diluted 1/400 in PBS/1%BSA and a monoclonal rat ant-mouse CD45R primary 
antibody (BD Bioscience) diluted 1/50 in PBS/1%BSA, respectively. Identification of 
activated myofibroblasts was conducted using a monoclonal mouse anti-mouse α smooth 
muscle actin (αSMA) primary antibody (Sigma) diluted 1/400 in PBS/1%BSA. 11HSD1 
was detected using an in-house polyclonal sheep anti-mouse 11HSD1 antibody diluted 
1/2000 in PBS/5%BSA. For details of the procedures please see to Section 2.5. 
Quantification of immunohistochemistry was conducted using Image Pro 6.2, 
Stereologer Anaylser 6 MediaCybernetics. See Section 2.5.10 for details.  
 
4.2.8 Quantitative real time polymerase chain reaction (qRT-PCR) 
Heart tissue was homogenised and RNA was extracted by the Trizol method as 
described in Section 2.5.2. RNA was reverse transcribed into cDNA as described in 
Section 2.5.3 and subsequent qRT-PCR was conducted as explained in Section 2.5.4. 
 
4.2.9 Statistics 
All values are expressed as mean ±SEM. Comparisons of survival and cause of death 
were by Fisher‟s exact test and Chi square test respectively. Comparisons of 
echocardiography, circulating corticosterone, histology and immunohistochemistry for 
2, 4 and 7 day data are by 2-way ANOVA with Bonferroni post-hoc tests with 
comparisons between genotype and surgery. Post-hoc tests were conducted when the 
ANOVA showed a genotype difference to P<0.05. An unpaired Student‟s t test was used 
to compare triphenyltetrazolium infarct size. Comparisons of real time qRT-PCR were 







There was no difference in mortality between C57Bl6 and 11HSD1
-/- 
mice after 
coronary artery ligation with survival being 76% and 78%, respectively (Table 4.1). No 
mortality was observed after sham operation. The number of unsuccessful surgeries, due 
to ligating the coronary artery below its branches thus causing an infarct of variable size 
was similar in C57Bl6 and 11HSD1
-/- 
mice (Table 4.1). Death occurring during or 
immediately after surgery was due to too much tissue damage or blood loss (7% in 
C57Bl6 and 9% in 11HSD1
-/-
). Mortality occurring 4-7 days after MI was due to cardiac 
rupture (blood in the chest cavity) or heart failure (enlarged heart) as determined by post 












76% (63/83) 78% (35/45) 
No MI (%) 
 
4% (3/83) 4% (2/45) 
Mice used in 
study 
72% (60/83) 73% (33/45) 




7% (6/83) 9% (4/45) 
Cardiac rupture 
 
8% (7/83) 7% (3/45) 
Heart failure  
 
8% (7/83) 7% (3/45) 
  
Table 4-1 Mortality after myocardial infarction surgery 
Survival, proportion of unsuccessful coronary artery ligation surgeries and cause of mortality 
were similar between C57Bl6 and 11HSD1
-/- 
mice up to 7 days after MI surgery. Raw numbers 




The impact of surgery on body and heart weight 
Body weight declined 1 day after sham and MI surgery to a similar extent in C57Bl6 and 
11HSD1
-/- 
mice (Figure 4.1). Weight recuperation was seen at day 4 and 7 but did not 
return to pre-operative levels in sham or MI mice. Heart weight was similar in all groups 
post-surgery with the exception of 11HSD1
-/- 
mice which had significantly heavier 
hearts than C57Bl6 controls 2 days after MI (P<0.05, Table 4.2). However when heart 





Figure 4-1 Body weight changes after myocardial infarction or sham surgery 
Body weight declined immediately after induction of myocardial infarction (MI) or sham operation 
in C57Bl6 and 11HSD1
-/-
 mice relative to pre-operative weight. Body weight was regained from 
day 4 in all groups. n=8 C57BL6 sham, n=12 C57BL6 MI, n=4 11HSD1
-/-
 sham, n=6 11HSD1
-/-
 
MI. Data are expressed as mean ± SEM.  
 
 Heart weight (g) Heart weight/body weight (mg/g) 
C57Bl6 11HSD1 
-/-
 C57Bl6 11HSD1 
-/-
 
Sham MI Sham MI Sham MI Sham MI 





































































MI did not alter raw heart weights or the heart weight: body weight ratio. n=8 C57BL6 sham, 
n=12 C57BL6 MI, n=4 11HSD1
-/-
 sham, n=6 11HSD1
-/-
 MI. Data are expressed as mean ± SEM. 
* P<0.05 C57Bl6 vs. 11HSD1
-/- 






Plasma corticosterone levels in C57Bl6 mice were similar 1 day after sham or MI 
operation (Figure 4.2). Whilst MI significantly elevated circulating corticosterone in 
11HSD1
-/- 





Infarct size  
Infarct size was assessed from TTC stained hearts. Hearts taken from sham operated 
mice were completely stained red indicating no ischaemic cell death. At day 1 the extent 
of left ventricular damage was comparable in C57Bl6 and 11HSD1
-/- 
mice (35.1 ± 1.0 





Figure 4-2 Circulating corticosterone after MI or sham surgery 
Circulating corticosterone levels 1 day after surgery, measured using a corticosterone 
radioimmunoassay. Genotype had no influence on circulating corticosterone levels after sham or 
MI surgery. n=8 C57BL6 sham, n=12 C57BL6 MI, n=4 11HSD1
-/-
 sham, n=6 11HSD1
-/-
 MI. Data 
are expressed as mean ± SEM. # P<0.05 sham vs. MI by 2 way ANOVA. 
 
Figure 4-3 Infarct size after MI 
Infarct size, assessed by TTC staining (expressed as a percent of the left ventricle) was the 
same in C57Bl6 and 11HSD1
-/- 
mice 1 day after coronary artery ligation surgery (n=6). Data are 




Post infarct neovascularisation 
The number of CD31 positive blood vessels (<200µm in diameter) in the left ventricle 
remained stable in sham and MI animals up to 4 days after surgery (Figure 4.4). At day 7 
after MI there was a significant increase in the number of CD31 positive vessels in 
C57Bl6 and 11HSD1
-/- 
mice relative to sham operated controls (P<0.001). These vessels 
were pericyte poor (Figure 4.5). The number of vessels was significantly greater in 
11HSD1
-/-
 mice at this time (P<0.05). It was notable that some vessels did not stain with 
CD31. These were distributed evenly across the myocardium and there was a similar 
number in all groups (Figure 4.4). Expression of the pro-angiogenic cytokine IL-8 was 
significantly greater in the myocardium of 11HSD1
-/- 
mice compared with C57Bl6 
controls at day 7 (Figure 4.6, P<0.01). However, expression of VEGFa mRNA was not 
different between C57BL6 and 11HSD1
-/-
 mice (Table 4.4). 
Cell proliferation, assessed by BrdU incorporation into replicating nuclei, was increased 
after MI in C57Bl6 and 11HSD1
-/- 
mice relative to sham-operated controls (Figures 4.4 
and 4.5). Positive cell staining was distributed across the left ventricle with the highest 
density of proliferating cells being seen on the infarct border. Coinciding with the 
increase in vessel density, cell proliferation was greater in 11HSD1
-/- 
mice than in 
C57Bl6 mice (P<0.01).  At 4 and 7 days post MI there was some non-vessel CD31 
positive cell staining on the infarct border. Attempts to co-localize BrdU with CD31, to 
determine whether the endothelial cells were proliferating cells were unsuccessful. 
Double staining sections with BrdU and the macrophage marker, mac 2, showed that 
these markers were not expressed together demonstrating that the cells proliferating are 




Figure 4-4 Angiogenesis after MI or sham surgery 
Vessel density was assessed by immunohistochemistry for the endothelial cell marker, CD31, 
and quantified by counting small (<200µm diameter), CD31 positive vessels in the left ventricle 
(n=4-12). Vessel density increases 7 days after MI compared with sham operated mice (a). 
Furthermore 11HSD1
-/-
 mice have enhanced vessel density relative to C57Bl6 mice at this time. 
The number of CD31 negative vessels was similar across the groups (b). Cell proliferation, 
assessed by BrdU incorporation into replicating nuclei, was increased after MI at day 7 in 
11HSD1
-/-





 sham, n=6 11HSD1
-/-
 MI. Data are expressed as mean ± SEM. #P<0.05 ### P<0.001 
Sham vs. MI, * P<0.05, *** P<0.001 C57Bl6 vs. 11HSD1
-/- 
by 2 way ANOVA. 
 
Figure 4-5  Immunohistological analysis of cardiac neovascularisation 
Arrows point to CD31 positive vessels in the infarct border (a). BrdU positive nuclei stained 
brown 7 days post MI (b). Sections were counterstained with haematoxylin. Colocalisation of 
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BrdU (blue/grey, open arrows) with mac 2 (brown, closed arrows) positive cells in the infarct 
border (c). Bars are 10µm.   
 
Figure 4-6 Interleukin-8 mRNA after MI or sham surgery 
Interleukin-8 (IL-8) mRNA expression (relative to sham-operated) and normalised to GAPDH 
housekeeping gene (n=6). IL-8 was increased in the 11HSD1
-/- 
mice relative to C57Bl6 controls 






Neutrophils were identified in the infarct and on the infarct border in haematoxylin and 
eosin stained sections (Figure 4.7). In sham-operated mice the number of neutrophils in 
the left ventricle was very low and remained the same over 7 days (Figure 4.8). In 
C57Bl6 mice 2 days after MI there was a significant increase in neutrophils in the heart 
compared with sham-operated controls (P<0.01). At days 4 and 7 the neutrophil count 
declined to similar numbers as the shams. 11HSD1
-/- 
mice had significantly greater 
neutrophil influx 2 days after MI compared with C57Bl6 mice (P<0.01). Numbers 
declined to sham levels 4 days post-MI. Expression of the neutrophil chemoattractants, 




Figure 4-7 Identification of neutrophils in haematoxylin and eosin stained sections 
Neutrophils were identified by their distinctive multi-lobed nuclei in haematoxylin and eosin 
(H&E) stained sections. Tiled H&E stained section (a). LV= left ventricle, RV= right ventricle, IA= 







Figure 4-8 Neutrophil influx after MI or sham surgery 
Neutrophils in the left ventricle were counted in haematoxylin and eosin stained sections and 
expressed as number per 40µm
2
 (a). Neutrophil numbers were increased after MI compared 
with sham-operated mice and this increase was greater in 11HSD1
-/- 
mice. Interleukin-6 (IL-6) 
mRNA expression relative to sham and normalised to GAPDH housekeeping gene was not 





 MI. For RT-PCR n=6 per group. Data are expressed as mean ± SEM. ## P<0.01, 
###P<0.001 sham vs. MI **P<0.01 C57Bl6 vs. 11HSD1
-/- 







Macrophage infiltration, shown by mac 2 immunoreactivity, was seen predominantly in 
the infarct and border zone (Figure 4.9). Staining was low in all sham operated groups. 
Mac 2 positive cells were detected 2 days after MI with significant increases in staining 
observed 4 and 7 days post-MI relative to sham in both strains of mice (P<0.001, Figure 
4.10). At 7 days after infarction macrophage staining was significantly augmented in 
11HSD1
-/- 
mice compared with C57Bl6 controls (P<0.001). Myocardial expression of 
monocyte chemoattractant protein-1 (MCP-1) mRNA, a chemokine involved in 
macrophage recruitment, was elevated 7 days after MI in the hearts of 11HSD1
-/- 
mice 






Figure 4-9 Identification of macrophages in heart sections 
Tiled section of a heart that has been immunolabelled with anti-mac 2 antibody to identify 
macrophages (brown) in the infarct border (IB) and counter-stained with haematoxylin (a). 
Pictures of mac 2 immunohistochemistry in the infarct border in C57Bl6 and 11HSD1
-/- 
mice 2, 4 





Figure 4-10 Macrophage infiltration after MI or sham surgery 
Macrophage infiltration shown by mac 2 immunoreactivity was quantified as percent of the 
infarct border (IB) stained (a).  Mac 2 immunoreactivity increased over the week post-MI with 
there being significantly more mac 2 positive cells in the infarct border of 11HSD1
-/- 
mice 
compared with C57Bl6 controls at day 7. b) Monocyte chemoattractant protein-1 (MCP-1) mRNA 
expression relative to sham and normalised to GAPDH housekeeping gene. MCP-1 was 
increased in the 11HSD1
-/- 
mice relative to sham at day 7. n=8 C57BL6 sham, n=12 C57BL6 MI, 
n=4 11HSD1
-/-
 sham, n=6 11HSD1
-/-
 MI. For RT-PCR n=6 per group. Data are expressed at 
mean ± SEM. ### P<0.001 sham vs. MI, **P<0.01, *** P<0.001 C57Bl6 vs. 11HSD1
-/- 
by 2 way 





The number of cells immunopositive for the alternatively activated macrophage marker, 
YM1, was elevated 4 and 7 days post-MI in both strains of mice, relative to sham-
operated controls in which staining was negligible (Figures 4.11 and 4.12). The pattern 
of staining was similar to that of mac 2 positive cells. 11HSD1
-/- 
mice had significantly 
more YM1 positive macrophages at 4 days after MI compared with C57Bl6 controls 
(P<0.05) with a similar trend at day 7. This relationship remained when expressed 




Figure 4-11 Identification of alternatively-activated macrophages by 
immunohistochemistry 
Alternatively activated macrophages were identified by immunohistochemistry for YM1.  





Figure 4-12 Alternatively-activated macrophage infiltration after MI or sham operation 
Alternatively-activated macrophage infiltration demonstrated by YM1 immunoreactivity was 
quantified as percentage of the infarct border (IB) stained (a). YM1 positive cells were also 
expressed as a percentage of mac2 positive macrophages in the infarct border (b). 
Immunoreactivity for YM1 was increased 4 and 7 days after MI. Moreover there were more YM1 
positive cells in the infarct borders of 11HSD1
-/- 
mice relative to C57Bl6 controls at day 4. n=8 
C57BL6 sham, n=12 C57BL6 MI, n=4 11HSD1
-/-
 sham, n=6 11HSD1
-/-
 MI. Data are expressed 
as mean ± SEM. # P<0.05, ## P<0.01 sham vs. MI, * P<0.05 C57Bl6 vs. 11HSD1
-/- 






Other inflammatory cells post MI 
Expression of the T cell marker, CD3, was seen in the infarct and border zone but not in 
hearts from sham-operated animals (Figure 4.13). The amount of staining was low 
relative to that of macrophages with maximum staining at day 2. Immunohistochemistry 
for the B cell marker, CD45R, stained a small number of cells in infarcted hearts only 
(Figure 4.13). The cells were located diffusely across the left ventricle. There were no 







Figure 4-13 Immunohistochemistry for inflammatory cells 
 (a) Immunohistochemistry with an anti-CD3 antibody showed that T cells infiltrate the 
myocardium of MI mice only. (b) Immunohistochemistry with an anti-CD45R antibody showed a 
small number of B cells in the heart after ligation only. Sections were counterstained with 







Immunohistochemistry detected α smooth muscle actin (αSMA) secreted from activated 
myofibroblasts in the infarct and border zone after myocardial infarction (Figure 4.14). 
It also detects the smooth muscle layer of vessels; however after MI the majority of 
staining was related to myofibroblasts (identified by its staining pattern). αSMA staining 
in the left ventricle was increased after MI at day 4 and 7 in C57Bl6 and 11HSD1
-/- 
mice 
(P<0.05). Genotype had no influence on αSMA immunoreactivity.  
 
Expression of GR, MR and 11HSD1 mRNAin the heart 
Expression of GR and MR mRNA in the hearts was comparable between C57Bl6 and 
11HSD1
-/- 
mice (Table 4.3) with MI having no effect. 11HSD1 mRNA was detected in 
C57Bl6 mice and infarction did not affect its expression. The CP values for 11HSD1 
mRNA in the 11HSD1
-/- 
mice were very high (34.5->35). Therefore it was not possible 
to accurately assess the amount of 11HSD1 mRNA. However these values do show that 
levels of the transcript were very low, almost beyond detection.  
 
Expression of 11HSD1 protein 
In sham operated mice 11HSD1 immuno-reactivity was restricted to cardiac fibroblasts 
and the smooth muscle of the cardiac vasculature (please refer to Chapter 3).11HSD1 
protein expression  after MI was similar to sham-operated controls but was also detected 
in inflammatory cells at all time-points (Figure 4.15). Upon close inspection, these 
inflammatory cells were identified as macrophages (Figure 4.15). Due to the quality of 





Figure 4-14 Fibroblast activation to myofibroblasts after MI or sham surgery 
Activated myofibroblasts were detected using immunohistochemistry for α smooth muscle actin. 
Positive staining increased after MI over 7 days. Sections were counterstained with 
haematoxylin. n=8 C57BL6 sham, n=12 C57BL6 MI, n=4 11HSD1
-/-





Data are expressed as mean ± SEM. Bar is 10µm. # P<0.05, ##P<0.01, ##P<0.001 sham vs. MI 
by 2 way ANOVA. 
 



























































Table 4-3 Expression of VEGFa, GR, MR and 11HSD1 mRNAs after MI surgery. 
Post-infarct expression of VEGFa, GR, MR and 11HSD1 in the heart relative to sham surgery 
and normalised to GAPDH (n=6). There were no changes observed across the groups. N/D is 







Figure 4-15 Immunohistochemistry for 11HSD1 after MI surgery 
11HSD1 immunohistochemistry showed positive cell staining in inflammatory cells (a, b) that 
upon close inspection resemble macrophages. c) negative control. Sections were counterstained 




Left ventricle dimensions and cardiac function 
There were no differences in left ventricle end diastolic area (LVEDA) at any time point 
between all groups suggesting that up to a week post-MI there has been no ventricular 
dilation (Table 4.4). Left ventricle end systolic area (LVESA) was significantly 
increased in C57Bl6 mice 4 and 7 days after MI compared to sham-operated controls 
suggesting systolic dysfunction and at day 2 and 4 in the 11HSD1
-/- 
mice. There were no 
differences in left ventricle end diastolic diameter (LVEDD) and end systolic diameter 
(LVESD) up to 4 days post MI between C57Bl6 and 11HSD1
-/- 
mice. At day 7 LVEDD 
was significantly elevated after MI in the C57Bl6 mice compared with sham but not 
relative to 11HSD1
-/- 
mice. In C57Bl6 mice MI was associated with a reduction in 
fractional shortening (FS) and ejection fraction (EF) compared with sham, that was 
evident from 2 days after coronary artery ligation; this did not change significantly up to 
7 days post surgery (Table 4.4 and Figure 4.16). In 11HSD1
-/- 
mice FS and EF were 
reduced from 2 days after MI to a similar extent as C57Bl6 mice. However from 7 days 
post MI there was a trend for improved FS whilst EF was significantly enhanced in 
11HSD1
-/- 
















































































































































































































Table 4-4 Left ventricle dimensions after MI or sham surgery  
There were no differences in left ventricle (LV) end diastolic area (EDA), end systolic diameter (ESD), posterior wall thickness at diastole 








suggesting systolic dysfunction. LV end diastolic diameter (EDD) was significantly increased 7 days post-MI in C57Bl6 mice compared with 
shams. Ejection fraction (EF%) was significantly decreased at all time points after MI. 11HSD1
-/- 
mice had significantly improved heart 
function 7 days post MI relative to C57Bl6 controls. Fractional shortening (FS%) was decreased after MI at all time points. n=8 C57BL6 
sham, n=12 C57BL6 MI, n=4 11HSD1
-/-
 sham, n=6 11HSD1
-/-
 MI. Data are expressed as mean ± SEM> # P<0.05, ## P<0.01, ###P<0.001 
sham vs. MI, * P<0.05 C57Bl6 vs. 11HSD1
-/- 










Figure 4-16 Left ventricle ejection fraction after sham or MI surgery 
Left ventricle function was expressed as ejection fraction using the equation (left ventricle end 
diastolic area- left ventricle end systolic area)/ left ventricle end diastolic area x 100. Ejection 
fraction declined after MI. 11HSD1
-/- 
mice showed improved heart function 7 days after MI 
compared with C57Bl6. n=8 C57BL6 sham, n=12 C57BL6 MI, n=4 11HSD1
-/-
 sham, n=6 
11HSD1
-/-
 MI. Data are expressed as mean ± SEM. ## P<0.01, ###P<0.001 sham vs. MI, * 
P<0.05 C57Bl6 vs. 11HSD1
-/- 










The aim of the current study was to determine whether the high circulating 
corticosterone immediately after MI is sufficient to protect the heart from initial 
ischaemic damage in 11HSD1
-/- 
mice. Furthermore, it addressed the mechanism of the 
previously reported enhancement of angiogenesis in these animals (Small et al., 2005, 
Small, 2005). The data presented here confirm this previous observation that vessel 
density is enhanced 7 days after MI in 11HSD1
-/- 
mice compared with C57Bl6 controls. 
This was associated with increased cell proliferation and augmented tissue IL-8 mRNA 
levels. Further investigation demonstrated that both the systemic stress-mediated release 
of corticosterone and the infarct size were comparable in 11HSD1
-/- 
and C57Bl6 control 
mice and, therefore, are unlikely to account for the changes in vessel density. 11HSD1
-/- 
mice have enhanced neutrophil and macrophage infiltration 2 and 7 days post-MI 
respectively. Moreover this was associated with an increase in alternatively-activated, 
reparative macrophage influx. By 7 days after MI, at the time when increased vessel 
density was clearly evident, there was an improvement in cardiac function in 11HSD1
-/-
 
mice. The 11HSD1 protein expression was detected in invading inflammatory cells 
along with cardiomyocytes, cardiac fibroblasts and vascular smooth muscle cells. The 
relative contribution of these cells types in mediating this altered healing response in the 
11HSD1
-/-
 mice is relatively unknown however. 
 
Recovery from surgery 
Previous characterisation has shown that 11HSD1
-/-
 mice have no underlying cardiac 
phenotype with normal cardiac architecture and function  (Kotelevtsev et al., 1997) 
(please refer to Chapter 3). Mortality rates and cause of death were similar in both 
strains of mice as was weight gain after surgery, demonstrating that early in infarct 
healing the mice do not develop a grossly abnormal phenotype. Weight loss was rapid 
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after surgery and regain of weight began 2 days after surgery as the mice recovered from 
the stress of the surgery. Evidence from Chapter 3 shows that 11HSD1
-/-
 mice have 
lower basal heart weight than C57Bl6 controls. However, no such difference was 
observed after surgery.  
 
Initial ischaemic damage 
11HSD1
-/-
 mice on the C57Bl6 background have no alteration in the function of the 
HPA axis relative to wild type controls (Paterson et al., 2006). In the current study 
circulating corticosterone levels were comparable between C57Bl6 and 11HSD1
-/-
 mice 
after MI or sham surgery. Glucocorticoids reduce ischaemic cell death when 
administered early and acutely after MI. A single dose of methylprednisolone, given 30 
minutes or 6 hours after MI, reduced ischaemic damage in a dog model (Libby et al., 
1973). Furthermore in a clinical study a single dose of methylprednisolone reduced 
infarct size and mortality (Libby et al., 1973, Morrison et al., 1976). The protective 
influence of glucocorticoids may be due to their ability to stabilise lysosymal 
membranes preventing the release of their damaging digestive enzymes into the cell 
(Lefer et al., 1980). Alternatively their positive effects may be attributed to their ability 
to activate endothelial nitric oxide synthase (eNOS) causing vasorelaxation and 
therefore increased coronary blood flow (Hafezi-Moghadam et al., 2002, Lefer et al., 
1980). Although 11HSD1
-/-
 mice are unable to regenerate corticosterone in the heart, 
infarct size was comparable between strains suggesting that the systemic release of 
corticosterone is sufficient to protect the heart from initial ischaemic cell death.  
 
Neovascularisation 
Angiogenesis, formation of new blood vessels from pre-existing vasculature, is a 
complex series of events involving cell proliferation, migration, capillary sprouting, 
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pruning and maturation (Simons, 2005, Ren et al., 2002, Grass et al., 2006). It is 
stimulated by a number of cytokines including IL-8, VEGF, platelet derived growth 
factor (PDGF) and fibroblast growth factor (FGF) as a response to hypoxia or 
inflammation (Xu et al., 2007, Korpisalo et al., 2008, Yau et al., 2005, Payne et al., 
2007, Ruixing et al., 2007, Greenberg et al., 2008, Fernandez et al., 2000).  The results 
presented here reproduce the previously reported enhancement in vessel density 7 days 
post MI in the 11HSD1
-/-
 mice relative to C57Bl6 controls (Small et al., 2005). In the 
present study this was found to be associated with increased cell proliferation, assessed 
by BrdU incorporation, and augmented tissue IL-8 mRNA expression. Vessels on the 
infarct border lacked pericytes at this stage (CD31 positive only), consistent with reports 
in the literature (Ren et al., 2002, Arras et al., 1998). A limitation of CD31 
immunohistochemistry was that in all groups some vessel structures showed no CD31 
immunoreactivity to this marker; potentially because expression of the antigen can alter 
as the cells mature (Ismail et al., 2003). Non-stained vessels were equivalent to a small 
but consistent proportion to those that stained positive for CD31 at all time points and, 
as such, was not a confounding variable in the current study. CD31 is a pan-endothelial 
cell marker and, therefore, it cannot distinguish between old and new vessels. 
Aminopeptidase N/CD13 is a specific marker of angiogenic vasculature but detection by 
immunohistochemistry requires gentle tissue fixation (Rangel et al., 2007, Bhagwat et 
al., 2001). Unfortunately, as the tissue was fixed in formalin, use of this marker was not 
possible. Alternatively, tagging of cNGR (a peptide sequence that homes to CD13 
positive cells) with a fluorophore has demonstrated its localisation to angiogenic sites on 
the infarct border 4 and 7 days after experimental MI (Buehler et al., 2006). Assessment 
of CD13 expression in tissue less heavily fixed, assessing endoglin/CD105 expression 
(another angiogenic endothelial cell marker) (van Laake et al., 2006) or using 
fluorescently-labelled cNGR should be considered for future studies.  
While it has been shown that 11HSD1
-/- 
mice have enhanced vessel density 7 days post-
MI the functionality of these vessels is yet to be elucidated.  Assessment of perfusion 
can be made using micro-angiography (Cheng et al., 2007) but resolution is too low for 
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accurate quantification (Bondke et al., 2007). Laser Doppler is an alternative but this 
method also has limitations as penetration depth is low (Scholz et al., 2002, Bondke et 
al., 2007). Perfusion of fluorescently-labelled microspheres, ultrasound contrast 
microbubbles or microbubbles tagged with endothelial cell specific antibodies are 
alternatives that could be considered in future studies (Liu et al., 2007, Dickie et al., 
2006). 
The increase in cell proliferation in 11HSD1
-/-
 mice is in line with a study by El-Helou et 
al. who show that dexamethasone treatment decreases post-infarct cell proliferation (El-
Helou et al., 2008). In order to identify which cells were proliferating double 
immunohistochemistry (traditional and confocal using fluorescently conjugated 
secondary antibodies) was attempted with limited success. BrdU and mac 2 were not co-
expressed indicating that macrophages were not proliferating. Unfortunately double 
labelling BrdU with CD31 (endothelial cells) or αSMA (fibroblasts) was unsuccessful. 
Based on evidence in the literature it is likely that the proliferation mostly involved 
endothelial cells and cardiac fibroblasts, with possibly a small contribution from 
cardiomyocytes (Virag and Murry, 2003, Lutgens et al., 1999). Increased proliferation of 
endothelial cells is consistent with the occurrence of increased angiogenesis, that has 
been previously shown in 11HSD1
-/-
 mice in vivo and in vitro (Small et al., 2005).  
In the current study 11HSD1
-/-
 mice exhibited enhanced IL-8 expression 7 days after MI 
compared with C57Bl6 controls. IL-8 is secreted by macrophages and endothelial cells 
in the healing infarcts, acts as a chemoattractant for bone marrow-derived endothelial 
progenitor cells and can promote endothelial cell proliferation (Li et al., 2003, Kocher et 
al., 2006). Blockade of CXCR2, the receptor for IL-8, prevents vessel sprouting in aortic 
rings highlighting its role in angiogenesis (Gelati et al., 2008).  Other factors involved in 
liberation of bone marrow-derived cells, such as stromal cell-derived factor (SDF)-1α, 
may be involved in enhancing angiogenesis in 11HSD1
-/-
 mice and warrant further 
investigation (Sasaki et al., 2007). 
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VEGF, another pro-angiogenic cytokine, is produced by cardiomyocytes, macrophages 
and vascular smooth muscle cells. It acts on the VEGF 2 receptor on endothelial cells 
promoting endothelial cell proliferation, migration and tube formation (Gu et al., 1999, 
Nahrendorf et al., 2007, Maulik and Thirunavukkarasu, 2008). Exogenous 
administration and endogenous upregulation of VEGFa following myocardial hypoxia is 
reported to mobilise endothelial progenitor cells and stimulate angiogenesis resulting in 
reduced infarct size and improved heart function (Kalka et al., 2000, Kido et al., 2005, 
Payne et al., 2007, Ruixing et al., 2007, Yau et al., 2005). In the present study no 
changes in VEGFa levels were observed suggesting that it is not an important 
contributory factor in this model. Vandervelde et al. found that VEGFa gene expression 
was unaltered up to 28 days after MI with the exception of at 7 days when it was 
decreased (Vandervelde et al., 2007). It was hypothesised that this was due to 
constitutively high VEGFa expression in control hearts and therefore their absolute 
mRNA quantities may still be high (Vandervelde et al., 2007). VEGF is not the only 
contributor to adult angiogenesis as alone it stimulates the production of aberrant, 
disorganised leaky vasculature and must be regulated to optimise its therapeutic 
potential (Bates and Harper, 2002, Payne et al., 2007). In a rabbit hindlimb model of 
ischaemia both VEGF and PDGF were required to improve perfusion (Korpisalo et al., 
2008). Furthermore PDGF is required for pericyte priming (aiding in vessel maturation, 
reducing vessel leakage) and can work synergistically with VEGF (Greenberg et al., 
2008). Other growth factors were not examined in this study and require further 
attention.  
Upregulation of angiogenic cytokines may be mediated directly through ischaemia. 
Under hypoxic conditions degradation of hypoxia inducible factor (HIF)-1α is blocked 
enabling it to translocate to the nucleus where it up-regulates its target genes involved in 
angiogenesis (Kido et al., 2005, Forsythe et al., 1996). Knockout of HIF-1α impairs 
development of the vasculature whereas over-expression after MI is associated with 
reduced infarct size and increased vessel density (Shohet and Garcia, 2007, Kido et al., 
2005). Angiogenesis can, therefore, be induced independent of inflammation (van Laake 
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et al., 2006). Although the weight of evidence points to inflammation as a mechanism 
for increased vessel density of 11HSD1
-/-
 mice after MI, activation of HIF-1α merits 
further consideration.  
 
Post infarct inflammation 
Ischaemia from coronary artery occlusion evokes a powerful inflammatory response. 
This is mediated by reactive oxygen species, and activation of toll-like receptors (TLR) 
and the complement cascade resulting in production of a plethora of cytokines and 
chemokines (Shishido et al., 2003, Sumitra et al., 2005).  Glucocorticoids inhibit the 
production of a range of inflammatory cytokines including IL-1β, IL-2, IL-3, IL-6, IL-
11, TNF-α, interferon (IFN)-α and chemokines such as IL-8, RANTES, MCP-1 and 
MIP-1α (Barnes, 1998, Cupps and Fauci, 1982, Galon et al., 2002, Park et al., 2009). In 
parallel, GR activation up-regulates anti-inflammatory mediators such as IL-10, TGF-β 
and lipocortin-1 and can modulate phagocytosis by macrophages (Galon et al., 2002, 
Cupps and Fauci, 1982, Barnes, 1998, Gilmour et al., 2006, Park et al., 2009). 
Leukocytes, macrophages, smooth muscle cells and cardiac fibroblasts express 11HSD1 
and the enzyme is upregulated in macrophages after activation (Gilmour et al., 2006, 
Thieringer et al., 2001, Brereton et al., 2001, Walker et al., 1991). 11HSD1 amplifies 
glucocorticoids locally and may serve to curtail the inflammatory response. In 11HSD1
-/-
 
mice macrophage infiltration into sites of inflammation in peritonitis, pleurisy and serum 
arthritis models is increased (Gilmour et al., 2006, Chapman et al., 2009, Coutinho 
2009). Excessive inflammation after MI can be detrimental and lead to cardiac rupture 
(Nian et al., 2004) but a certain amount is required for adequate scar formation (van 
Amerongen et al., 2007).  
In the absence of inflammation neutrophils circulate in blood without interacting with 
the vessel wall (Frangogiannis et al., 2002). From 6 hours after infarction inflammatory 
mediators such as IL-6, IL-8 and TNF-α are up-regulated in the myocardium and act as 
potent neutrophil chemoattractants (Vandervelde et al., 2007, Dewald et al., 2004, 
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Fielding et al., 2008, Coelho et al., 2008, Frangogiannis et al., 2002). Concurrent with 
the increase in inflammatory cytokines, there is also an increase in anti-inflammatory 
and anti-angiogenic mediators such as IL-10 and interferon-γ inducible protein (IP)-10 
which have roles in preventing immature granulation tissue deposition and angiogenesis 
(Vandervelde et al., 2007, Yang et al., 2000, Frangogiannis et al., 2001).  In this model 
there was no difference in expression of IL-6 and IL-8 two days after infarction. 
Previous studies have shown that acute surgical trauma can result in cytokine 
expression, making detection of local changes difficult to detect until at least 3 days post 
surgery (Nossuli et al., 2000).  Surgical trauma may therefore have interfered with 
detection of changes in cytokine expression in the current study. In addition cytokine 
expression was assessed in pieces of heart tissue that contained both the infarct and 
healthy tissue. It is possible that including the healthy tissue diluted the expression of the 
cytokines making it less likely to detect changes.   
When an inflammatory stimulus is present neutrophils roll slowly along the post 
capillary venules, before becoming tethered to the endothelium in a process mediated by 
adhesion molecule expression (Frangogiannis et al., 2002). Local stimuli, such as IL-8, 
can induce neutrophil metamorphosis prior to translocation into the tissue (Thelen et al., 
1988). The results presented here show that neutrophil infiltration peaked early after 
infarction (day 2) and declined to sham levels by day 4; consistent with the current 
literature (Dewald et al., 2004).  Furthermore the peak of neutrophil infiltration was 
significantly augmented in 11HSD1
-/-
 mice. Mice deficient in glucocorticoids following 
adrenalectomy have increased expression of the adhesion molecules (L-selectin on 
neutrophils and ICAM-1 and VCAM-1 on endothelial cells) that have a role in tethering 
neutrophils to the endothelium (Cavalcanti et al., 2007). Reduced availability of 
glucocorticoids in the 11HSD1
-/-
 mice may provide a similar stimulus for enhanced 
attraction of neutrophils post-MI. Expression of adhesion molecules early after 
infarction requires further investigation. Glucocorticoids reduce neutrophil apoptosis in 
vitro suggesting that the increase seen in intact neutrophil numbers in the 11HSD1
-/- 
mice is unlikely to be due to delayed apoptosis (Ruiz et al., 2002). 
 163 
 
There is conflicting evidence regarding the influence of neutrophils on infarct healing.  
Neutrophils are an important source of oxidant stress and, therefore, can increase 
cardiomyocyte death in the infarct; particularly when they enter the heart after 
reperfusion (Kin et al., 2006, Rossi, 1986, Jordan et al., 1999). Administration of a 
neutrophil-neutralising antibody to rats just prior to MI reduces apoptosis diminishing 
the extent of the infarct. Furthermore, in patients high circulating IL-6 and neutrophil 
counts are associated with increased mortality after MI (Kin et al., 2006, Jaremo and 
Nilsson, 2008). However, neutrophils also remove necrotic cells and provide a stimulus 
for monocyte infiltration and angiogenesis, both of which are vital in infarct healing 
(Frangogiannis et al., 2002, Savill et al., 1989a, Nozawa et al., 2006). Thus selective 
neutrophil depletion 1 day before and for the 4 days following MI was reported to impair 
necrotic cell removal in mice 7 days post-MI (Heymans et al., 1999). Timing is likely to 
be important in the eventual influence of neutrophils. In the present study, increased 
alternate macrophage activation and angiogenesis is consistent with the beneficial 
influence of neutrophils in the heart 2 days after infarction. Investigation of IL-4 
expression, as the major neutrophil derived mediator of these outcomes (Brandt et al., 




Under basal conditions monocytes patrol the vessel wall and extravasate within an hour 
in response to the relevant inflammatory stimuli (Auffray et al., 2007). In the myocardial 
infarct they are recruited by chemokines such as MCP-1, MIP-1α, MIP-1β and MIP-2, 
with MCP-1 being substantially the most potent (Frangogiannis et al., 2002). Over-
expression of MCP-1 is associated with increased macrophage infiltration and a 
reduction in scar size in a murine model of MI (Morimoto et al., 2006).  Once in the 
infarct monocytes differentiate into macrophages, which can then secrete additional 
MCP-1 (Morimoto et al., 2006, Kakio et al., 2000, MacKinnon et al., 2008).  The results 
presented here show that, in C57Bl6 and 11HSD1
-/-
 mice, infiltration by mac 2 positive 
cells increased over the week following MI.  Furthermore 11HSD1
-/-
 mice had enhanced 
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macrophage staining and increased MCP-1 mRNA expression 7 days after MI compared 
with C57Bl6 mice.  
Nahrendorf et al. suggested that there is a particular subset of monocytes involved in 
infarct healing that are „alternatively-activated‟ and pro-angiogenic. These cells are 
characterised by low expression of ly6C (a monocyte/macrophage and endothelial cell 
differentiation cell surface antigen) and high expression of CD11c (an integrin expressed 
on monocytes, macrophages and dendritic cells) (Nahrendorf et al., 2007). Unlike 
classically-activated macrophages that secrete pro-inflammatory mediators and display 
phagocytic behaviour, alternatively-activated macrophages secrete anti-inflammatory 
and pro-angiogenic cytokines such as IL-4 and IL-8 (Loke et al., 2002, Mosser and 










 monocytes peaked 5-7 days post-MI (Nahrendorf et al., 
2007). Using a different approach (immunohistochemistry) I found that 11HSD1
-/-  
mice 
have significantly more YM1 immuno-positive, alternatively activated macrophages in 
the infarct border 4 days post-MI. At day 7 after MI these changes were still evident but 
no longer significant. This observation suggests that in 11HSD1
-/- 
mice alternate 
macrophage activation may take place at an earlier time point than in wild type mice. 
Characterisation of hearts 4 and 7 days after MI by flow cytometry may provide more 
evidence for this. Alternatively-activated macrophages are the likely source of IL-8, 
expression of which was increased at the time of angiogenesis in the 11HSD1
-/- 
mice. 
These macrophages have also been associated with myofibroblast accumulation and 
wound healing (Nahrendorf et al., 2007), and thus may have an effect on scar formation 
(please refer to Chapter 5).  
The importance of inflammatory cells in angiogenesis has been demonstrated by several 
intervention studies. Deficiency of neutrophils in a cancer model prior to the „angiogenic 
switch‟ reduces angiogenesis and tumour growth (Nozawa et al., 2006). Macrophage 
depletion, achieved by administration of liposome-encapsulated clodronate which is 
lethal upon phagocytosis, reduces angiogenesis after MI and in aortic ring explants 
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(Nahrendorf et al., 2007, Fraccarollo et al., 2008, van Amerongen et al., 2007, Gelati et 
al., 2008). This effect in aortic rings is reversed by replenishment with bone marrow-
derived macrophages suggesting that vessel sprouting is strongly influenced by the 
presence of inflammatory cells  (Gelati et al., 2008). Macrophages have been shown to 
be a vital component of tumour angiogenesis as depletion reduces angiogenic factor 
production and tumour size to a similar extent to glucocorticoid treatment (Banciu et al., 
2008a). Furthermore over-expression of MCP-1 augments capillary density and 
preserves heart function (Morimoto et al., 2006). The inflammatory response also has a 
vital role in other infarct healing processes. Scar formation is impaired and cardiac 
function is depressed when monocytes are depleted (van Amerongen et al., 2007, 
Fraccarollo et al., 2008, Nahrendorf et al., 2007) . Moreover direct injection of a human 
activated macrophage suspension into rat hearts immediately after infarction increases 
vessel density, reduces ventricular dilation and an improves heart function 5 weeks post-
MI (Leor et al., 2006). It would be very interesting to investigate whether monocyte 
depletion by clodronate administration (Fraccarollo et al., 2008, Nahrendorf et al., 2007, 
van Amerongen et al., 2007) or conditional ablation of CD11b cells mediated by the 
diphtheria toxin receptor (Duffield et al., 2005) would prevent the enhanced vessel 
density in the 11HSD1
-/-
 mice compared with C57Bl6 controls.  
Studies examining renal ischaemia/reperfusion injury suggest that T and B cells might 
have a vital role in the healing response in the kidney (Burne-Taney et al., 2005). 
Furthermore, T cells secrete IL-4, a cytokine known to programme macrophages to the 
alternatively-activated phenotype (Loke et al., 2002). The role of these lymphocytes is 
relatively unknown after cardiac ischaemia but they are present during the healing phase 
(Liao and Cheng, 2006). Immunohistochemistry for T cells showed that the peak in 
infiltration was 2 days post-MI while few cells showed B cell immunoreactivity 
suggesting that, whilst these cells are part of infarct healing, their role may be limited. 





Another component in the healing response post-MI involves the differentiation of 
cardiac fibroblasts to myofibroblasts. Such transformation, stimulated by reactive 
oxygen species and TGF-β produced by macrophages, leads to the secretion of factors 
able to modulate the extracellular matrix, mediate inflammation and increases collagen 
synthesis (Cleutjens et al., 1995, Desmouliere et al., 1993, Fadok et al., 1998, Porter and 
Turner, 2009). Myofibroblast activation, assessed by immunostaining for the secreted α 
smooth muscle actin, increased over the week after infarction, peaking at day 7. There 
was no evidence for a difference in staining between the strains despite 11HSD1
-/- 
mice 
having increased infiltration of macrophages which can aid in fibroblast activation 
(Desmouliere et al., 1993, Cleutjens et al., 1995, Fadok et al., 1998). This has important 
implications when considering the long-term outcome in 11HSD1
-/- 
mice after MI (see 
Chapter 5). Activation of myofibroblast MR has been implicated to exacerbate fibrosis 
(Brilla et al., 1993, Lijnen and Petrov, 2000) and, therefore, reduced glucocorticoid 
generation in 11HSD1
-/- 
mice might prevent this (see Chapter 5).  
Expression of steroid-related genes 
GR expression has been localised to cardiomyocytes, cardiac fibroblasts, vascular 
smooth muscle cells and endothelial cells, whilst MR expression has been found in 
cardiomyocytes, vascular smooth muscle cells and endothelial cells (Sheppard and 
Autelitano, 2002, Lombes et al., 1995, Walker, 2007b, Yang and Zhang, 2004, Takeda 
et al., 2007, Ullian, 1999, Hadoke et al., 2006, Christy et al., 2003). Cardiac GR mRNA 
expression does not change after MI (Silvestre et al., 1999). Expression of MR, in 
contrast, has been shown to be upregulated 14 and 28 days after infarction respectively 
(Milik et al., 2007, Takeda et al., 2007). However, Silvestre et al. found no such 
difference (Takeda et al., 2007, Milik et al., 2007, Silvestre et al., 1999). The results 
presented here show no change in the expression of mRNA for either receptor at any of 
the time points post infarction and in either genotype. In the current study activation of 
GR and MR were not assessed.  
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11HSD1 is reported to be expressed at a basal level in myocardial fibroblasts, 
cardiomyocytes and smooth muscle of the cardiac vasculature (please refer to Chapter 3) 
(Sheppard and Autelitano, 2002, Klusonova et al., 2009). MI had no effect on 11HSD1 
mRNA expression at any time point in C57Bl6 mice. This result is consistent with 
previous work from this laboratory that found no difference in 11HSD1 activity 7 days 
post-MI, and with reports that activity is not altered in failing human hearts (Slight et al., 
1996, Small, 2005). Here we observed immunoreactive 11HSD1 in infiltrating 
macrophages which may alter their phenotype in the heart. 11HSD2 is also reported to 
be expressed in the myocardium in fibroblasts (Slight et al., 1993, Slight et al., 1996, 
Takeda et al., 2007). In the current study 11HSD2 mRNA and protein expression were 
not investigated due to lack of satisfactory primers for qRT-PCR and antibodies for 
immunohistochemistry. The limited literature suggests that 11HSD2 mRNA expression 
increases 14 days post-MI and after chronic intermittent hypoxia but there is no 
difference in failing human hearts (Takeda et al., 2007, Slight et al., 1996, Klusonova et 
al., 2009). It is difficult to make definitive conclusions regarding expression of GR, MR 
and the 11HSD enzymes post-MI due to the lack of data and consistency in the 
literature.  
As mentioned previously glucocorticoids are potent immuno-modulatory hormones. As 
hypothesised, 11HSD1
-/- 
mice exhibit enhanced inflammation which is in agreement 
with previous work that showing that these mice have worse inflammation in models of 
sterile peritonitis and arthritis (Gilmour et al., 2006, Coutinho 2009). Glucocorticoids are 
also known inhibit angiogenesis in vitro and in vivo via the glucocorticoid receptor. It 
has been shown that aldosterone does not affect angiogenesis in human bone marrow 
derived-endothelial cells (Chen et al., 2004). In aortic ring cultures the decrease in 
angiogenesis produced by glucocorticoids can be prevented by a glucocorticoid, but not 
by a mineralocorticoid receptor antagonist (Small et al., 2005). In addition, the GR 
antagonist, RU38486, reduces angiogenesis 7 days post-MI relative to vehicle treated 
controls (Small et al., 2005). These studies suggest that enhanced angiogenesis in the 
11HSD1
-/-
 mouse is not mediated by reduced glucocorticoid signalling via the MR but 
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rather via the GR. However, Fraccarollo et al. demonstrate that the MR antagonist 
epleronone can enhance angiogenesis 7 days after MI (Fraccarollo et al., 2008). It is 
possible that the angiostatic effect of glucocorticoids may be mediated by activation of 
both the GR and MR. Many studies that have shown glucocorticoids can inhibit 
angiogenesis but cannot conclude definitively that this is independent of inflammation.  
 
Cardiac function 
It is clear from the literature that enhanced angiogenesis on the infarct border post-MI 
improves heart function (Engel et al., 2006, Liu et al., 2007, Sasaki et al., 2007, Orlic et 
al., 2001, Kido et al., 2005, Kocher et al., 2006).  Whilst ejection fraction was not 
different between control and 11HSD1
-/- 
mice early after infarction, by 7 days after MI, 
at the time when increased vessel density was clear there was an improvement in 
ejection fraction. Fractional shortening showed the same trend but did not reach 
significance reflecting the inferior accuracy of the measurement of ventricle diameter. 
The initial decline in heart function is mediated due to systolic dysfunction as seen here 
and in previous studies (Shioura et al., 2007). Dysfunction of the myocardium may 
reflect the loss of viable tissue and altered calcium handling in those cells remaining on 
the infarct border (Mork et al., 2009, Shioura et al., 2007). Cardiomyocytes isolated 
from the septum of hearts 7 days post-MI have longer contractions and calcium 
transients relative to sham and are associated with impaired cardiac function (Mork et 
al., 2009). It is probable that increasing blood supply to the infarct border will improve 
cardiomyocyte contractility and prevent infarct expansion by salvage of cardiomyocytes 
(Liu et al., 2007). 
Improving heart function by enhancing angiogenesis is well established within the field 
and various approaches are being taken to investigate this. Translation of strategies such 
as direct myocardial injection of putative cell progenitors or angiogenic factors have had 
limited clinical success to date (Sasaki et al., 2007, Orlic et al., 2001, Kastrup et al., 
2006, Lasala and Minguell, 2009, Meyer et al., 2006). An alternative approach is to 
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manipulate endogenous mechanisms involved in infarct healing so that the associated 
angiogenic response is enhanced. The results presented here show that 11HSD1
-/- 
mice 
have enhanced vessel density and improved heart function that is preceded by 
augmented inflammation and, in particular, by alternatively-activated macrophage 
infiltration. It is interesting to draw parallels from this study to one by Wagner et al. who 
found, in a murine model of left pulmonary artery ligation, that dexamethasone 
treatment reduced inflammation and angiogenesis (Wagner et al., 2008). One must bear 
in mind that angiogenesis is a dynamic process that involves vessel pruning and 
maturation and, therefore, the enhancement in vessel density in the 11HSD1
-/- 
mice may 
not be maintained. Vessel pruning and maturation is complete 4 weeks after MI 
therefore this is a vital time-point to reassess vessel density (Ren et al., 2002, Grass et 
al., 2006). Infarct healing is also complete by this time and it is important to know 
whether these early differences in infarct healing can alter scar formation and cardiac 





The effect of 11HSD1 deficiency on longer term infarct healing 
5.1 Introduction 
Cytokines and growth factors act in concert to regulate the dynamic process of 
angiogenesis that includes vessel formation, pruning and maturation. The stimulation of 
post-infarct angiogenesis has been the primary focus of work by many laboratories while 
the remodelling of such vessels has been relatively overlooked (Small et al., 2005, Kido 
et al., 2005, Kocher et al., 2006, Engel et al., 2006). 11HSD1 deficiency has been shown 
to augment angiogenesis in a variety of models, including after MI at 7 days (Chapter 4 
(Small et al., 2005, Small, 2005)) however, whether the vessels are retained is yet to be 
determined and is the subject of this chapter. 
During neovascularisation the complex interplay of growth factors leads to the 
production of highly organised vasculature that can be capable of perfusion (Conway et 
al., 2001, Greenberg et al., 2008, Korpisalo et al., 2008, Risau, 1997). Stimulation of 
angiogenesis with exogenous administration of single growth factors, such as VEGF, 
does increase vessel density but it produces aberrant, disorganised and leaky vasculature 
(Kocher et al., 2006, Kido et al., 2005, Conway et al., 2001). Factors such as PDGF, 
Ang-1, the Tie 2 receptor and TGF-β1 stabilise vessels by recruitment of pericytes and 
by tightening smooth muscle cell interactions during vessel maturation (Conway et al., 
2001, Greenberg et al., 2008, Korpisalo et al., 2008, Thurston et al., 1999, Ramsauer et 
al., 2002). The addition of a pericyte coat to immature vessels is vital in stabilisation as 
it can inhibit further endothelial cell proliferation and migration (Conway et al., 2001). 
However, factors involved in vessel regression (such as Ang-2) also play an essential 
role in angiogenesis; eliminating excess vessels by endothelial cell death and promoting 
an organised vessel network (Conway et al., 2001, Patan, 2000, Grass et al., 2006, 
Maisonpierre et al., 1997). Vessel stability increases with pericyte coverage and this 
prevents superfluous vessel regression. Post-infarct angiogenesis is established 7 days 
after MI (Chapter 4 and (Small et al., 2005, Grass et al., 2006, Ren et al., 2002)) with 
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vessel pruning occurring between 7 and 21 days, and full maturation complete 28 days 
after infarction (Ren et al., 2002, Grass et al., 2006); accompanying this process is the 
completion of infarct healing and scar formation. It is possible that the increase in vessel 
density in the 11HSD1
-/-
 mice is transient and not subject to pruning (Jujo et al., 2008, 
Grass et al., 2006). Sustained enhancement of vessel density is associated with improved 
cardiac function therefore, establishment of the longevity of these vessels is vital  (Liu et 
al., 2007, Sasaki et al., 2007). Improving perfusion to the infarct border may prevent 
infarct expansion by salvaging cardiomyocytes, along with improving cardiomyocyte 
contractility (Maulik and Thirunavukkarasu, 2008, Sasaki et al., 2007, Payne et al., 
2007).  
Fibrosis is stimulated by the post-infarct inflammatory response, which is enhanced in 
11HSD1
-/-
 mice (Chapter 4). Macrophage secretion of transforming growth factor-β 
(TGF-β) activates myofibroblast production of collagen (Desmouliere et al., 1993, 
Cleutjens et al., 1995, Fadok et al., 1998). Subsequent collagen production starts from 3-
7 days after infarction and increases further by 28 days (Dean et al., 2005, Virag and 
Murry, 2003).  Collagen deposition in the infarct scar is vital for stabilising damaged 
tissue (van Amerongen et al., 2007). Conversely, increased ventricular stiffness resulting 
from fibrosis can impair cardiac function (van Heerebeek et al., 2008, Du et al., 2003). 
There is a fine balance between inadequate and excessive fibrosis (Du et al., 2003, 
Schellings et al., 2009). 11HSD1
-/-
 mice have enhanced macrophage infiltration 7 days 
after MI (Chapter 4) suggesting that the subsequent fibrotic response might be enhanced. 
However, enhanced angiogenesis has been associated with beneficial effects on scar 
characteristics as it can reduce scar thinning and left ventricle chamber dilation (Engel et 
al., 2006, Kido et al., 2005, Orlic et al., 2001).  
In the current study it is hypothesised that the enhanced vessel density previously 
reported at 7 days after MI in 11HSD1
-/-
 mice (Chapter 4 (Small et al., 2005)) is retained 
after healing is complete at 28 days and that this translates into sustained improvement 
in cardiac function. Furthermore, it is investigated whether the increase in vessel density 




5.2.1 Coronary artery ligation 
Male C57Bl6 mice (Harlan, UK) and 11HSD1 homozygous null (
-/-
) mice aged 10-12 
weeks were used for all experiments. Mice underwent coronary artery ligation for 




Cardiac function was assessed by echocardiography as described in Section 2.3.2. Mice 
underwent echocardiography 7, 14, 21 and 28 days after surgery in order to obtain serial 
measurements of ventricular dimensions. The observer was blinded for the purpose of 
echocardiography measurements and all other subsequent analysis of tissue.  
 
5.2.3 Tissue collection 
For analysis of circulating corticosterone levels blood was taken weekly, prior to 
echocardiography, by tail tip at 7:30am (the diurnal nadir) as described in Section 2.3.3. 
Mice were killed by cervical dislocation after echocardiography. The hearts were 
excised, washed in ice-cold PBS, weighed then bisected down the longitudinal axis. It 







5.2.4 Circulating corticosterone 
A corticosterone radioimmunoassay was conducted on plasma samples to determine 




Identification of CD31 positive and α smooth muscle actin (αSMA) positive vessels was 
conducted using a monoclonal rat anti-mouse CD31 primary antibody (BD Bioscience) 
diluted 1/50 in PBS/1%BSA, and a monoclonal mouse anti-mouse αSMA primary 
antibody (Sigma) diluted 1/400 in PBS/1%BSA, respectively. For details of the 
procedure please see Section 2.5.1. Small immuno-positive vessels (<200µm diameter) 
were counted in the left ventricle using Image Pro 6.2, Stereologer Anaylser 6 
MediaCybernetics as described in Section 2.5.2. 
 
5.2.6 Histology 
Collagen deposition and assessment of infarct scar characteristics were assessed from 
heart sections stained with Picrosirius Red and Masson‟s Trichrome by Susan Harvey 
(Medical Research Council/ Centre for Inflammation Research Histology Service). 
Quantative assessment of collagen deposition, scar size, scar thickness and epicardial or 
endocardial infarct lengths was conducted using Image Pro6.2, Stereologer Analyser 6 







All values are expressed as mean ± SEM. Analysis of mortality and cause of death data 
were conducted using Fisher‟s exact test and the Chi squared test. Comparisons of body 
weight, organ weight, echocardiography and circulating corticosterone are by 2-way 
ANOVA with Bonferroni post-hoc tests comparing genotype and time. Repeated 
measures test were used to compare the measurements made at various time points. 












Mortality and the impact of surgery on body and organ weight 
Mortality and its cause after MI were similar to that presented in Chapter 4 (Table 5.1) 
Survival until the end of the study was 76% and 64% for C57Bl6 and 11HSD1
-/-
 mice 
respectively (p=NS). C57Bl6 mice started to gain weight relative to their pre-surgery 
weight from 14 days after induction of MI (Figure 5.1). In contrast 11HSD1
-/-
 mice did 
not regain the post-operative weight loss for the duration for the 28 day study (P<0.05). 
However, 11HSD1
-/-
 mice were significantly heavier than their C57Bl6 counterparts 
before the surgery and up to 7 days later despite being the same age (P<0.05, Figure 
5.1). Heart, lung, liver and kidney weights were similar between C57Bl6 and 11HSD1
-/-
 
mice, whether expressed in grams or relative to body weight, at 28 days after MI (Table 
5.2). However, spleen weight was significantly lower 28 days post infarction in 
11HSD1
-/-













Survival 76.9% (10/13) 64.3% (9/14) 
Cause of death (% of all mice) 
Surgery 15.4% (2/13) 14.3% (2/14) 
Cardiac rupture 0% (0/13) 7.1% (1/14) 
Heart failure 7.7% (1/13) 14.3% (2/14) 
Table 5-1 Mortality after myocardial infarction surgery 
Survival and cause of death were similar between C57Bl6 and 11HSD1
-/- 
mice up to 28 days 
after surgery. Raw numbers are in brackets.  
 







Heart 0.16 ± 0.01 0.17 ± 0.01 6.10 ± 0.42 5.87 ± 0.22 
Lung 0.17 ± 0.01 0.17 ± 0.01 6.22 ± 0.39 5.84 ± 0.27 
Kidney 0.34 ± 0.01 0.36± 002 12.54 ± 0.75 12.29 ± 0.54 
Liver 1.34 ± 0.08 1.17 ± 0.05 50.28 ± 4.08 40.63 ± 2.20 
Spleen 0.12 ± 0.01 0.08 ± 0.01 * 4.63 ± 0.59 2.88 ± 0.30 * 
Table 5-2 Organ weights 28 days after MI surgery 
Heart, lung, liver, kidney and spleen weights were measured 28 days after surgery and 
expressed relative to body weight. 11HSD1
-/- 
mice had significantly lighter spleens than C57Bl6 
mice at this time point. n= 10 C57BL6 MI, n=9 11HSD1
-/-
 MI. Data are expressed as mean ± 
SEM. *P<0.05 C57Bl6 vs. 11HSD1
-/- 





Figure 5-1 Body weight changes after myocardial infarction (MI) or sham surgery 
a) 11HSD1
-/- 
mice lost weight after MI and did not regain this over the 28 days post surgery while 
C57BL6 mice gained weight. Actual mouse body weight over the 28 day period (b). Black line= 
C57Bl6 mice, green line= 11HSD1
-/-
 mice. n= 10 C57BL6 MI, n=9 11HSD1
-/-
 MI. Data are 
expressed as mean ± SEM. *P<0.05, **P<0.01 C57Bl6 vs. 11HSD1
-/-





Plasma corticosterone decreased dramatically to almost baseline levels within 7 days of 
the initial increase 1 day after MI (P<0.001, Figure 5.2). This decline was similar in 
C57Bl6 and 11HSD1
-/-
 mice and was maintained up to 28 days post infarction. 
 
Maintenance of neovascularisation 28 days post infarction 
The density of small CD31 positive vessels seen 7 days post-MI was retained at 28 days, 
after infarct healing was complete (Figure 5.3 and Figure 5.4). The significant increase 
in vessel density seen in 11HSD1
-/-
 mice relative to C57Bl6 controls was maintained 
(day 7, 1.82±0.22 vs. 1.33±0.09; day 28, 2.20±0.17 vs. 1.59±0.15 vessels per 400µm
2
). 
Immunohistological staining for αSMA showed that there was also a significant increase 
in small, smooth muscle-coated vessels in the 11HSD1
-/- 
animals compared with controls 
(Figure 5.3 and Figure 5.4). These CD31 and αSMA positive vessels were found 
predominantly on the infarct border with a few CD31 positive, αSMA negative vessels 










Figure 5-2 Circulating corticosterone after MI surgery 
Circulating corticosterone measured by radioimmunoassay up to 28 days post-MI. Plasma 
corticosterone reduced dramatically by 7 days after the initial increase (that occurred 1 day after 
MI) and did not change up to 28 days post-MI with genotype having no influence. n= 10 C57BL6 
MI, n=9 11HSD1
-/-
 MI except for 1 day MI when n=6. Data are expressed as mean ± SEM. 

























Figure 5-3 Immunohistological analysis of neovascularisation 
Vessels stained in brown for (a) CD31 (endothelial cells) and (b) α smooth muscle actin (αSMA, 
smooth muscle) on the infarct border. c) Double immunolabelling of CD31 (open arrow, brown) 




Figure 5-4 Neovascularisation after MI surgery 
Vessel density was assessed by counting small (<200µm diameter) vessels in the left ventricle. 
11HSD1
-/- 
mice have increased CD31 (a) and αSMA (b) positive vessel density 28 days post-MI 
relative to C57Bl6 mice. n= 10 C57BL6 MI, n=9 11HSD1
-/-
 MI. Data are expressed as mean ± 




Fibrosis and scar dimensions during infarct healing 
Fibrosis evaluated by Picrosirius Red staining as a percent of the left ventricle staining 
for collagen (Figure 5.5) was comparable between control and 11HSD1
-/- 
mice (Figure 
5.6). Collagen was seen primarily in the scar tissue and in the infarct border entwined 
between cells (Figure 5.5). Scar size, assessed by Masson‟s Trichrome staining was also 
comparable between the groups (Figure 5.5 and Figure 5.6). 11HSD1
-/- 
mice had 
significantly reduced infarct thinning than C57Bl6 mice (P<0.001) and the scars had a 

















Figure 5-5 Histological analysis of fibrosis and scar formation 28 days post-MI surgery 
Tiled images of sections stained with Picrosirius Red (a) to detect collagen deposition in pink 
and Masson’s Trichrome (b) to identify the infarct scar in blue. Dense collagen is found in the 
infarct scar (c) and border zone (d). Typical examples of Masson’s Trichrome stained scars from 
C57Bl6 (e) and 11HSD1
-/-




Figure 5-6 Fibrosis and scar formation 28 days after MI surgery 
Collagen deposition (a) and scar size (b) as a percent of the left ventricle (%) were assessed 
from Picrosirius Red and Masson’s Trichrome-stained sections respectively and were similar in 
C57Bl6 and 11HSD1
-/- 
mice. n= 10 C57BL6 MI, n=9 11HSD1
-/-
 MI.  Data are expressed as mean 






Figure 5-7 Assessment of scar characteristics 28 days after MI surgery 
Analysis of scar dimensions was from Masson’s Trichrome stained sections. Scar thickness was 
averaged from 3 points taken across the scar and was significantly greater in 11HSD1
-/- 
mice 
compared with C57Bl6 controls (a). Epicardial (b) and endocardial (c) infarct lengths were 
expressed as a percentage of the epicardial and endocardial left ventricle length. There was a 
tendency for 11HSD1
-/- 
mice to have shorter scars than C57Bl6 mice. n= 10 C57BL6 MI, n=9 
11HSD1
-/-





Post infarct cardiac function 
Left ventricle dimensions, evaluated by echocardiography, were comparable in C57Bl6 
and 11HSD1
-/- 
mice at all time points (Table 5.3). There was no progressive increase in 
LVEDA demonstrating that there was no progressive left ventricle dilation in the 
C57Bl6 mice and this was comparable to 11HSD1
-/- 
mice (Table 5.3). This suggests that 
dysfunction was not associated with left ventricular dilation. In both groups of animals 
ejection fraction was depressed after induction of MI when compared to baseline 
(Chapter 3) and sham operated animals (Chapter 4). At day 7 after MI ejection fraction 
was significantly higher in 11HSD1
-/- 
mice relative to C57Bl6 mice as reported in 
Chapter 4. The improvement in ejection fraction was maintained at 14 and 28 days post-















Figure 5-8 Quantified data from echocardiography up to 28 days post-MI 
Left ventricle function was expressed as ejection fraction using the equation: (left ventricle end 
diastolic area- left ventricle end systolic area)/ left ventricle end diastolic area x 100. Ejection 
fraction was significantly augmented in 11HSD1
-/- 
mice 7, 14 and 28 days post-MI relative to 
C57Bl6 controls. n= 10 C57BL6 MI, n=9 11HSD1
-/-
 MI. Data are expressed as mean ± SEM. 
*P<0.05, **P<0.01.  C57Bl6 vs. 11HSD1
-/- 














LVEDA 15.70 ±0.70 16.17 ±1.34 12.17 ±1.09 15.36 ±1.23 15.87 ±1.60 17.23 ±1.16 15.03 ±1.20 16.9 ±1.56 
LVESA 11.31 ±0.52 9.88 ±1.08 8.40 ±0.86 8.89 ±0.70 10.05 ±0.88 10.02 ±1.07 11.16 ±1.28 9.69 ±0.87 
LVEDD 3.95 ±0.33 3.66 ±0.19 3.42 ±0.12 3.60 ±0.17 3.63 ±0.18 3.69 ±0.12 3.71 ±0.12 3.58 ±0.24 
LVESD 3.86 ±0.16 2.65 ±0.16 2.61 ±0.13 2.78 ±0.20 2.88 ±0.16 2.77 ±0.18 2.86 ±0.11 2.46 ±0.23 
PWD 0.94 ±0.06 0.97 ±0.06 0.84 ±0.06 1.03 ±0.07 0.95 ±0.07 1.04 ±0.09 0.99 ±0.06 1.03 ±0.07 
PWS 1.02 ±0.04 1.08 ±0.05 0.99 ±0.05 1.05 ±0.08 1.07±0.07 0.97 ±0.10 1.08 ±0.04 1.13 ±0.06 
EF (%) 28.58 ±1.51 39.03±2.21
*
 31.48 ±1.98 41.46±2.68
*
 35.22 ±3.32 42.54 ±4.01 26.65 ±3.75 41.60±3.83
**
 
FS (%) 25.15 ±3.07 27.66 ±1.54 23.74 ±3.10 23.03 ±4.03 20.49 ±2.93 25.95 ±3.37 22.38 ±3.59 32.05 ±3.41 
Table 5-3 Left ventricle dimensions after MI surgery 
There were no differences in LVEDA (left ventricle end diastolic area), LVESA (left ventricle end systolic area), LVEDD (left ventricle end 
diastolic diameter), LVESD (left ventricle end systolic diameter), PWD (posterior wall thickness at diastole) or PWS (posterior wall thickness 
at systole). Whilst fractional shortening was not significantly different at any time point ejection fraction was significantly enhanced in the 
11HSD1
-/- 
mice compared with C57Bl6 mice at days 7, 14 and 28 post-MI. n= 10 C57BL6 MI, n=9 11HSD1
-/-
 MI. Data are expressed as 
mean ± SEM. *P<0.05, **P<0.01 C57Bl6 vs. 11HSD1
-/- 










The aim of the present study was to investigate whether the enhancement in vessel 
density and the improvement in cardiac function in 11HSD1
-/-
 mice during early infarct 
healing were retained after infarct healing was complete. Furthermore, the effect of 
11HSD1 deficiency on scar formation was assessed.  This study showed that the 
increase in vessel density was maintained in 11HSD1
-/- 
mice 28 days after MI, relative to 
C57Bl6 mice, and that these vessels matured becoming pericyte coated. These 
differences were associated with a sustained increase in cardiac contractility. Collagen 
content and scar size were comparable between the groups but, 11HSD1
-/-
 mice had 
reduced infarct thinning and infarcts had a tendency to be shorter. 
 
Recovery from surgery and organ weights 
Mortality rates and cause were similar between the strains of mice demonstrating that as 
infarct healing progresses to completion, 11HSD1
-/-
 mice did not develop a grossly 
abnormal phenotype. While C57Bl6 mice started to gain weight 14 days after surgery 
11HSD1
-/-
 mice did not even regain the preoperative weight that was lost and this was 
not associated with altered food intake. However, at baseline 11HSD1
-/-
 mice were 
heavier than C57Bl6 mice of the same age and while weight was not regained in these 
mice there was no significant difference in actual body weights between the strains of 
mice at day 14 onwards. This is not likely to be due to an altered stress response as 
circulating corticosterone levels were the same in both groups of mice at all time points. 
Heart weights 28 days after MI were similar in C57Bl6 and 11HSD1
-/-
 mice and, 
likewise, were comparable to heart weights in sham and MI animals when assessed at 
day 7 (please see Chapter 4). Any loss of heart weight due to infarct thinning seems to 
have been compensated to a similar degree in both strains. Some groups have reported 
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an increase in heart weight from 28 days post-MI relative to sham due to progressive 
cardiomyocyte hypertrophy (Fazel et al., 2006, Tirziu et al., 2007). Although there were 
no parallel sham-operated mice in the present long term study the data provides no 
evidence for additional compensatory hypertrophy. It would be interesting to re-examine 
this at a later time point when the mice develop heart failure and generally changes in 
hypertrophy are more evident (Shioura et al., 2007, Pfeffer and Braunwald, 1990).  
Other organ weights, with the exception of the spleen, did not differ between C57Bl6 
and 11HSD1
-/-
 mice. Surprisingly, 11HSD1
-/-
 mice had significantly lighter spleens than 
those of C57Bl6 controls.  There is little in the literature regarding the effect of MI on 
spleen weight; however, in a mouse model of viral myocarditis increased inflammation 
was associated with reduced spleen size (Kanda et al., 2004). This would be consistent 
with the data presented here showing that 11HSD1
-/-
 mice have enhanced inflammation 
during infarct healing. Furthermore non-selective inhibition of the 11HSD enzymes by 
glycyrrhetinic acid reduced spleen weight by encouraging splenocyte apoptosis 
(Horigome et al., 2001). This group hypothesised that increased cell death was a result 
of elevated circulating corticosterone (Horigome et al., 2001). However no difference in 
plasma corticosterone was observed in the current study suggesting that the effect of loss 
of 11HSD1
 
on spleen weight might be mediated by a different mechanism in our model. 
A recent publication provides evidence for the spleen being a reservoir for the 
monocytes that are liberated after MI (Swirski et al., 2009).  It is possible that increased 
monocyte liberation from the spleen may be the source of increased monocyte 
infiltration into the heart. 
Basal corticosterone at the diurnal nadir is about 40nmol/L in C57Bl6 mice (Paterson et 
al., 2006). There was over an 8 fold increase in plasma corticosterone concentration 1 
day after MI, consistent with HPA axis activation after MI. Activation was similar in 
both strains of mice and in both plasma concentrations declined towards baseline by 7 
days and were maintained at this low level over the 28 day period. Plasma levels did not 
decline to the expected basal concentrations which may reflect that the animals have not 
returned to full health. Previous work has suggested that 11HSD1
-/-
 mice have a 
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prolonged stress response to restraint (Harris et al., 2001). However the data presented 
here shows that the post-infarct stress response is transient and is similar to that in 
C57Bl6 mice.  
 
Maintenance of neovascularisation 
Assembly of a highly organised vasculature requires the interaction of growth factors 
involved in cell proliferation and migration (VEGF, IL-8) (Kido et al., 2005, Kocher et 
al., 2006, Li et al., 2003), vessel pruning (Ang-2) (Maisonpierre et al., 1997), pericyte 
recruitment (PDGF) and vessel stabilisation (PDGF, Ang-1, the Tie-2 receptor and TGF-
β1) (Ramsauer et al., 2002, Korpisalo et al., 2008, Greenberg et al., 2008, Thurston et 
al., 1999, Patan, 2000, Conway et al., 2001). Data presented previously ((Small et al., 
2005) and Chapter 4) showed that 11HSD1
-/-
 mice have increased vessel density that is 
associated with increased cell proliferation and cardiac IL-8 mRNA expression 7 days 
post-MI. However, for this increase in vessel density to be influential in later left 
ventricle remodelling it must be retained. Apoptosis of endothelial cells precipitates 
angiogenic vessel regression occurring 7-21 days post-MI; disposing of excess 
vasculature (Conway et al., 2001, Grass et al., 2006, Patan, 2000). Over this time vessels 
are also stabilised by addition of smooth muscle positive pericytes and cell-to-cell 
junctions are tightened to prevent leakage (Conway et al., 2001). Vessels lose their 
plasticity and are mature by 28 days post-MI (Ren et al., 2002, Grass et al., 2006, 
Dewald et al., 2004). Immunohistochemistry data show that 11HSD1
-/-
 mice maintained 
the enhanced vessel density 28 days post-MI, relative to C57Bl6 controls. There was 
also evidence that these vessels had become coated with smooth muscle cells, likely to 
be pericytes and suggesting longevity.  
There has been some debate regarding the origin of pericytes. It has been suggested that 
they may differentiate from mesenchymal stem cells (Bexell et al., 2009), mononuclear 
cells (Conway et al., 2001), epicardial cells (Dettman et al., 1998) and fibroblasts 





enhanced cellular proliferation in the heart 7 days after MI, which may promote 
formation of both the endothelial cell and the pericyte layer in neovessels. TGF-β 
initiates differentiation of cells to pericytes (Bergers and Song, 2005) that are 
subsequently attracted to the vascular endothelial cells by PDGF, which is produced by 
the endothelial cells themselves (Greenberg et al., 2008). Increased differentiation of 
cells to pericytes may be the cause of increased pericyte-coated vessel density in 
11HSD1
-/- 
mice.  The enhanced infiltration of macrophages in 11HSD1
-/- 
mice (Chapter 
4) may increase TGF-β, levels thus encouraging pericyte development. Assessment of 
cardiac TGF-β in these mice warrants investigation. 
VEGF has been shown to be a negative regulator of PDGF, preventing pericyte 
recruitment (Greenberg et al., 2008). The delay in this process prolongs the plasticity 
window, enabling endothelial cell proliferation and vessel remodelling (Ren et al., 2002, 
Grass et al., 2006). mRNA expression of VEGF was similar in C57Bl6 and 11HSD1
-/- 
mice  up to 7 days after MI (Chapter 4). However, perhaps assessing expression of this 
growth factor at 2 weeks, when pericytes are being recruited, would demonstrate 
whether there is altered regulation of pericyte recruitment in the 11HSD1
-/- 
mice. Double 
labelling has shown co-expression of α SMA and β-catenin, an adhesion molecule 
present at adheren junctions, suggesting communication occurs between pericyte cells 
and may aid in vessel maturation (Njauw et al., 2008).  
Commonly, pericytes are associated with vessel stability but they have much more 
diverse functions. Pericytes, like smooth muscle cells, can alter vessel tone in response 
to vasoactive substances (Kawamura et al., 2004, Kutcher and Herman, 2009). They are 
found in high density at the blood brain barrier where they form a tight boundary 
(Ramsauer et al., 2002, Thomas, 1999). Interestingly in this location pericytes can 
exhibit macrophage like phagocytic behaviour (Thomas, 1999). Some have hypothesised 
that they could indeed be brain macrophage precursors (Bergers and Song, 2005, 





Post infarct resolution of inflammation 
It was demonstrated in Chapter 4 that 11HSD1
-/-
 mice have an enhanced inflammatory 
response in parallel with augmented angiogenesis in the healing phase post-MI. The 
processes governing the resolution of inflammation are unclear. There is conflicting 
evidence regarding the effect of deficiency of IL-10, a cytokine reported to inhibit 
production of inflammatory cytokines (Yang et al., 2000, Zymek et al., 2007). The 
importance of resolution of inflammation has been shown in studies in which the anti-
inflammatory and anti-angiogenic thrombospondin-1 (TSP-1) has been knocked out. 
Deficiency of TSP-1 elevates and extends inflammation and is associated with scar 
expansion and adverse remodelling (Frangogiannis et al., 2005). While anti-
inflammatory cytokines were not examined in the current study evidence presented here 
indicates that defective resolution of inflammation was not an issue in the 11HSD1
-/-
 
model. The inflammatory cells seen in the infarct area and infarct border up to 7 days 
post-MI were replaced with a collagenous scar at day 28.   
 
Fibrosis and scar formation 
The post-infarct inflammatory response is vital in stimulating the fibrotic process (van 
Amerongen et al., 2007). Despite an increase in inflammation within 7 days of MI in the 
11HSD1
-/-
 mice there was no subsequent increase in collagen deposition. Scar formation 
and fibrosis are processes that occur over time and are initiated soon after the initial 
ischaemic event. Increased vascular permeability as a result of MI and disruption of the 
extracellular matrix by collagenase, matrix metalloprotease and serine protease enzymes 
enables extravasation of plasma proteins into the infarct during the inflammatory phase 
of MI healing producing a temporary fibrin-based matrix (Dobaczewski et al., 2006, 
Dobaczewski et al., 2009). This creates a temporary scaffold for migrating cells. This 
matrix is gradually lysed and replaced by a more organised matrix of fibronectin and 
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hyaluronan as the healing response progresses (Dobaczewski et al., 2006). Quiescent 
fibroblasts undergo a phenotypic change to myofibroblasts, stimulated by TGF-β 
secreted by macrophages (Cleutjens et al., 1995, Desmouliere et al., 1993, Fadok et al., 
1998). Depletion of macrophages reduces collagen deposition demonstrating their 
importance in the fibrotic response (van Amerongen et al., 2007).  Myofibroblasts are 
characterised by their high capacity for proliferation, secretion of αSMA and collagen 
(Virag and Murry, 2003, Lutgens et al., 1999, Porter and Turner, 2009, van Amerongen 
et al., 2008). The transient nature of this activation has been demonstrated by 
immunohistochemistry for αSMA. In the present study myofibroblast activation 
increased up to 7 days post-MI (Chapter 4) but by 28 days post-MI all staining was 
associated with vessel smooth muscle. Deposition of collagen starts from 3 days post MI 
and increases progressively up to 180 days after infarction (Yang et al., 2002) (Virag 
and Murry, 2003, Dean et al., 2005) and its cross-linking is vital in providing tensile 
strength and structural integrity to the weakened myocardium (Dean et al., 2005, Virag 
and Murry, 2003). The production of collagen may also serve to promote the quiescent 
phenotype of fibroblasts thus providing a negative feedback mechanism. Dermal 
fibroblasts stimulated with TGF-β show decreased collagen production in response to a 
collagen rich environment (Clark et al., 1995). This may prevent excessive fibrosis 
which may facilitate cardiac arrhythmias (Zannad and Radauceanu, 2005, Li et al., 1999, 
Kostin et al., 2002). 
In the current study collagen deposition and scar area, found in the apical region, were 
comparable in C57Bl6 and 11HSD1
-/- 
mice. This area is particularly vulnerable as it is a 
thin part of the heart with the greatest curvature. Damage here leads to a more 
pronounced decline in heart function (Pfeffer and Braunwald, 1990). Histology showed 
that 11HSD1
-/- 
mice had reduced infarct thinning and the infarct length had a tendency to 
be shorter. Improving blood supply may prevent infarct expansion by cardiomyocyte 
salvage as suggested by the changes in the scar characteristics. Furthermore a thicker 
scar may be protective against cardiac rupture (Nahrendorf et al., 2006). The 
modification of the scar characteristics independent of actual scar area is well reported in 
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the literature (Nahrendorf et al., 2006, Garcia et al., 2007, Hammerman et al., 1983a, 
Hammerman et al., 1983b, Brown et al., 1983). In humans infarct expansion is greatest 
in patients with higher blood pressure and greater vascular resistance and these patients 
are more likely to develop complications (Pfeffer and Braunwald, 1990, Pierard et al., 
1987). Unfortunately blood pressure was not measured in the current study. This should 
be considered in future work. Fibrillar and non-fibrillar collagen is found in the 
myocardium with fibrillar collagen type I being the most abundant (Shamhart and 
Meszaros, 2009). In cardiac pathology  the abundance of strong, stiff collagen I and 
elastic collagen III increases (Pauschinger et al., 1999). Furthermore, the proportion of 
collagen I relative to III increases favouring production of a stiffer scar (Pauschinger et 
al., 1999). It is possible that the relative abundance of these different types of collagen in 
the scar may vary between the 11HSD1
-/-
 and C57Bl6 mice having an effect on the 
contractility of the heart. While it was not possible to differentiate between collagen 
types from the Picrosirius Red stained sections they can be identified using 
immunohistochemistry or quantitative RT-PCR and as such this should be considered in 
future studies.  
 
Cardiac function post-MI 
Data presented in Chapter 4 showed that 11HSD1
-/- 
mice have improved ejection 
fraction 7 days post-MI. It is hypothesised that this was due to the parallel increase in 
vessel density in the left ventricle. Importantly this improvement in heart function was 
maintained up to 28 days post-MI in the 11HSD1
-/- 
mice compared to C57Bl6 controls 
and was associated with increased density of mature blood vessels. The source of the 
increased post-infarct ejection fraction in 11HSD1
-/- 
mice may be improved perfusion to 
the infarct border enhancing cardiomyocyte contractility and/or prevention of infarct 
expansion by salvage of cardiomyocytes, as suggested by reduced infarct thinning and 





The left ventricle undergoes remodelling to maintain cardiac output and is associated 
with alterations in cardiac architecture (Pfeffer and Braunwald, 1990). After MI 
myocytes, particularly those at the infarct border, change to a distorted, irregular shape 
(Kocher et al., 2001) and become hypertrophic to compensate for the myocytes lost after 
infarction. This is often inadequate for maintenance of cardiac function. Subsequent left 
ventricle dilation due to slippage of cardiomyocytes can lead to the development of heart 
failure (Pfeffer and Braunwald, 1990, Shioura et al., 2007). In Chapter 4 the data 
demonstrated that the decline in heart function was due to systolic dysfunction; the end 
systolic volumes assessed in the current study demonstrate that there was no further 
decline in systolic function. In humans increased end systolic volume is a powerful 
predictor of death (Pfeffer and Braunwald, 1990, White et al., 1987). The 28 day data 
are consistent with Shioura et al who found systolic dysfunction up to 28 days post-MI 
that worsened at 10 weeks as determined by the Millar pressure volume loop (Shioura et 
al., 2007). In their study the decline in diastolic function was more gradual and showed 
significance at 10 weeks only (Shioura et al., 2007) fitting with the lack of diastolic 
dysfunction in this model. LVEDA did not progressively increase over time in either 
strain suggesting that the improvement in cardiac function in 11HSD1
-/- 
mice was not 
due to prevention of ventricular dilation. Several other studies have shown that dilation 
is associated with worsened heart function by this time after MI (Pfeffer and Braunwald, 
1990, Yang et al., 2000). It may be that the echocardiography used here was not 
sufficiently sensitive to detect such changes. MRI could determine whether this is a real 
issue. Alternatively the results might suggest that the improvement in heart function in 
11HSD1
-/- 
compared with C57Bl6 mice may be by a mechanism independent of left 
ventricle dilation, such as those suggested above; improved infarct border 
cardiomyocyte contractility due to enhanced perfusion, thicker, shorter scars or altered 
collagen composition. 
Experimental studies that aim to enhance post-infarct angiogenesis often concentrate on 
the initial angiogenic response and many fail to investigate vessel remodelling and 
maturation, processes that have a strong influence on vessel longevity. Here we have 
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shown that the acute enhancement in vessel density in 11HSD1
-/-
 mice during the 
healing phase post-MI is maintained after healing is complete. Moreover, these vessels 
have resisted pruning, are mature, are pericyte-coated and are likely to be capable of 
carrying a blood supply. While actual scar size was not changed it is possible that the 
alterations in scar dimensions may have greater importance. Certainly, a shorter thicker 
scar may confer protection from cardiac rupture and may improve heart function. 
Importantly the acute improvement in heart function at 7 days after MI was maintained 
at 28 days. It seems logical that this would extend into the longer term as the mice 
develop heart failure. For such findings to have clinical relevance the effect of 
pharmacological inhibition of 11HSD1 must be investigated. Pharmacological inhibition 
of 11HSD1 has proved beneficial in murine models of obesity, diabetes and 
atherosclerosis (Hermanowski-Vosatka et al., 2005). Whether inhibition of 11HSD1 
immediately after MI is sufficient to confer protection is uncertain. It may be possible 
that there are predetermined effects of the genetic deletion that aids in post-infarct 
healing. In the next Chapter I investigate whether pharmacological inhibition of 





The effect of pharmacological inhibition of 11HSD1 on recovery after myocardial 
infarction 
6.1 Introduction 
It has previously been demonstrated that mice deficient for the glucocorticoid 
regenerating enzyme, 11HSD1, have enhanced angiogenesis and cardiac function 7 days 
after MI that persists for at least 28 days (Chapter 4 and Chapter 5  and (Small et al., 
2005)).  This is preceded by enhanced infiltration of neutrophils and macrophages 
(Chapter 4). While this is itself, an interesting observation, its impact would be 
considerably increased if inhibition of 11HSD1 could be exploited clinically. 
Manipulation of tissue levels of glucocorticoids using pharmacological inhibitors of 
11HSD1 is attractive. Early 11HSD1 inhibitors, including carbenoxolone and 
glycyrrhetinic acid also had effects that were consistent with 11HSD2 inhibition, such as 
increasing blood pressure and lowering plasma potassium in humans (Andrews et al., 
2003). Selective small molecule inhibitors of 11HSD1 are currently under development 
and have been successful in rodent models of disease. Inhibition of 11HSD1 has proved 
beneficial in mouse models of obesity, diabetes and atherosclerosis (Hermanowski-
Vosatka et al., 2005, Veniant et al., 2009, Lloyd et al., 2009). There have been very few 
drugs tested clinically to date however there are 11HSD1 inhibitors that are in clinical 
trials for the treatment of diabetes (Hawkins, 2008).  
The aim of the present study was to investigate the influence of 11HSD1 inhibition 
using a commercially available 11HSD1 inhibitor known as compound 544 (3-(1-
adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4] triazolo [4,3-α] azepine). This inhibitor was 
developed by Merck, has previously been used successfully in mice and has oral 
bioavailability (Hermanowski-Vosatka et al., 2005). We hypothesize that administration 
of compound 544 in the diet would recapitulate the effect of genetic deletion of 
11HSD1. Drug treated mice were predicted to show enhanced inflammation, 




6.2.1 Study design 
Male C57Bl6 mice (Harlan, UK) were allowed 1 week to acclimatise after their arrival.  
After this period they were split into pairs and their body weight and food intake were 
monitored daily for a further week. Subsequently mice were randomised to receive sham 
or MI operation and vehicle or inhibitor diet. Previous work has shown that 
administering the 11HSD1 inhibitor, compound 544 (Enamine, Ukraine), in food is an 
effective method of dosing (Hermanowski-Vosatka et al., 2005). Mice were fed vehicle 
(0.5% methylcellulose, 5% Tween 80) or compound 544 (30mg/kg/day in the vehicle 
solution). For details of the diet recipe please refer to Section 2.3.4. After monitoring 
consumption of vehicle containing diet for one week, and considering previous in-house 
studies where food intake has been monitored, it was decided that the mice would eat on 
average 10g food per day. An intraperitoneal injection of vehicle or 10mg/kg inhibitor 
was given immediately after surgery followed by vehicle or inhibitor diet. Food tubes 
and body weight were monitored daily to check drug intake.  
 
6.2.2 Coronary artery ligation 
Male C57Bl6 mice (Harlan, UK) aged 10-12 weeks were used for all experiments. Mice 
underwent coronary artery ligation for induction of MI or sham-operation, as described 
in Section 2.3.1. 
 
6.2.3 Echocardiography 
Cardiac function was assessed by echocardiography as described in Section 2.3.2. Mice 
underwent echocardiography 7 days after surgery in order to obtain measurements of 
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ventricular dimensions. The observer was blinded to treatment for the purpose of 
echocardiography measurements and all other subsequent analysis of tissues.  
 
6.2.4 Tissue collection 
For analysis of circulating corticosterone levels blood was taken 7 days after surgery, 
prior to echocardiography, by tail tip at 7:30am (the diurnal nadir), as described in 
Section 2.3.3. One hour prior to sacrifice mice were injected intra-peritoneally with 
2.5mg BrdU dissolved in saline. Mice were killed by cervical dislocation after 
echocardiography. The hearts were excised, washed in ice cold PBS, weighed and then 
bisected down the longitudinal axis. They were fixed in 10% neutral buffered formalin 
for 24 hours for use in immunohistochemistry.  
 
6.2.5 Corticosterone radioimmunoassay 
A radioimmunoassay was conducted to determine circulating levels of corticosterone 
after myocardial infarction, as described in Section 2.5.1.  
 
6.2.6 Immunohistochemistry 
Identification of macrophages, vascular endothelial cells and proliferating cells was 
conducted using: a monoclonal rat anti-mouse mac 2 primary antibody (Cedarlane) 
diluted 1/6000 in PBS/1%BSA; a monoclonal rat anti-mouse CD31 primary antibody 
(BD Bioscience) diluted 1/50 in PBS/1% BSA; and a monoclonal mouse anti-mouse 
BrdU primary antibody (Sigma) diluted 1/1000 in TBS/10% normal goat 
serum/5%BSA, respectively.  For details of the procedure please refer to Section 2.5.1. 
Quantification of immunohistochemistry was conducted using Image Pro 6.2, 
Stereologer Anaylser 6 MediaCybernetics. Macrophage infiltration was quantified as the 
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percent of infarct border stained. Small CD31 positive vessels (<200µm diameter) and 
BrdU positive nuclei were counted in the left ventricle as described in Section 2.5.2. 
 
6.2.7 Statistics 
All values are expressed as mean ±SEM. All comparisons were made using 2-way 




The impact of surgery on food intake, body and organ weight 
Mouse food intake varied greatly from day to day but there was no difference between 
the groups on any day (Figure 6.1). There was difficulty in monitoring food intake 
accurately as mice developed a habit of removing food from the tubes and spreading it 
around the cage. Ingestion of the diet declined immediately after surgery (at day 7) and 
remained low for the first 2 days in all groups (P<0.05 between day 7 and 8). Body 
weight was stable prior to sham or MI operations but tended to decline after surgery on 
day 7, in line with the decrease in food intake, although this failed to reach statistical 
significance. Mice in all groups returned to pre-operative weight by 7 days post-surgery 
(Figure 6.1). At the end of the study, 7 days after surgery, heart weights were similar in 
sham-operated and MI animals regardless of the drug treatment (Table 6.1). Furthermore 
other organ weights (liver, kidney, spleen, thymus, adrenal gland) did not vary either 
(Table 6.1).  
 
Circulating corticosterone 
Plasma corticosterone levels were comparable 7 days after MI or sham-operations 









Figure 6-1 Body weight and food intake after myocardial infarction (MI) or sham surgery 
a) Food intake and body weight were stable before surgery, after which they declined. Food 
intake and body weight increased from 2 days after surgery. Arrows denote day of surgery. n=4 
vehicle sham, n=4 vehicle MI, n=5 inhibitor sham, n=7 inhibitor MI. Data are expressed as mean 




Organ weights VEHICLE INHIBITOR 
Sham MI Sham MI 
Heart (mg) 0.16±0.01 0.18±0.02 0.15±0.01 0.16±0.01 
Heart (rel. to body weight) 7.22±0.67 6.07±1.17 6.62±0.15 7.24±0.43 
Liver (mg) 1.31±0.05 1.29±0.04 1.35±0.06 1.20±0.02 
Liver (rel. to body weight) 57.54±1.61 57.12±1.46 58.41±1.43 54.61±2.31 
Kidney (mg) 0.38±0.02 0.38±0.02 0.38±0.01 0.38±0.04 
Kidney (rel. to body weight) 16.71±1.11 16.95±1.85 16.46±0.28 16.63±1.68 
Spleen (mg) 0.10±0.01 0.13±0.01 0.12±0.02 0.10±0.01 
Spleen (rel. to body weight) 4.32±0.41 5.81±0.88 5.28±0.73 4.33±0.59 
Thymus (mg) 0.06±0.01 0.05±0.01 0.06±0.01 0.06±0.01 
Thymus (rel. to body 
weight) 
2.76±0.34 1.96±0.48 2.44±0.41 2.60±0.23 
Adrenal gland (mg) 0.01±0.01 0.01±0.01 0.01±0.01 0.01±0.01 
Adrenal gland (rel. to body 
weight) 
0.55±0.11 0.31±0.03 0.63±0.24 0.51±0.11 
Table 6-1 Organ weights after MI or sham surgery 
Weights of heart, liver, kidney, spleen and adrenal glands and expressed relative to body weight. 
There were no differences between any of the groups. n=4 vehicle sham, n=4 vehicle MI, n=5 







Figure 6-2 Circulating corticosterone after MI or sham surgery 
There were no differences in circulating corticosterone levels between the groups 7 days after 
MI or sham surgery, as assessed by radioimmunoassay. n=4 vehicle sham, n=4 vehicle MI, n=5 













Macrophage infiltration, shown by mac 2 immuno-reactivity, was seen predominantly in 
the infarct and border zone. Macrophage staining was significantly greater 7 days after 
MI compared with sham-operated mice (in which staining was negligible; Figure 6.3). 
Administration of the 11HSD1 inhibitor had no effect on the extent of macrophage 
infiltration into the infarcted myocardium.  
 
Post infarct neovascularisation  
The density of small CD31 positive vessels was increased 7 days post-MI relative to 
sham-operated controls both in vehicle and in inhibitor treated groups (Figure 6.4). 
Administration of compound 544 had no effect on the vascularity of the left ventricle. 
The number of cells proliferating was significantly enhanced after MI, relative to sham-
operated mice (Figure 6.4). There was a trend for this to be further enhanced in mice 
treated with compound 544, but this failed to reach significance (P=0.11).  
 
Left ventricle dimensions and cardiac function 
There were no differences in left ventricle end diastolic area (LVEDA) between the 
groups (Table 6.2). However, left ventricle end systolic area (LVESA) was significantly 
greater after MI relative to sham-operated mice, suggesting systolic dysfunction. 
LVESA was similar in vehicle and inhibitor treated mice. Other left ventricle 
dimensions measured did not vary between the groups. Ejection fraction and fractional 
shortening were both significantly reduced post-MI relative to sham-operated controls 
(Figure 6.5 and Table 6.2). Treatment with the 11HSD1 inhibitor had no effect on 





Figure 6-3 Macrophage infiltration after MI or sham surgery 
Macrophages identified by mac-2 immuno-reactivity and quantified as a percentage of the infarct 
border (IB) stained. Mac 2 staining was increased after MI relative to sham-operated mice. 
Treatment with Compound 544 had no effect. n=4 vehicle sham, n=4 vehicle MI, n=5 inhibitor 
sham, n=7 inhibitor MI. Data are expressed as mean ±SEM. ## P<0.01, ### P<0.001 Sham vs. 











Figure 6-4 Neovascularisation after MI or sham surgery 
a) Vessel density was assessed by counting small (<200µm diameter) vessels in the left 
ventricle.  b) Cell proliferation assessed by BrdU incorporation into replicating nuclei, was 
quantified as number of positive cells per mm
2
. Vessel density and cell proliferation were 
increased after MI compared with sham-operated groups but drug treatment had no effect. n=4 
vehicle sham, n=4 vehicle MI, n=5 inhibitor sham, n=7 inhibitor MI. Data are expressed as mean 






Figure 6-5 Quantified data from echocardiography up to 7 days post-MI or sham-
operation. 
Left ventricle function was expressed as ejection fraction and fractional shortening using the 
following equations: Ejection fraction = (left ventricle end diastolic area- left ventricle end systolic 
area)/ left ventricle end diastolic area x 100. Fractional shortening = (left ventricle end diastolic 
diameter- left ventricle end systolic diameter)/ left ventricle end diastolic diameter x 100. Ejection 
fraction and fractional shortening were decreased after MI but drug treatment had no effect. n=4 
vehicle sham, n=4 vehicle MI, n=5 inhibitor sham, n=7 inhibitor MI. Data are expressed as mean 




 VEHICLE INHIBITOR 
Sham MI Sham MI 
LVEDA 16.43±2.04 12.31±0.73 14.74±1.22 13.93±1.26 
LVESA 4.55±0.54 8.75±1.20# 5.13±0.67 9.50±1.09# 
LVEDD 3.97±0.34 3.59±0.11 3.86±0.15 3.49±0.25 
LVESD 1.94±0.14 2.68±0.24  2.05±0.11 2.60±0.25  
PWD 0.81±0.11 0.92±0.08 0.77±0.04 1.03±0.12 
PWS 1.19±0.11 1.17±0.04 1.38±0.08 1.25±0.10 
EF% 71.6±3.32 29.74±6.55 ### 65.72±2.23 32.41±2.89 ### 
FS% 50.82±1.42 25.58±5.69 ## 46.60±.4.07 26.00±3.31 ## 
Table 6-2 Left ventricle dimensions after MI or sham surgery 
LVEDA (left ventricle end diastolic area), LVEDD (left ventricle end diastolic diameter), LVESD 
(left ventricle end systolic diameter), PWD (posterior wall thickness at diastole) and PWS 
(posterior wall thickness at systole) did not vary between the groups. LVESA (left ventricle end 
systolic area) was increased after MI but did not vary between vehicle and inhibitor treated mice. 
Ejection fraction (EF%) and fractional shortening (FS%) were decreased after MI with drug 
treatment having no effect. n=4 vehicle sham, n=4 vehicle MI, n=5 inhibitor sham, n=7 inhibitor 







The aim of the present study was to investigate whether pharmacological inhibition of 
11HSD1 after MI would reproduce the beneficial effects of genetically induced 11HSD1 
deficiency on murine myocardial infarct healing. It was found, however, that compound 
544 treated mice had similar macrophage infiltration, angiogenesis and cardiac function 
to vehicle treated mice 7 days after MI.  
The therapeutic benefit of 11HSD1 inhibition was initially shown with non-selective 
liquorice derivatives (Monder et al., 1989). Carbenoxolone reduced plasma cholesterol, 
glucose production and improved insulin sensitivity in humans but also had detrimental 
effects consistent with inhibition of 11HSD2 (Andrews et al., 2003, Walker et al., 1995). 
More recently, selective inhibitors of 11HSD1 have been developed including, 
BVT.14225 (Biovitrum), PF-00915275 (Pfizer) and compound 544 with IC50s of 52, 15 
and 97nM respectively, indicating high potency (Barf et al., 2002, Courtney et al., 2008, 
Hermanowski-Vosatka et al., 2005). Oral administration of compound 544 was shown to 
produce 60 and 70% inhibition of serum 11HSD1 activity after 1 hour at 10mg/kg and 
30mg/kg doses, respectively. This declined rapidly with inhibition being 10 and 30% by 
4 hours (Hermanowski-Vosatka et al., 2005). In the same study it was show that 
administration of the inhibitor in the chow of apoE deficient mice at a dose of 
approximately 10/mg/kg/day for 8 weeks reduced atherosclerotic plaque progression and 
improved the lipid profile. Based on these data, a dose of 30mg/kg/day in chow was 
chosen to achieve effective enzyme inhibition after MI in the current study. Food intake 
was monitored daily prior to surgery to determine the quantity of drug to be added to the 
food to attain the required dose of compound 544. Two mice were placed in each cage 
(my own observations were that mice regain the weight lost after surgery quicker when 
allowed to recover in groups rather than on their own) thus making it hard to precisely 
measure the food intake of each mouse. However, data collected in this investigation and 
in previous studies indicate food intake at approximately 10g per day. Alternatively, 
other studies have shown that 12 week old male C57Bl6 mice eat on average 4.1g of 
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standard chow per day (Lewis et al., 2005). In the present study intake varied from 0 to 
30g per day. Accurate assessment of food intake proved difficult as food was taken from 
the tubes by mice and spread across the cage in the bedding. If the estimate intake (4.1g) 
from Lewis et al is correct it is likely that the dose of 11HSD1 inhibitor received would 
be closer to 10mg/kg/day rather than 30mg/kg/day (Lewis et al., 2005). Hermanowski-
Vosatka et al found that the lower dose of 10mg/kg/day was sufficient to produce 
physiological effects in a model of atherosclerosis suggesting that this may be enough in 
post-infarct healing too (Hermanowski-Vosatka et al., 2005). Other work in our 
laboratory has demonstrated that an oral dose of 30mg/kg compound 544 produces 47% 
inhibition of hepatic 11HSD1 reductase activity 4 hours after administration (Iqbal, 
personal communication). This demonstrates that such a dose does not fully inhibit 
11HSD1 and may be the reason that that the drug did not reproduce the same effect as 
the knockout. 
 After surgery, food intake was consistently reduced so the dose delivered may have 
been much lower and insufficient to achieve effective enzyme inhibition. Mice received 
an intra-peritoneal bolus dose of 30mg/kg immediately after surgery which means that 
11HSD1 is likely to be inhibited in the first few hours following MI but, after this, and 
up to at least day 2 when food intake increased; there may have been little enzyme 
inhibition (Hermanowski-Vosatka et al., 2005). Tissue measurements of 11HSD1 
activity were not measured in the current study therefore I cannot rule out the possibility 
that the 11HSD1 inhibitor was not functional in this model.  
Pharmacological inhibitors of 11HSD1 have been reported to have varying effects on 
body weight. In models of obesity and metabolic syndrome such inhibition has been 
shown to reduce or have no effect on body weight (Hermanowski-Vosatka et al., 2005, 
Veniant et al., 2009, Lloyd et al., 2009). In the current study administration of an 
11HSD1 inhibitor had no effect on body weight after surgery. Heart weights were 
similar in both MI and sham-operated groups also in accordance with previous findings 
(Chapter 4) with drug treatment having no affect either. It has been shown that 
glucocorticoids can reduce thymus and adrenal gland weight (Brooks et al., 2005). 
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Administration of an 11HSD1 inhibitor did not have an effect on the thymus or adrenal 
gland weight in the present study.  Additionally, circulating corticosterone levels were 
similar in vehicle and inhibitor treated animals. This observation is in agreement with 
other groups that have used 11HSD1 inhibitors for 7 days in a variety of models 
(Veniant et al., 2009, Hermanowski-Vosatka et al., 2005, Lloyd et al., 2009). Data 
presented here demonstrates that pharmacological inhibition of 11HSD1 is unlikely to 
have deleterious effects on activation of the hypothalamic-pituitary-adrenal axis 
(Hermanowski-Vosatka et al., 2005, Veniant et al., 2009). 
Ischaemia associated with MI provokes a powerful inflammatory response that is 
characterised by neutrophil infiltration early in infarct healing followed by macrophages 
at 4-7 days after infarction (Chapter 4). Previous work has shown that 11HSD1
-/-
 mice 
have enhanced neutrophil recruitment at 2 days post-MI relative to C57Bl6 mice 
(Chapter 4).  Alternatively-activated macrophage and general macrophage infiltration 
was significantly increased in the 11HSD1
-/-
 mice at days 4 and 7 after MI respectively 
(Chapter 4). In the current study macrophage infiltration was increased 7 days after MI, 
relative to sham-operated animals, consistent with previous work (Chapter 4) (Dewald et 
al., 2004, Yang et al., 2002). However, treatment with compound 544 had no effect on 
macrophage content assessed by mac 2 immuno-reactivity. It was established in Chapter 
4 that 11HSD1
-/-
 mice have enhanced angiogenesis (Small et al., 2005, Small, 2005), 
demonstrated by increased vessel density and cell proliferation, 7 days post-MI. In the 
current study these parameters were increased 7 days after MI relative to sham as shown 
previously (Chapter 4) (Lutgens et al., 1999, Small et al., 2005, Virag and Murry, 2003, 
Ren et al., 2002, Grass et al., 2006). Whilst administration of compound 544 did not 
influence vessel density, relative to vehicle treatment, there was a trend for increased 
cell proliferation in the drug treated group. This suggests that administration of an 
11HSD1 inhibitor may have direct effects on cell replication.  
The results presented in this chapter are preliminary with low n numbers in some of the 
groups. It is, therefore, difficult to make firm conclusions from the data. However, there 
are several possible reasons why the inhibitor did not reproduce the outcomes previously 
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observed in the 11HSD1
-/-
 mice. Firstly, the concentration of the inhibitor achieved in 
target tissues may not have been sufficient to achieve enzyme inhibition, as discussed 
above. The ability of the drug to inhibit 11HSD1 in vivo was based on work conducted 
by others in the lab (Iqbal, personal communication) and was not measured in the 
current study.  Assessment of 11HSD1 activity in the heart should be conducted in 
future studies as there is a small possibility that compound 544 was not functional. 
Alternatively sufficient inhibition may have been achieved but not until later in the 
infarct healing process. It was noted that inhibition of the enzyme may have been low in 
the first few days after surgery due to reduced food intake. The negative outcome of the 
study may indicate that modification of events occurring in this early phase are critical 
in determining the later inflammatory and angiogenic responses. These events may 
include the enhancement in neutrophil infiltration that we have noted previously 
(Chapter 4). Neutrophil death provides a stimulus for monocyte infiltration (Mosser and 
Edwards, 2008, Savill et al., 1989a, Savill et al., 1989b). Post-infarct macrophage 
infiltration is strongly associated with angiogenesis (van Amerongen et al., 2007, 
Nahrendorf et al., 2007, Fraccarollo et al., 2008) and a reduction in this influx may 
reduce the stimulus for new blood vessel growth. Neutrophils are an important source of 
IL-4, a cytokine vital in determining macrophage phenotype (Brandt et al., 2000, Loke et 
al., 2002) and, as such, a reduction in this cytokine may reduce the abundance of 
alternatively activated macrophages. In a previous study (Chapter 4), the number of 
alternatively-activated macrophages was different between 11HSD1
-/-
 and C57Bl6 mice 
at day 4 but not day 7. For that reason they were not quantified in the current study. 
Alternatively-activated macrophages secrete IL-8, which was increased in 11HSD1
-/-
 
mice 7 days post-MI (Chapter 4), and therefore it would be useful to look at its 
expression as a surrogate for alternatively-activated macrophage infiltration (Loke et al., 
2002, Mosser and Edwards, 2008).  Neutrophils have also been more directly linked to 
angiogenesis. Depletion of neutrophils prior to the „angiogenic switch‟ in tumours can 
prevent blood vessel growth (Nozawa et al., 2006). Further studies are required to assess 
the impact of pharmacological 11HSD1 inhibition on early infarct healing processes and 
their role in determining longer term outcome. 
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Another explanation for the lack of effectiveness of 11HSD1 inhibitor administered after 
MI is that inhibition of the 11HSD1 is necessary before induction of myocardial injury. 
It was noted in Chapter 3 that 11HSD1
-/-
 mice have significantly lighter hearts that 
C57Bl6 controls. In addition, 11HSD1 gets upregulated upon differentiation of 
monocytes to macrophages (Gilmour et al., 2006) and inhibition of the enzyme delays 
attainment of macrophage phagocytic competence (Gilmour et al., 2006). It is possible 
that reduced glucocorticoid regeneration prior to onset of MI may have altered the 
healing response.  Programming of monocytes by reduced local glucocorticoids prior to 
injury may alter their phenotype. Mononuclear cells are liberated from the bone marrow 
along with progenitor cells post-MI and have been implicated in angiogenesis (Shintani 
et al., 2001, Orlic et al., 2001, Kastrup et al., 2006). Alterations in the propensity of cells 
to be mobilised from this location may have an effect on inflammation and angiogenesis 
and, indeed, 11HSD1 is expressed in the bone marrow (Hardy et al., 2006, Sasaki et al., 
2007, Orlic et al., 2001, Kastrup et al., 2006). It is possible that reduced glucocorticoid 
regeneration in the bone marrow has an effect on the maturation state and liberation 
potential of inflammatory and progenitor cells. These issues could be tackled by pre-
treatment of mice with the 11HSD1 inhibitor prior to MI.  
Interestingly, it has previously been shown from this laboratory that the non-selective 
11HSD1 inhibitor, carbenoxolone, can prevent the anti-angiogenic effect of 11-
dehydrocorticosterone, but not corticosterone, in isolated aortic rings demonstrating that 
locally regenerated glucocorticoids are anti-angiogenic (Small et al., 2005). One of the 
mechanisms by which glucocorticoids mediate their angiostatic effect is via reduction of 
cell proliferation (Banciu et al., 2008b). There was a trend for cell proliferation, assessed 
by BrdU incorporation into replicating nuclei, to be increased in treated mice, although 
there was no parallel increase in vessel density. Angiogenesis involves co-ordination of 
several steps, including proliferation endothelial cells and pericytes, and enhancing one 
aspect of the process does not necessarily result in robust blood vessel growth (Kido et 
al., 2005, Greenberg et al., 2008, Korpisalo et al., 2008, Risau, 1997).  
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While the data presented here suggest that compound 544 has no effect on murine 
infarct healing it is important to bear in mind several methodological issues. It is likely 
that inhibition of 11HSD1 was insufficient until day 3. It is probable that this window 
early in infarct healing is important in coordinating the latter healing response. 
Increasing the concentration of the drug in the food given just after surgery or altering 
route of administration may be beneficial. Repeated gavaging and/or intra peritoneal 
injections may result in extra stress (i.e., greater systemic corticosterone) but use of a 
mini-pump to deliver the dose of drug throughout the study may be more effective 
(Balcombe et al., 2004). 
Administration of the MR antagonist, epleronone, to rats after MI enhances 
inflammation and angiogenesis, and improves left ventricular remodelling (Fraccarollo 
et al., 2008). Whilst epleronone has been used successfully in the clinic it may cause 
hyperkalaemia and does not prevent the adverse effects of GR activation in infarct 
healing (Pitt et al., 2005). Inhibition of 11HSD1 is an attractive alternative. Selective 
small molecule inhibitors of 11HSD1 are still under development and are now entering 
clinical trials for other diseases (Tu et al., 2008, Su et al., 2009, Hawkins, 2008). An 
Incyte compound (INCB013739) has entered phase II clinical trials and has been shown 
to improve insulin sensitivity, plasma LDL cholesterol and plasma total cholesterol in 
patients with type 2 diabetes (Hawkins, 2008). Furthermore there was a trend for 
improved fasting glucose, insulin sensitivity and plasma triglycerides in inhibitor treated 
patients (Hawkins, 2008). Trials to determine the effectiveness of such inhibitors in 
atherosclerosis and obesity are on the horizon. The preliminary data presented here 
unfortunately is not conclusive and the use of 11HSD1 inhibitors post-MI certainly 








The first aim of this thesis was to investigate whether the previously reported beneficial 
effects of 11HSD1 deficiency were related to an underlying cardiac phenotype (Chapter 
3). Secondly, I aimed to characterise the healing response after MI in 11HSD1
-/- 
mice 
and to investigate if the enhanced angiogenic response in 11HSD1
-/- 
mice would be 
preceded by enhanced inflammation (Chapter 4). In Chapter 5 I investigated whether the 
enhancement in vessel density and cardiac function remained in the long term. The final 
aim of this thesis was to establish whether the effect of the 11HSD1
-/-
 could be 
recapitulated using a commercially bought 11HSD1 inhibitor (Chapter 6). 
 
7.1 Basal cardiac phenotype 
The metabolic and vascular influence of 11HSD1
-/-
 in mice has been studied extensively 
in this laboratory (Walker and Seckl, 2003, Hadoke et al., 2001, Kotelevtsev et al., 1997, 
Morton et al., 2004, Morton et al., 2001, Hadoke et al., 2006, Christy et al., 2003, 
Paterson et al., 2006), but until now the cardiac phenotype was relatively unknown. The 
work described in this thesis establishes that 11HSD1
-/-
 mice have significantly lighter 
hearts compared to C57Bl6 mice and this is not related to reduced body weight. The 
gross inspection of hearts from 11HSD1
-/-
 mice indicated that the reduction in heart 
weight may be due to a decrease in cardiomyocyte cross-sectional area, which should be 
confirmed by morphometric measurements in future studies. Glucocorticoids stimulate 
expression of genes that promote cellular hypertrophic and I can speculate that a local 
reduction in corticosterone might reduce cardiomyocyte size via this mechanism 
(Yoshikawa et al., 2009). These observations may have implications when considering 
the response of 11HSD1
-/-
 mice to MI.  Hypertrophy of the non-infarcted myocardium is 
part of the healing response after MI, which compensates for cardiomyocyte loss and is 
apparent by 4 weeks after experimental MI in mice (Mork et al., 2007). It is possible that 
11HSD1
-/-
 mice have a modified response to this in infarct healing due to underlying 
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differences in their cardiomyocytes. However, the studies presented in Chapters 4 and 5 
demonstrate that there was no indication of differences in heart weight between 
11HSD1
-/-
 and C57Bl6 mice up to 4 weeks after MI, suggesting that this is not the case 
in this time frame. It may be of interest to culture cardiomyocytes from 11HSD1
-/-
 and 
C57Bl6 mice and compare their response to hypertrophic stimuli, such as phenylephrine 
(Gan et al., 2005). Alternatively, the hypertrophic response could be compared in vivo, 
for example, using the aortic constriction model of left ventricular pressure overload. 
Importantly, despite the decreased heart weight there were no overt structural 
abnormalities in the 11HSD1
-/-
 hearts relative to controls and cardiac function was 
similar. 
 
7.2 What mediates the increase in angiogenesis after MI in 11HSD1-/- mice? 
Angiogenesis is enhanced in 11HSD1
-/-
 mice, relative to C57Bl6 controls 7 days post-
MI and is associated with augmented myocardial IL-8 mRNA expression and increased 
cell proliferation (Chapter 4). The enhancement of cardiac function occurs in parallel to 
this neovascularisation and has been demonstrated in several other studies (Engel et al., 
2006, Sasaki et al., 2007, Small, 2005, Payne et al., 2007, Orlic et al., 2001, Kastrup et 
al., 2006, Kido et al., 2005, Fujii et al., 2009, Siragusa et al., 2010, Yang et al., 2010). 
Several other factors such as SDF-1α, GM-CSF and G-CSF have also been implicated in 
increasing vessel density post-MI and warrant further investigation in this model 
(Takahashi et al., 2006, Sasaki et al., 2007, Lakkisto et al., 2010). Most studies 
examining infarct angiogenesis use standard mature vessel markers such as CD31 and 
von Willebrand factor and, therefore, do not truly distinguish between new and old 
vessels. In order to identify new blood vessels immuno-labelling specific markers of 
angiogenic vasculature such as APN/CD13 and CD105/endoglin could be used (Rangel 
et al., 2007, Bhagwat et al., 2001, van Laake et al., 2006). An alternative method would 
be to use fluorophore tagged cNGR, a peptide sequence that homes to CD13 positive 





 mice have a sustained enhancement in vessel density after infarct healing has 
completed (Chapter 5). Moreover, the vessels were pericyte coated suggesting maturity 
and it is likely that they will be maintained in the long term (Grass et al., 2006, Ren et 
al., 2002). The functionality of these vessels on the infarct border is yet to be elucidated.  
Assessment of perfusion can be made using micro-angiography (Cheng et al., 2007) but 
resolution is too low for accurate quantification (Bondke et al., 2007). Laser Doppler is 
an alternative, but this method also has limitations as penetration depth is low (Scholz et 
al., 2002, Bondke et al., 2007). Perfusion of fluorescently labelled microspheres, 
ultrasound contrast microbubbles or microbubbles tagged with endothelial cell specific 
antibodies are alternatives that could be considered in future studies (Liu et al., 2007, 
Dickie et al., 2006). 
11HSD1
-/-
 mice also have an augmented inflammatory response post-MI, demonstrated 
by increased neutrophil and macrophage infiltration along with enhanced MCP-1 mRNA 
expression. Interestingly, 11HSD1
-/-
 mice have significantly lighter spleens 28 days after 
MI relative to C57Bl6 controls (Chapter 5). A recent publication provides evidence for 
the spleen being a reservoir for the monocytes that are liberated after MI (Swirski et al., 
2009).  It is possible that increased monocyte liberation from the spleen in 11HSD1
-/-
 
mice may be the source of increased monocyte infiltration into the heart. It is well 
established that glucocorticoids have immuno-modulatory actions including, inhibiting 
the production of inflammatory cytokines, upregulating anti-inflammatory mediators and 
modulating phagocytosis by macrophages (Galon et al., 2002, Cupps and Fauci, 1982, 
Barnes, 1998, Gilmour et al., 2006, Park et al., 2009). 11HSD1 is upregulated during the 
maturation of monocytes to macrophages and the local amplification of glucocorticoids 
by this enzyme may serve to curtail the inflammatory response (Gilmour et al., 2006, 
Chapman et al., 2009). The enhancement of inflammation in 11HSD1
-/-
 mice has been 
demonstrated in a variety of models including peritonitis, pleurisy and serum arthritis 
models, (Gilmour et al., 2006, Chapman et al., 2009, Coutinho 2009).  
Interestingly, data presented in Chapter 4 demonstrates an increase in alternatively-
activated, pro-resolution, angiogenic macrophages (M2) in the 11HSD1
-/-
 mice, relative 
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to C57Bl6 controls, 4 days after MI. Maturation of macrophages to this M2 phenotype is 
stimulated by IL-4 which is reportedly secreted by neutrophils (Mosser and Edwards, 
2008, Loke et al., 2002, Brandt et al., 2000). An investigation of IL-4 expression, as the 
major neutrophil-derived mediator of alternate macrophage programming (Loke et al., 
2002, Brandt et al., 2000), would be worthwhile to establish the contribution of 
neutrophils in 11HSD1
-/-
 mice. There is increasing support for the role of macrophages 
in stimulating angiogenesis, particularly in cancer models (Sica et al., 2006, Mosser and 
Edwards, 2008). Macrophage depletion, achieved by administration of liposome-
encapsulated clodronate, reduces angiogenesis in aortic ring explants and this effect can 
be reversed by replenishment with bone marrow-derived macrophages  (Gelati et al., 
2008). Furthermore, in rodent models of MI, clodronate can reduce angiogenesis and 
scar formation, and impair cardiac function (Fraccarollo et al., 2008, Nahrendorf et al., 
2007, van Amerongen et al., 2007). The work presented in this thesis shows that IL-8, an 
angiogenic chemokine secreted by M2 macrophages, was increased just after their peak, 
at day 7 providing a link between macrophages and angiogenesis in this model.   
As glucocorticoids can inhibit both inflammation and angiogenesis it is unknown 
whether the enhancement in angiogenesis in 11HSD1
-/-
 mice is a direct effect of reduced 
local glucocorticoids or whether it is secondary to the enhancement in inflammation in 
this model. I cannot rule out direct inhibition of angiogenesis by glucocorticoids but the 
weight of evidence does support a key contribution of inflammatory cells. Assessment of 
angiogenesis after macrophage depletion using clodronate (van Amerongen et al., 2007, 
Nahrendorf et al., 2007, Fraccarollo et al., 2008) or by conditional ablation of CD11b 
positive cells, mediated by the diphtheria toxin receptor (Duffield et al., 2005), would 
confirm a role for these cells.  
 
7.3 Post-infarct scar formation 
Excessive inflammation is associated with enhanced fibrosis (Liu et al., 2009). Despite 





 mice. While actual scar size and collagen content did not differ between the 
C57Bl6 and 11HSD1
-/-
 mice, the C57Bl6 mice had significantly thinner scars that had a 
tendency to be longer by 4 weeks post-MI.  Scar thinning is correlated with risk of 
cardiac rupture (Dai et al., 2005, Nahrendorf et al., 2006). Glucocorticoids have been 
shown to have adverse effects on scar formation in several experimental models (Vivaldi 
et al., 1987) .  Chronic administration of a high dose of methylprednisolone to dogs 
enhanced scar thinning, increased infarct length and impaired cardiac function with no 
effect on total collagen or histological appearance (Hammerman et al., 1983a). As 
expected, the converse is seen in 11HSD1
-/- 
mice. The authors of the previous studies 
postulate that these adverse effects of glucocorticoids are due to diminished removal of 
necrotic tissue resulting from inhibition of inflammation. Hammerman et al and Brown 
et al support this hypothesis by showing that non-steroidal anti-inflammatory drugs, 
such as ibuprofen and indomethacin, have a similar effect on infarct scar dimensions 
(Hammerman et al., 1983b, Brown et al., 1983). Perhaps 11HSD1
-/-
 mice have faster 
replacement of necrotic tissue with granulation tissue. Prolongation of this process may 
mean that the weakened infarct undergoes expansion prior to deposition of normal 
collagen (Virag and Murry, 2003). It would be interesting to look at an intermediate time 
point (week 2) to see whether the area of necrosis is greater in C567Bl6 mice. Infarct 
expansion can be affected by blood pressure (Pfeffer and Braunwald, 1990, Pierard et 
al., 1987). Genetic deletion of 11HSD1 has no effect on basal blood pressure, while 
11HSD2
-/-
 mice are hypertensive (Kotelevtsev et al., 1999, Kotelevtsev et al., 1997). 
Blood pressure was not measured in the current study and there have been no published 
reports of altered blood pressure or alterations in vascular function in 11HSD1
-/-
 mice 
(Hadoke et al., 2001). However, recent work has demonstrated that carefully measured 
blood pressure is lower in 11HSD1/ApoE double knockout mice relative to ApoE 
knockout controls (Iqbal, personal communication). Blood pressure should be measured 
by tail cuff or carotid artery cannulation in future studies. 
Importantly, the improvement in cardiac function observed 7 days post-MI in the 
11HSD1
-/-
 mice was maintained at 4 weeks, in parallel with the sustained enhancement 
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of vessel density in the infarct border. The trend for a reduction in scar length in 
11HSD1
-/-
 mice suggests that the increase in vessel density may enhance cardiomyocyte 
salvage in the infarct border. This could be the source of improved function. 
Alternatively, the type of collagen making up the scar could be different. A scar with a 
high proportion of the elastic collagen type III, relative to the stiff type 1, may favour 
improved cardiac function. This can be investigated using immunohistochemistry. While 
it is exciting that 11HSD1
-/-
 mice have improved heart function 4 weeks after MI, it is 
dangerous to over interpret data from a midterm assessment. It has been reported 
previously that significant improvements in cardiac function 4 weeks after MI were not 
observed after 3 months (van Laake et al., 2008). A longer term study with the 11HSD1
-
/-
 mice to allow development of heart failure is required to determine the true long term 
potential of 11HSD1 inhibition after MI.  
 
7.4 The potential impact of metabolic changes 
One aspect of the 11HSD1
-/-
 mouse phenotype that may have a role in recovery post-MI, 
but was beyond the scope of this thesis, was the possible effect of the knockout on post-
infarct metabolism. After MI, systemic release of glucocorticoids can have effects on the 
metabolic status of the individual by altering the turnover of free and stored energy 
(Opie, 1971, Walker, 2007). Glucocorticoids increase hepatic gluconeogenesis, fatty 
acid and glucose release, along with inhibiting insulin secretion from the pancreas 
(Walker, 2007a). After MI, glucose utilisation in the heart increases at the expense of 
fatty acid metabolism, due to the anoxic conditions, and this leads to accumulation of 
lactate and hydrogen ions which can impair cardiac function (Opie, 1971). In patients, a 
high level of circulating glucose after admission for MI is positively correlated with 
development of heart failure and mortality risk (Kosiborod, 2008) and is inversely 
correlated with ejection fraction after coronary angioplasty or thrombolysis (Ceriello, 
2008). The benefits of using insulin to reduce plasma glucose after MI is somewhat 
contentious; however, there is evidence that such therapy may lower mortality 
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(Kosiborod, 2008). It has previously been shown that 11HSD1
-/-
 mice resist high fat 
feeding, have enhanced glucose tolerance, an improved lipid profile and insulin 
sensitivity (Morton et al., 2004, Morton et al., 2001, Kotelevtsev et al., 1997). It is 
possible that these changes in 11HSD1
-/-
 mice may translate to alterations on the 
metabolic disturbances associated with MI. While the post-infarct effect of 11HSD1 
deletion on hormonal or metabolic pathways was not investigated the data presented 
here strongly suggests that the beneficial effects are mediated within the heart. 
Furthermore, data presented in this thesis demonstrate that there was no difference in 
circulating corticosterone at any of the time points investigated.  
 
7.5 Therapeutic potential of pharmacological 11HSD1 inhibition 
Administration of a small molecule inhibitor of 11HSD1 did not recapitulate the effect 
of genetic deletion of 11HSD1 on infarct healing in terms of inflammation, angiogenesis 
and cardiac function. This was a preliminary study and, therefore, it is is hard to make 
firm conclusions regarding the data. The inhibitor (compound 544) used had already 
been shown to inhibit 11HSD1 in vivo and proved effective in models of diabetes, 
obesity and atherosclerosis (Hermanowski-Vosatka et al., 2005, Iqbal, personal 
communication). However, the drug was administered in the food, intake of which was 
severely compromised immediately after surgery; only a very low dose is likely to have 
been received in the first 2 days after surgery. This dose may have been insufficient to 
adequately inhibit 11HSD1 activity during the infarct healing phase. The results of this 
study may, therefore, point to a key role of events occurring early after MI in 
determining the eventual outcome.  It is likely that the enhanced neutrophil influx 
observed 2 days after MI in the 11HSD1
-/-
 mice did not occur in the inhibitor treated 
group, thus, potentially reducing the stimulus for downstream infarct healing events 
(Savill et al., 1989b, Savill et al., 1989a, Loke et al., 2002, Brandt et al., 2000). To avoid 
this confounding issue it would be advisable to use an implanted osmotic mini pump to 
administer the 11HSD1 inhibitor in future studies. Furthermore the inhibition of 
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11HSD1 in the heart should also be measured in order to be fully confident that the 
inhibitor is indeed inhibiting the enzyme. The time at which 11HSD1 inhibition 
commences may be paramount in improving the infarct healing response.  As effects of 
11HSD1 deficiency on inflammation are observed in the early days after MI 
pharmacological inhibitors of 11HSD1 should be administered within the first day after 
MI.  It is also possible that the reason compound 544 did not recapitulate the 11HSD1
-/-
 
mice was because of programmed differences in 11HSD1
-/-
 compared with the C57Bl6 
mice. 11HSD1 is expressed in the bone marrow and alterations in the propensity of 
mononuclear and progenitor cells to be mobilised from this location may have an effect 
on inflammation and angiogenesis (Hardy et al., 2006, Orlic et al., 2001, Sasaki et al., 
2007, Kastrup et al., 2006). Inhibition of 11HSD1 before infarction may therefore, be 
necessary in order to prime the system for a modified inflammatory response. 
Comparisons of outcomes when an 11HSD1 inhibitor is administered prior to surgery 
will also be of interest. Flow cytometric analysis in Chapter 4 showed that there was no 
difference in the number and type of monocytes in the bone marrow, at least at 7 days 
post-MI, but other cell types and their behaviour warrant further investigation. 
 
7.6 The roles of GR and MR after MI 
The majority of evidence from experimental and clinical studies suggests that 
glucocorticoids are protective when administered initially after MI as they reduce infarct 
size via stimulation of the GR (Libby et al., 1973, Morrison et al., 1976, Hafezi-
Moghadam et al., 2002). In the present study the systemic stress release of 
corticosterone after MI was comparable in C57Bl6 and 11HSD1
-/-
 mice and infarct size 
was not affected by genotype. Endogenous glucocorticoids can activate both the GR and 
MR due to their high homology (Funder and Mihailidou, 2009). However, as there are 
no obvious surrogate markers for their activation it is hard to determine the relative 
contribution of activation of GR and MR in MI healing. Additionally, receptor specific 
inhibitors have effects beyond those in the heart.  It is, therefore, difficult to know for 
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certain whether the beneficial effects of the 11HSD1 knockout are due to reduced GR or 
MR signalling.  Evidence certainly suggests that the beneficial role of glucocorticoids on 
initial infarct size is mediated by the GR (Hafezi-Moghadam et al., 2002) while the 
detrimental influence of glucocorticoids is likely to be mediated by activation of the MR 
(Mihailidou et al., 2009). Inhibition of inflammation by GR activation is well 
established. Less acknowledged is the ability of MR to mediate inhibition of 
inflammation after MI (Galon et al., 2002, Cupps and Fauci, 1982, Barnes, 1998). 
Immediate MR blockade, with epleronone, after infarction enhances both inflammation 
and angiogenesis, reduces infarct expansion and improves cardiac function 7 days post-
MI in rats without influencing infarct size (Fraccarollo et al., 2008). Prevention of 
monocyte infiltration with clodronate abrogated the beneficial effects of MR 
antagonism, demonstrating the pivotal role of inflammation in MR mediated 
improvement in myocardial infarct healing (Fraccarollo et al., 2008). MR antagonists 
can suppress NF-κB activation, thus inhibiting inflammation (Sun et al., 2002).  In 
addition, in a rat model of MI spironolactone treatment, starting immediately after MI 
and continuing for 14 days, improves cardiac function and decreases interstitial fibrosis 
and apoptosis, despite no change in infarct area or collagen volume (Takeda et al., 
2007). There is limited evidence regarding the direct angiostatic potential of 
mineralocorticoids whereas glucocorticoids are well established as potent angiostatic 
agents (Longenecker et al., 1982, Ullian, 1999, Folkman and Ingber, 1987, Hori et al., 
1996, Steinbrech et al., 2000, Yano et al., 2006). Mice treated with the GR antagonist, 
RU38486, exhibited enhanced angiogenesis 7 days post-MI, relative to vehicle treated 
controls (Small et al., 2005, Small, 2005). This suggests that the reduced glucocorticoid 
regeneration in 11HSD1
-/-
 mice can enhance angiogenesis through reduced GR 
signalling whilst enhanced inflammation may be mediated by reduced GR and MR 
signalling. The post-infarct response of the 11HSD1
-/-
 mice is similar to that of 
pharmacological MR blockade in rats which suggests that the beneficial effects of 
reduced tissue regeneration of corticosterone are mediated by reduced MR activation in 
the healing phase. 
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The detrimental effects of glucocorticoids on post-MI scar formation may be mediated 
by either GR or MR. However, there is overwhelming evidence for the role of MR 
mediated fibrosis induced by the action of aldosterone in other models. Infusion of 
aldosterone, or its precursor, to uni-nephrectomised rats drinking 1% NaCl solution 
leads to cardiac fibrosis and hypertrophy (Young and Funder, 1996, Rickard et al., 
2006). These effects were reversed by the co-administration of an MR antagonist 
demonstrating that this is a MR mediated effect (Young and Funder, 1996, Rickard et 
al., 2006). In these studies blood pressure was increased, yet several others have shown 
that the fibrosis is independent of blood pressure. Nagata et al and Kobayashi et al 
achieved a decrease in fibrosis and hypertrophy using a non-antihypertensive dose of 
epleronone (Nagata et al., 2006) (Kobayashi et al., 2006). There is some evidence that 
glucocorticoid action on MR may vary according to tissue and the oxidative conditions. 





ATPase pump under basal conditions (Funder and Mihailidou, 2009). When the cells are 
under oxidative stress cortisol mimics aldosterone and increases the activity of this 
pump (Funder and Mihailidou, 2009). As MI creates a state of oxidative stress it follows 
that, under these conditions, glucocorticoids could act as MR agonists.  
Blockade of MR has been shown to be beneficial in patients with heart failure and after 
MI. In the RALES study (Randomized ALdactone Evaluation Study) patients with 
severe heart failure and an ejection fraction of 35% or lower were given spironolactone 
on top of standard therapy (Pitt et al., 1999). Two years later those receiving 
spironolactone had a 30% reduction in risk of death and this was attributed to a 
reduction in progression of heart failure and sudden cardiac death (Pitt et al., 1999). In 
the EPHESUS clinical study (Eplerenone Post-Acute Myocardial Infarction Heart 
Failure Efficacy and Survival) patients were randomised to receive eplerenone or 
placebo from 3-14 days after MI (Pitt et al., 2005). At 30 days the risk of death was 
reduced by 31% in eplerenone treated groups (Pitt et al., 2005). This was associated with 
a decrease in blood pressure (Pitt et al., 2005). A more recent analysis of this study, after 
a 16 month follow up, showed that this benefit was only found when eplerenone 
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treatment was started 3-7 days after MI and was absent when treatment started 7 days 
after MI (Adamopoulos et al., 2009).  These beneficial effects are found in parallel with 
reduced collagen turnover (Iraqi et al., 2009).  
While epleronone is beneficial after MI and in the treatment of heart failure it does have 
side effects. There has been an increase in the hospitalisation and subsequent death of 
elderly patients from hyperkalemia as a result of administration of MR antagonists, 
especially when used in conjunction with other cardiovascular drugs such as beta 
blockers (McMurray and O'Meara, 2004). These elderly patients are more susceptible to 
hyperkalemia due to reduced production of aldosterone (McMurray and O'Meara, 2004). 
Caution must be taken when administering MR blockers to this population and perhaps 
11HSD1 inhibition could be a particularly useful alternative therapy in such cases.   
 
7.7 Progenitor and stem cells 
There is now plentiful evidence to suggest that enhancement of angiogenesis on the 
infarct border improves cardiac function after MI (Yamahara and Itoh, 2009, van der 
Laan et al., 2009). Strategies to enhance angiogenesis include direct injection of growth 
factors (e.g. VEGF) to stimulate angiogenesis directly, or injection of factors (e.g. SDF-
1α and G-CSF) that enhance mobilisation of progenitor cells from the bone marrow. 
Such techniques have been associated with enhanced angiogenesis and improved cardiac 
function, however there is also considerable evidence contending this (Ellis et al., 2006, 
Losordo et al., 1998, Simons, 2005, Ruixing et al., 2007, Pitchford et al., 2009, Sasaki et 
al., 2007, Orlic et al., 2001). Injection of bone marrow-derived cells (BMDC) directly 
into the infarcted heart has had more success (Lasala and Minguell, 2009). The BOOST 
clinical trial demonstrated that an intra-coronary injection of BMDC can improve 
ejection fraction, but not left ventricle systolic function 18 months after MI (Meyer et 
al., 2006). This is being followed up by BOOST 2 which aims to give a more 
comprehensive assessment of the mechanism of improved cardiac function. BMDC have 
also been shown to enhance cardiac regeneration (Fazel et al., 2006). In more recent 
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clinical trials BMDCs have shown to improve left ventricle function at 6 months and 2 
years (Plewka et al., 2009, Assmus et al., 2010). Furthermore, at 2 years this was 
associated with a reduction in occurrence of adverse cardiovascular events (Plewka et 
al., 2009, Assmus et al., 2010). Endothelial progenitor cells (EPC) are one of the BMDC 
populations that are reported to have a role in post-infarct angiogenesis. Particularly 
relevant for the work presented here is that monocytes express some of the typical EPC 
markers and can demonstrate similar behaviour (Apostolakis et al., 2009). It is possible 
that this is the source of the enhanced angiogenesis in the 11HSD1 deficient model as 
11HSD1 is expressed in the bone marrow. The mechanism of BMDC is unclear; 
however evidence is mounting for a paracrine mechanism (Chien, 2006, Frantz et al., 
2008). BMDCs transfected with growth factors have proved particularly impressive in 
animal models lending support for this (Yau et al., 2005, Payne et al., 2007).  Despite a 
great deal of evidence suggesting that these techniques are beneficial to infarct healing, 
there is also considerable evidence suggesting there is no benefit (Terrovitis et al., 2004, 
Maekawa et al., 2004, Jujo et al., 2008). Inconsistency in the purification of cells, cell 
number and route of administration are some of the confounding variables that make it 
difficult to directly compare these studies. 
 
7.8 Concluding remarks 
Previous work had shown that deficiency of 11HSD1 is associated with increased vessel 
formation in experimental models of angiogenesis in vitro and in vivo, including in the 
healing myocardium of mice that have undergone MI (Small et al., 2005).  Data 
presented in this thesis extends these observations and demonstrates that increased 
neovascularisation during infarct healing in 11HSD1
-/- 
mice follows augmented 
accumulation of neutrophils and of alternatively activated macrophages, and is in 
parallel with increased expression of the pro-angiogenic chemokine, IL-8, and enhanced 
cell proliferation.  Simultaneous with increased neovascularisation is an improvement in 





mice, by which time vessels on the infarct border have matured, and is 
associated with a reduction in scar thinning and with sustained improvement in cardiac 
function. Further studies are required to determine whether this benefit of 11HSD1 
inhibition continues into the long term as the animals develop heart failure. 11HSD1 
inhibitors are currently under development for diseases such as obesity, diabetes and 
atherosclerosis (Hermanowski-Vosatka et al., 2005). Indeed, orally bio-available, 
selective inhibitors of 11HSD1 are already in clinical trials for type 2 diabetes. The 
evidence presented here indicates that small molecule inhibitors of 11HSD1 may also be 
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Appendix 1: Solutions 
Acid alcohol 
300ml 74 OP + 3ml concentrated HCl. 
ACK red blood cell lysis buffer 
8.29g NH4Cl (0.15M), 1g KHCO3 (1mM), 37.2mg NA2EDTA (0.1mM). Add 800ml 
water; adjust to pH 7.2-7.4 with 2N HCl. Add water up to 1 litre. Filter sterilize through 
0.2µM filter.  
Alkaline tap water 
400ml tap water + 2-3 drops of ammonia 
Anaesthetic 
To make a 5ml solution add 0.5ml medetomidine, 0.38ml ketamine and 0.5ml atropine 
to 3.62ml sterile saline or water for injections. 
Aniline blue 
2.5g Aniline blue +2ml acetic acid, glacial + 100ml distilled water 
Borate buffer (130mM Boric acid, 67.5mM Na OH) 
4.125g boric acid + 1.75 concentrated HCl + 500ml distilled water. pH to 7.6 then add 
2.5g BSA fraction V. Store at -20°C. 
BrdU 





Dissolve 50mg collagenase type IA-S in 99ml PBS then add 11ml fetal calf serum.  
Citrate buffer 
1.92g citrate buffer in 1000ml distilled water, pH to 6.0 then add 1ml Tween 20 
DEPC treated water 
100µl diethyl pyrocarbonate (DEPC) in 100ml distilled water. Left overnight before 
autoclaving.  
DAB (3, 3'-diaminobenzidine) Substrate 
To 5ml distilled water add 2 drop buffer solution, mix well, 4 drops DAB stock solution, 
mix well and 2 drops hydrogen peroxide, mix well. All reagents are provided in the kit.  
2N HCl 
20ml 10N HCl to 80ml distilled water 
Mouse on Mouse (MOM) blocking solution 
To 2.5ml PBS or TBS add 2 drops MOM blocking solution. 
Picrosirius Red 
0.5g Direct Red in 500ml saturated picric acid 
Phosphomolybdic-phosphotungstic acid  
25 ml 5% phosphomolybdic acid + 25 ml 5% phosphotungstic acid 
Phosphate buffered saline 
1 tablet per 200ml distilled water 
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SG Substrate kit 
To 5ml PBS (pH7.5) add 3 drops of chromagen, mix well, 3 drops hydrogen peroxide 
and mix well. Reagents are provided in the kit 
Tail buffer 
0.05M Tris HCl, 0.1M EDTA, 0.1M NaCl, 1% SDS 
TE buffer 
50mM Tris Base, 1MM EDTA, pH8.0 
Triphenyltetrazolium 
Tetrasodiumchloride 1%: 1g in 100ml phos buffer at pH7.4 
Tris buffered saline (TBS)-Tween 
30.5g Tris base, 45g NaCl, 2.5ml Tween 20 in 500ml distilled water for 20x stock. 
Diluted 1 in 10 for working stock. For TBS make omit the Tween 
Tris-EDTA buffer 
1.21g Tris base, 0.37g EDTA in 100ml distilled water. pH to 9.0. Diluted 1 in 10 for 
working stock and add 0.5ml Tween 20.  
Trypsin 
1g Trypsin, 1g CaCl in 800ml distilled water, pH to 7.4, make up to 1000ml.  
Weigert’s iron haematoxylin 
Solution A 1g haematoxylin + 100ml 95% ethanol 
Solution B 4ml 29% ferric chloride in water + 95ml distilled water + 1ml HCl 
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